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Prader-Willi syndrome (PWS) is caused by a loss of paternally expressed genes in an 
imprinted region of chromosome 15q. Among the canonical PWS phenotypes are hyperphagic 
obesity, central hypogonadism, and low growth hormone. Rare microdeletion PWS patients 
define a 91 kb minimum critical deletion region encompassing three genes, including the non-
coding SNORD116.  
Induced pluripotent stem cells were generated from skin cells of three large deletion (5-6 
Mb) PWS patients and one novel microdeletion (118 kb) PWS patient. We found that genes 
within the PWS region, including SNRPN and NDN, showed persistence of DNA methylation 
after iPSC reprogramming and differentiation to neurons. Genes within the PWS minimum 
critical deletion region remain silenced in both PWS large deletion and microdeletion iPSC 
following reprogramming.  
We find that NHLH2 and PC1 (protein and transcript) are reduced in PWS patient iPSC-
derived neurons. Nhlh2 and Pcsk1 expression are reduced in hypothalami of fasted Snord116
p-/m+
 
mice while hypothalamic AgRP and Npy remain elevated following refeeding in association with 
relative hyperphagia. Nhlh2
-/-
 mice have growth deficiencies from 4-7 weeks of age, develop 
hyperphagic obesity as adults, and are hypogonadal. Nhlh2 promotes expression of the 
 
 
prohormone convertase, Pcsk1 (PC1). PC1 is a neuroendocrine prohormone convertase that 
catalyzes the processing of hormones to “mature,” active hormones.  
Humans and mice deficient in PC1 display hyperphagic obesity, hypogonadism, 
decreased growth hormone, and hypoinsulinemic diabetes due to impaired prohormone 
processing. Snord116
p-/m+
 mice display in vivo functional defects in prohormone processing of 
proinsulin, proGHRH, and proghrelin in association with reductions in islet, hypothalamic, and 
stomach PC1 content. Our findings suggest that the major neuroendocrine features of PWS are 
due to PC1 deficiency which results from absence of functional SNORD116. 
In addition to hyperphagic obesity and endocrinopathies, global developmental delay 
(delayed motor milestones, delayed language development) is a major characteristic of the 
Prader-Willi syndrome (PWS). We identified neuroanatomical defects in iPSC-derived neurons 
of individuals with PWS and mice deficient for Snord116. iPSC-derived neurons from PWS 
patients and neurons from Snord116
p-/m+
 mice, have smaller soma and decreased numbers of 
neurites. Reduced neuron cell body size is apparent in utero and persists at least until 4 weeks of 
age in Snord116
p-/m+
 mice. The reduction in neuronal soma size is associated with smaller 
neuronal nucleoli.  
There are also developmental defects in the endocrine pancreas of Snord116
p-/m+
 animals 
that persist into adulthood (≥20 weeks). Mice lacking Snord116 have smaller pancreatic islets 
and within the islet the percentage of δ-cells is increased, while the percentage of α-cells is 
reduced. In Snord116
p-/m+
 isolated islets, Sst and Hhex are upregulated while Ins1, Ins2, Pdx1, 
Nkx6-1, and Pax6 are downregulated. There is a 3-fold increase in the percentage of 
 
 
polyhormonal cells in the neonatal islets of Snord116
p-/m+
 mice, which was due to an increase in 
cells co-positive with somatostatin. Snord116 may play a role in islet cell lineage specification.  
Overall, this work suggests that the Snord116 gene cluster is important for developmental 
processes in the brain as well as endocrine pancreas and prohormone processing in multiple 
tissues. Loss of elements within this cluster could account for the PWS by virtue of effects on the 
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Body weight is controlled by complex interactions among genes, the products of genes, 
epigenetic factors, and environmental factors.  
 
Obesity Prevalence, Medical Consequences, and Barriers to Successful 
Treatment of Obesity 
Obesity and its resultant metabolic derangements are a major public health concern in the United 
States and abroad. In 2008, the direct cost of medical spending related to overweight and obesity was 
estimated to be between $86 to $147 billion  (1). Positive energy imbalance resulting in excess adiposity 
leads to overweight (BMI 25-30) and obesity (BMI >30) (2). Obesity rates in US adults, as measured by 
the National health examination survey (NHANES), were relatively constant between 1960-1980 at 
12.8% (3). However, by 1994, the prevalence of obesity in US adults nearly doubled, to 22.5% (3). Rates 
of obesity have continued to rise, and the most recent data (NHANES 2013-2014) estimates that the 
prevalence of obesity in US adult women is 40.4% and in US adult men is 35.0% (4). Obesity prevalence 
among children in the US has also increased in recent decades and currently 17.0% of US children and 
adolescents aged 2-19 years are obese; pediatric obesity is defined as BMI ≥95% of Centers for Disease 
Control and Prevention BMI-for-age growth charts (5).  
World-wide mortality due to chronic conditions is now more frequent than that due to infectious 
disease (6). Elevated BMI (≥30) is associated with increased mortality from all causes, especially 
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mortality due to cardiovascular disease, certain forms of cancer, type 2 diabetes, sleep apnea, and stroke 
(7, 8). The risk for these diseases as well as morbidity from all causes increases as BMI increases (8). 
These findings have been confirmed by multiple groups using different measures of body weight and 
adiposity (8-10). Findings indicating overweight is associated with decreased mortality failed to fully 
control for smoking status, age, and illness-related weight loss and therefore those results should be 
interpreted with caution (11).   
A plethora of weight loss programs (targeting both decreased food intake and increased energy 
expenditure) are available (12). The US diet industry comprises a multibillion dollar industry (12). A 
PubMed search for “weight loss” yields 112,234 results (13). Losing weight is difficult and maintaining 
weight loss is an even greater challenge. Reported adherence to commercially available weight loss 
programs is widely variable, with some as low as 23% (14). More than half of the participants fail to 
achieve clinically meaningful weight loss (≥5%) one year into lifestyle intervention programs and ~80% 
of individuals that are successful in losing weight do not sustain the weight loss (15, 16). 
Pharmacologically-assisted weight loss can lead to more weight reduction than lifestyle modifications 
alone, however total weight loss is still generally ≤9% of initial weight  (17). Currently, roux-en-y gastric 
bypass surgery is the most effective method to achieve long term weight loss (18-20). 
Although the overall failure rate for long term weight loss is high, the National Weight Control 
Registry (NWCR) has followed more than 4,000 adults that have been successful in maintaining long 
term weight loss (15, 21). The NWCR defines long term weight loss as reduction of body weight by at 
least 13.6 kg and maintenance for at least 1 year (15, 21). Mean daily self-reported caloric intake was 
1,381 kilocalories; self-reported food intake generally underestimates actual caloric intake by 20-30%, 
thus NWCR participants likely eat closer to 1,800 kilocalories daily (15).  The mean weekly self-reported 
caloric expenditure in physical activity is 2,919 kilocalories which is on average, 417 kilocalories 
expended daily (15). The mean BMI, weight, and age of registry members is 24.56 ± 4.03 kg/m
2
, 69.85 ± 
14.47 kg, and 45.29 ± 11.77 years, respectively (15).  
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Careful studies by Leibel, Rosenbaum, and colleagues identify that non-resting energy 
expenditure is decreased by ~300-400 kilocalories/day in weight-reduced subjects beyond what was 
predicted by weight loss alone (22). Weight-reduced subjects are also hyperphagic relative to never obese 
individuals (23). In the aggregate, these data suggest that the major barrier to long term weight loss 
maintenance is the hypometabolic and hyperphagic state of weight-reduced individuals.  
An obesogenic environment may “promote obesity and encourage the expression of a genetic 
predisposition to gain weight” (24).  In the majority of individuals (i.e. those without highly penetrant 
monogenic or syndromic obesity), the obese state is preventable in the absence of an obesogenic 
environment (3). The rapid rate of increase in obesity prevalence over the past decades cannot be 
explained by increased frequency of risk alleles in the human population (25, 26).  
Better understanding of the biological processes controlling energy intake at the physiological, 
cellular and molecular levels may identify drugable targets for: 1) active weight loss, 2) weight loss 
maintenance, and 3) reducing the risk of weight gain in vulnerable populations, such as those with a 
defined genetic predisposition to obesity. 
 
Monogenic and Syndromic Obesities 
 The first evidence that the hypothalamus regulates body weight is from the early 20
th
 century, 
when Frolich noted that hyperphagia and rapid weight gain were associated with the presence of a tumor 
in a patient’s hypothalamus (27). Rodent models demonstrate that lesions to the ventromedial 
hypothalamic area cause hyperphagia and obesity while lesions to the lateral hypothalamic area cause 
severe aphagia leading to death (28-30). In the 1950’s, Douglas Coleman performed a series of parabiosis 
experiments in mice homozygous for spontaneous mutations associated with severe obesity, the ob/ob 
and db/db mice, as well as wild type mice. Coleman found that when ob/ob mice were parabiosed to 
either db/db mice or wild type mice, the ob/ob mice decreased food intake and reduced their body weight 
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(31). The db/db mice did not reduce food intake or body weight upon parabiosis to the ob/ob mice or wild 
type mice (31). From this, Douglas Coleman inferred that the ob/ob mice were deficient in the circulating 
satiety factor, while the db/db mice lacked its receptor (31). His hypothesis was later proven to be correct 
when Rudy Leibel and collaborators cloned the ob and db genes, which are now known as Leptin (Lep) 
and the Leptin Receptor (LepR), respectively (32-34).  
Following the cloning of Lep and LepR, human patients with extreme obesity were screened for 
mutations in the two genes (Table 1.1). A handful of individuals with such mutations were identified (35, 
36). Individuals with mutations in leptin are hyperphagic, obese, have central hypogonadism, and have 
decreased circulating levels of thyroid hormones and growth hormone (37). The phenotypes of 
congenitally leptin or leptin receptor deficient individuals overlap with those of weight-reduced 
individuals. Administration of recombinant leptin to congenitally leptin deficient individuals reversed 
hyperphagia, normalized body weight, allowed for appropriately timed pubertal development, and 
increased plasma thyroid hormone levels (37). Human patients with leptin receptor mutations are also 
hyperphagic, obese, centrally hypogonadal, and have reductions in circulating thyrotropin and growth 
hormone (35). Since the leptin receptor is inactive (or not expressed) in these patients administration of 
recombinant leptin is not a viable therapeutic option. There is still no treatment beyond the notoriously 






Table 1.1: Monogenic and Syndromic Obesities 
Gene Name Clinical Features Location/Prevalence 
Leptin (LEP) Obesity, hyperphagia, 
undetectable circulating leptin, 
hypogonadism, frequent 
infections 
7q31.3, very rare 
Leptin Receptor (LEPR) Obesity, hyperphagia, very high 
circulating leptin, hypogonadism 
1p31, very rare 
Prohormone Convertase 1 (PCSK1) Obesity, hyperphagia, 
hypogonadism, intestinal 
hormone processing defect, 
elevated proinsulin, low GH 
5q15-q21, very rare 
Proopiomelanocortin (POMC) Obesity, high circulating leptin 
level, ACTH deficiency, pale 
skin, red hair (hypopigmentation) 
2p23.3, very rare 
Melanocortin 4 Receptor (MC4R) Obesity, hyperphagia, decreased 
resting energy expenditure, 
accelerated growth, increased 
final height 
18q22, 0.5-1%, Most common 
form of monogenic obesity 
Prader-Willi Syndrome (PWS) Obesity, hypogonadism, 
neonatile hypotonia, short 
stature, hyperphagia, small 
hands, feet 
Chr 15q11.2-11.13, 1/15,000, Most 
common form of syndromic 
obesity 
WAGR Syndrome Obesity, impaired memory, 
hyperactivity, impaired pain 
sensation, Wilms tumor, 
ambiguous genitalia, mental 
retardation 
11p13-p12, Obesity present when 
BDNF deficiency occurs, rare, 




The study of monogenic and syndromic obesities enables elucidation of cellular-molecular 
pathways that regulate body weight. Identification of these pathways and the gene products acting within 
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them may inform novel therapeutic targets for the treatment of obesity. Identification of genetic traits that 
encourage a minority of individuals to remain lean in the current, obesogenic environment may also 
inform novel anti-obesity therapeutic targets. The fact that body weight is a trait that is genetically, 
physiologically, and biologically controlled should enhance the empathy of the general public and of 
physicians treating obese patients. The development and intractability of obesity is not solely due to a 
lack of “will power,” “self control,” or “poor lifestyle choices.” 
 
The Prader-Willi Syndrome, a Syndromic Obesity 
Prader-Willi syndrome (PWS) is a syndromic obesity (Table 1.1) caused by a loss of paternally 
expressed genes on 15q11.2-13 (Figure 1.1) (38). The hallmark phenotype of PWS is hyperphagic 
obesity; however, patients initially present with neonatal hypotonia and infantial hypophagia. Individuals 
with PWS also have hypogonadotropic hypogonadism, decreased linear growth and low circulating GH, 
global developmental delay, cognitive impairment, hyperghrelinemia, relative hypoinsulinemia, 
hypoadrenalism, and hypothyroidism.  
 
The Genetic Basis of Prader-Willi Syndrome  
 At the most basic level, Prader-Willi syndrome (PWS) is caused by a loss of paternally expressed 
genes on 15q11-13 (38). There are four major genetic mechanisms by which paternal gene expression can 
be lost on 15q: (1) paternal deletion on 15q11-q13, (2) maternal uniparental disomy (UPD) 15, (3) 
imprinting defects, and (4) very rarely chromosomal rearrangements disrupting PWS region paternal gene 
expression (38). 
The most common genetic cause (~70%) of PWS is a de novo 5-7 Mb deletion on paternal 
15q11-q13 (38). The common breakpoints are flanked by multiple copies of tandem repeats; these low 
copy tandem repeats (250-400 kb) are subject to homologous pairing during meiosis which can result in 
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deletions (38). About 25% of PWS patients have maternal uniparental disomy 15; although two copies of 
the PWS region genes are inheritied, genes normally expressed from the paternal chromosome are 
silenced due to maternal DNA imprinting (38). UPD 15 typically arrises from an error in meiosis causing 
two maternal chromosome 15’s to be contributed to the egg (38). If this egg is fertilized by a normal (with 
respect to chromosome number) sperm, the zygote will have 47 chromosomes (38). This typically causes 
miscarriage due to trisomy 15 (38). However, in some instances, trisomy 15 rescue can occur in which 
one of the chromosome 15’s is lost from the trisomic cell. If the lost chromosome is the paternal 
chromosome 15, then UPD 15 results (38). Imprinting center defects (~1-3%) can occur due to 
incomplete erasure of the maternal DNA imprint during spermatogenesis or from a de novo or inherited 
microdeletion of the DNA imprinting center (38). An inherited microdeletion can be contributed from the 
paternal grandmother to the father (38). In this instance, there is a 50% chance of having another child 
with PWS (38).  
The most common diagnostic test for PWS analyzes DNA methylation levels at the SNRPN gene 
from genomic DNA extracted from peripheral blood (39). The SNRPN gene is used for this test because 
of its differentially methylated CpG island. The genomic DNA is treated with sodium bisulfate which 
converts unmethylated cytosines to uracil; treated DNA is subjected to a multiplex PCR reaction using 
fluorescently tagged primers amplifying either the uracil-containing SNRPN CpG island (not methylated) 
or the cytosine-containing SNRPN CpG island (methylated) (40). If the uracil-containing product (not 
methylated) is absent but the cytosine-containing product (methylated) is present, PWS (in context of 
clinical status) can be diagnosed (40). This assay cannot distinguish between genetic subtypes of PWS 
and will not diagnose microdeletions on 15q11-13 as it only tests the SNRPN gene (40). Methylation-
specific multiplex ligation probe amplification assays (MS-MLPA) can distinguish between, Type 1 or 
Type 2 large deletion (see below) and UPD, the most common causes of PWS (40). 
Type 1 and Type 2 deletions are the most common mutations in PWS, and differ in their proximal 
breakpoint (Figure 1.1) (41). Breakpoints 1 and 2 are separated by ~500 - ~720 kb (42). Although exact 
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breakpoints vary among individuals, breakpoint 1 clusters proximal to the D15S541 locus (42). 
Breakpoint 2 clusters between the D15S541 and D15S543 loci (42). Distal breakpoint 3 is located 
between D15S1002 and D15S1048 loci (43). About 4.2 Mb separates BP2 and BP3. Within that region 
reside four protein coding non-imprinted genes, TUBGCP5, CYFIP1, NIPA1, NIPA2 (41). In the PWS 
deletion region of both Type 1 and Type 2 deletion patients are 6 imprinted, protein coding genes, 
expressed only from the paternal chromosome: MKRN3, MAGEL2, NECDIN, C15ORF2, SNURF, and 
SNRPN (41). Also included in the PWS deletion region are 5 imprinted, paternally expressed single copy 
snoRNA genes including SNORD116 (41). UBE3A and ATP10A are two maternally expressed genes also 
between breakpoints 2 and 3; the loss of UBE3A is sufficient to cause Angelman Syndrome. GABRB3, 
GABRA5, GABRG3, OCA2, and HERC2, are non-imprinted protein coding genes also found in the 






Figure 1.1: The PWS genetic locus on chromosome 15q11-13. Type 1 and Type 2 “large” paternal 
deletions are the most common cause of Prader-Willi syndrome. As there are multiple paternally-
expressed genes in the deletion interval, identification of a unifying molecular mechanism for the disease 
has proven challenging. Identification of individuals harboring microdeletions displaying all major PWS 
disease phenotypes have narrowed down the causative region to a locus containing 3 paternally-





Microdeletions Causing PWS 
Five paternal microdeletion (118-237 kbp) PWS patients have been identified (44-48). The 
overlap among these patients’ paternal deletion region identifies a 91 kb minimum critical deletion region 
sufficient to cause the major physical and neuroendocrine phenotypes of PWS (Figure 1.2). This region 
contains three non-coding RNA genes: SNORD109A, SNORD116, and IPW. SNORD109A is 100% 
homologous to SNORD109B which is 3’ of SNORD115 and is not included in the deleted region of any of 
the four microdeletion patients (44-48). By virtue of a non-deleted copy, SNORD109A deficiency is not 
the likely molecular candidate for PWS. All PWS microdeletion patients present with the major PWS 







Figure 1.2: The minimum critical deletion region sufficient to cause the major phenotypes of 
Prader-Willi syndrome. The overlap among the five identified PWS microdeletion patients identified a 












Sahoo et al. 
2008 
Patient 3: 
de Smith et 
al. 2009 
Patient 4: 
Duker et al. 
2010 
Patient 5: Bieth 
et al. 2015 
BMI 46 n/a 39 50 
31 (BMI z-score 
+2.2 at age 14) 
Hyperphagia Yes Yes Yes Yes Yes 
Food Foraging Yes n/a n/a Yes Yes 
Obesity Yes Yes Yes Yes Yes 
Neonatal feeding difficulty Yes Yes Yes Yes Yes 
Neonatal hypotonia Yes Yes Yes Yes Yes 
Low GH n/a n/a Yes Yes n/a 
Hypogonadism n/a Yes Yes Yes Yes 





















Skin Picking Yes n/a Yes No Yes 
Hyperghrelinemia n/a n/a n/a n/a Yes 











shaped upper lip 


















Scoliosis mild No No No No 
Seizure Activity Yes n/a n/a Yes n/a 
n/a = not assessed 
 
The Clinical Presentation and Endocrinopathies of Prader-Willi Syndrome 
The clinical presentation of an individual with Prader-Willi syndrome begins in infancy with poor 
muscle tone and feeding difficulties (Tables 1.3 – 1.4) (39). Miller and Driscoll have followed the natural 
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history of a large cohort of individuals with PWS over many years and have identified several distinct 
“nutritional phases” (Table 1.4). As infants, PWS patients exhibit failure to thrive, and often cannot feed 
without the assistance of a feeding device (Nutritional phase 1) (39). By the age 25 months patients are 
growing at a normal rate; it is not until about 4.5 years of age on average that patients exhibit a markedly 
increased interest in food (Nutritional phase 2) (49). Around 8 years of age, PWS patients typically enter 
nutritional phase 3 of the disease, and become profoundly hyperphagic. In nutritional phase 3, PWS 
patients are constantly thinking about food and report reduced levels of satiety, even immediately after 
finishing a meal (49). While consuming a meal, PWS patients typically are already thinking about the 
next meal (49). Individuals with PWS remain in phase 3 for the duration of their adult lives (49). Obesity 
of PWS patients can be treated by strict dietary measures, including the installation of locks on cabinet, 
refrigerator, and pantry doors (49).  
Some patients with PWS have undergone various bariatric surgery procedures in order to reduce 
obesity. However complications, including stomach rupture from overeating, are high and weight loss 
success rates from are lower than that of BMI-matched controls (50). At this time, bariatric surgery is not 
a recommended approach to treat the disease (50). There are currently no FDA-approved therapies to 
ameliorate the hyperphagic obesity in PWS. Obesity and its related complications are the major cause of 
morbidity in individuals with PWS. 
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Table 1.3: Holm Criteria for PWS Diagnosis & Correlation with PWS Genotype (Adapted from: 
Holm et al, 1993; Cassidy & Driscoll, 2009). For children ≤3 y/o five points are required for diagnosis 
and four must be from the major group; for individuals >3 y/o through adulthood, eight points are 
required for diagnosis, at least five points must be from the major group. 
 
Symptom Description Holm Points 
Characteristic facial Features Narrow bifrontal diameter, almond-shaped palpebral 
fissures, narrow nasal bridge, thin upper lip, downturned 
mouth 
1 pt 
Neonatal and infantile hypotonia, 
poor suck 
Improves with age 1 pt 
Feeding problems, poor weight 
gain in infancy 
Special feeding techniques used 1 pt 
Weight gain, rapid onset at 1-6 
years 
May be controlled by caloric restriction and daily exercise 1 pt 
Hypogonadism, hypogenitalism Genital hypoplasia, incomplete and delayed puberty, 
infertility 
1 pt 
Global developmental delay Delayed motor milestones, delayed language development 1 pt 
Chromosomal abnormality in 
15q11-q13 region 
5-7 Mb deletion, maternal uniparental disomy, 
microdeletion of HBII-85/HBII-52, imprinting disorder 
1 pt 
Hyperphagia Obsession with food, food foraging, may steal food, may 
have pica behavior 
1 pt 
Hypopigmentation Fair hair, eyes, skin for family ½ pt 
Decreased saliva volume Leads to dry mouth, thick and viscous saliva, dental 
caries, possibly contributes to articulation problems 
½ pt 
Short stature Considering genetic background by age 15 (in the absence 
of hGH therapy) 
½ pt 
Skin picking May lead to infection, chronic open wounds, scarring ½ pt 
Small hands and/or feet,  Short total hand, <25th percentile for hands, short feet 
with short toes, <10th percentile for feet, present by 10 
years of age unless growth hormone treated 
½ point 
Narrow hands, straight ulnar 
border 
narrow palm with hypoplastic hypothenar bulge ½ pt 
Reduced fetal movement, 
infantile lethargy 
Improves with age ½ pt 
Behavior problems Temper tantrums, obsessive compulsive behavior, 
stubbornness, rigidity, stealing, lying 
½ pt 
Short sleep duration, sleep apnea  ½ pt 
Eye abnormalities  Myopia, strabismus, esotropia ½ pt 
Speech articulation defect  ½ pt 
Scoliosis and/or kyphosis Can occur at any age, beginning in infancy, may require 
surgery 
AF 
Hip Dysplasia May be undetected due to hypotonia AF 
Osteopenia/Osteoporosis May cause increased fracture rate AF 
Seizures Generally easily controlled AF 
High Pain Threshold May lead to decreased recognition of severe injury or 
illness 
AF 
Decreased or inability to vomit Some never vomit, vomiting often reflects very serious 
illness 
AF 
Easy bruising No known cause AF 
Altered temperature perception 
and regulation 
Altered perception of ambient temperature; occasionally 
infantile hypothermia, fevers of unknown origin 
AF 
Early adrenarche In contrast to holm major criteria of late onset of puberty AF 
Unusual skill with jigsaw 
puzzles 
 AF 
Normal neuromuscular features  AF 





Table 1.4: Nutritional Phases of Prader Willi Syndrome (Adapted from: Miller et al. 2011). 
Nutritional Phase Description Age Experienced 
Phase 0 Decreased fetal movement, lower 
birth weight 
in utero 
Phase 1a Hypotonia, difficulty feeding 0-9 months 
Phase 1b No difficulty feeding, normal 
growth 
9 – 25 months 
Phase 2a Growing above what is predicted 
by growth curve, no perceived 
increase in appetite or excessive 
calories 
2.1 – 4.5 years 
Phase 2b Weight continues to increase, 
appetite continues to increase 
4.5 – 8 years 
Phase 3 Hyperphagia 8 years - adulthood 
 
 
 Although hyperphagic obesity is the hallmark phenotype of Prader-Willi syndrome, there are 
many other phenotypes that accompany the disease. Individuals with PWS also have hypogonadotropic 
gonadism, global developmental delay (delayed motor milestones and delayed language development), 
decreased linear growth with low growth hormone, and cognitive disability. Human recombinant growth 
hormone (hGH) supplementation is an FDA approved treatment for PWS (39). Long term hGH treatment 
can lower plasma lipid levels, decrease percent body fat, increase height, and increase strength and agility 
in individuals with PWS (39). However, hGH treatment does not resolve the hyperphagia nor obesity of 
PWS patients (39).  
Hyperghrelinemia preceding the onset of obesity is a unique clinical feature of PWS that is not 
seen in common obesity or other syndromic or monogenetic obesities (51-57). GH-deficient patients and 
individuals with anorexia nervosa are also reported to have increased circulating levels of ghrelin (58). 
Ghrelin levels are reported to be 3 to 4 times higher than those of controls in PWS patients as young as 4 
months of age (52, 59). Treatment of individuals with PWS with long-acting octreotide (an antagonist at 
GHSR) significantly reduced circulating total ghrelin levels; however, there was no change in 
hyperphagia or body weight (60). It is also unclear if it is the mature, active ghrelin hormone that is 
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elevated in the circulation as the antibodies used in many total ghrelin ELISAs can detect both proghrelin 
and mature ghrelin (see Chapter 3). Furthermore, hyperghrelinemia in PWS can be detected during the 
failure to thrive period, thus it is unlikely that the high circulating ghrelin levels per se drive the 
phenotype. 
Due to its essential role in the regulation of body weight, circulating leptin levels were assessed in 
individuals with PWS; however, serum leptin levels in patients with PWS do not differ significantly when 
compared to patients with common obesity (i.e. controlled for adiposity) (61). PWS patients have about a 
25% reduction in circulating BDNF compared to adiposity-matched controls (62). Circulating BDNF is 
also reduced in individuals with common obesity compared to lean controls (62). PWS patients have also 
been reported by several groups to have relative hypoinsulinemia compared to age- and BMI-matched 
controls (38, 63). However, ~25% of individuals with PWS are reported to develop T2DM (64). 
Central adrenal insufficiency in response to metyrapone stimulation has been reported in 60% of 
individuals with PWS (65). Several sudden deaths have occurred following the start of recombinant GH 
therapy in PWS and there is a high rate of sudden death during acute illness, which may be associated 
with adrenal insufficiency (66, 67). Furthermore, three pediatric patients were found to have below-
average-sized adrenal glands upon autopsy (66). Hypothyroidism has also been reported in PWS patients, 
although estimates vary among studies. Butler et al. report that 2% of PWS patients had hypothyroidism, 
while Miller et al. report 19%, Vaiani et al. report 72% (68-70). Festen et al. found that 25% of children 
with PWS have hypothyroidism prior to starting GH treatment; this was not significantly affected by one 
year of recombinant GH therapy (71). 
 
The Molecular Genetics of Prader-Willi Syndrome 
 Many studies have been conducted on post-mortem brain tissue from Prader-Willi 
syndrome patients; interpretation of the results from these studies are limited by small sample size, 
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variability between subjects, and possible death-related complications. Nonetheless, Gabreels et al., 
identified reductions in PC2 as well as its chaperone, 7B2, by immunohistochemistry in post-mortem 
hypothalamic PVN and SON of individuals with PWS (72). Furthermore, the hypothalami of these 
subjects showed reduced staining for processed vasopressin, but all five studied PWS patients showed 
robust staining for provasopressin (72). A small decrease in PC1 staining was found in the SON and PVN 
as well (72). A -1.5 fold-change downregulation of NHLH2 was identified by whole genome microarray 
analysis of lymphoblast RNA from individuals with PWS compared to controls (73). NHLH2 is a 
transcription factor that promotes transcription of PCSK1 and PCSK2 (74). Nhlh2 null mice are obese and 
hypogonadal (75). Human patients and mice hypomorphic for PCSK1 are obese; PC1 and PC2 often work 
together to process prohormones (76). 
Decreased neuronal nucleolar size is also observed in Purkinje neurons from human PWS brain 
tissue compared to unaffected controls (77). A PWS mouse model with loss of PWS region paternal gene 
expression also displays a reduction in the diameter of Purkinje neuron nucleoli. Increased and more 
numerous neuronal nucleoli are observed in a mouse model in which the maternal imprinting center is 
deleted and PWS region genes are expressed from both maternal and paternal alleles (77). Consistent with 
cellular-level structural defects in PWS neurons, tissue-level structural changes have also been reported in 
PWS patient brains. MRIs show ventriculomegaly in 100% of PWS patients scanned, decreased volume 
of brain tissue in parietal-occipital lobe (50%), sylvian fissure polymicrogyria (60%), incomplete insular 
closure (65%), and decreased cerebellar volume (78, 79). These data suggest that PWS region genes play 
important roles in the developing and mature brain. 
In a study of five post mortem PWS subject brains, the total number of cells in the PVN was 38% 
less than that of control brains (80). Furthermore, the volume of oxytocin-expressing neurons in the PVN 
was 54% lower than that of controls (80). Oxytocin receptor knockout mice develop obesity past 12 
weeks of age (81). Oxytocin knockout mice have similar body weights to wild type, but do display 
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increased intake of sweetened beverages in comparison to wild type (82). Loss of these neurons may 
contribute to an imbalance of orexigenic signaling in the PWS brain.  
Differential serotonin receptor expression in the brain has also been reported from post mortem 
analysis of patients with PWS (83). PWS patients have higher hippocampal levels of fully edited 
serotonin receptor 5-HT2cR (83). Specifically, SNORD115 contains sequence complementarity to a 
portion of “exon Vb” of 5-HT2cR and can regulate pre-mRNA splicing of 5-HT2cR by binding to a 
silencing element in exon Vb (83). Loss of SNORD115 results in increased levels of the the fully edited, 
less functional, serotonin receptor 5-HT2cR (83). Serotonin is synthesized in the brainstem and is 
expressed in the arcuate, paraventricular, and lateral nuclei of the hypothalamus (84). In humans, 
hypothalamic levels of serotonin are inversely correlated with body weight (85). Four asymptomatic 
individuals from Angelman syndrome families have been identified with paternal deletions encompassing 
all of SNORD115 and SNORD109B, but not SNORD116 and other PWS region genes (86). All four 
patients are asymptomatic and do not have PWS (86). Furthermore, SNORD115 is not included in the 
PWS minimum critical deletion interval (Figure 1.2). Deletion of SNORD115 is not sufficient to cause 
Prader-Willi syndrome nor is its deletion necessary to cause Prader-Willi syndrome. 
SNORD109A is one of the three genes in the PWS minimum critical deletion region (Figure 1.2). 
SNORD109A is 100% homologous to SNORD109B. The four asymptomatic Angelman syndrome family 
members were essentially “heterozygous” for SNORD109, as they lost one of two expressed copies of the 
gene. Four of the five PWS microdeletion patients are also “heterozygous” for SNORD109 as they two 
have lost one of two copies of this gene. Because one group of SNORD109 heterozygotes are 
asymptomatic, this further supports the argument that SNORD109 is not likely a major driver of the PWS 
phenotype. SNORD109 is also not conserved among mammals - there is no SNORD109 gene in mice - 
further supporting its likely inessential role in PWS. 
19 
 
IPW is a paternally expressed, long non-coding RNA initially identified by Rachel Wevrick and 
Uta Francke in 1994 (87). IPW is alternatively spliced to multiple copies of a 147 bp repeat that are 
arranged in a head-to-tail orientation and interrupted by insertion of an intracisternal A particle sequence 
(88). It is one of the three paternally expressed, non-coding RNA genes in the PWS minimum critical 
deletion region (Figure 1.2). Since then, only one publication has focused on the molecular genetics of 
IPW. Benvenisty and colleagues performed RNA sequencing on induced pluripotent stem cells (iPSCs) 
from PWS patients, WT embryonic stem cells (ESCs), and parthenogenetic ESCs (containing only 
maternal genetic material) and found that maternally-expressed genes in the DLK-DIO3 region of 
chromosome 14 were upregulated in PWS iPSCs and parthenogenetic ESCs (89). Although the authors 
did not measure expression of these genes in stem cell-derived neurons, qRT-PCR from post-mortem 
cerebrum brain tissue identifies that MEG3, MIR370, and MIR409, which are DLK-DIO3 region genes, 
are upregulated in PWS patient neural tissue (89). Overexpression of IPW downregulates DLK-DIO3 
region genes associated with enrichment of the repressive chromatin mark, H3K9me3, in this region (89). 
In PWS iPSCs and parthenogenetic ESCs H3K9me3 chromatin marks were reduced compared to WT 
ESCs (89). While IPW is well conserved among primates (human, chimpanzee, gorilla, orangutan, rhesus, 
marmoset) there is low homology between primates and mouse (88, 89). This may limit the utility of a 
mouse knockout model to further investigate physiological functions of Ipw in vivo. However, other 
technologies, such as CRISPR/Cas9-induced deletion in ESCs to create an “isogenic” deletion model of 
IPW that can be investigated in hypothalamic stem cell-derived neurons could be utilized to further 
investigate potential contributions of this gene to the PWS phenotype (see discussion/future directions 
section for further detail). 
 
Mouse Models of PWS 
More than a dozen mouse models of Prader-Willi syndrome have been generated; to date none 
recapitulate the hyperphagic obesity characteristic of individuals with PWS (90). Several PWS large 
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deletion mouse models have been generated and they do not survive past one week of age (90). Ndn is 
important for neuronal differentiation and maturation (90). Necdin over-expression in PC-12 cells 
accelerates neurite extension in response to NGF, while embryos null for Ndn have impaired axonal 
elongation and reduced innervation of target organs (90). Immunohistochemistry analysis of Ndn
-/-
 
hypothalami identified a 30% reduction in the number of oxytocin-expressing neurons in the PVH and a 
25% reduction of LHRH-expressing neurons in the preoptic area (90). Necdin can also interact with 
TrkA, the p75 neurotrophin receptor; Ndn-knockout mice have increased pain tolerance, a phenotype of 
some individuals with PWS (90). Knock-down in Ndn also reduces GnRH expression (90). However, four 
independent models of Ndn null mice have been generated and they are fertile, do not have growth 
deficiencies, and do not develop obesity (90). Two patients with paternal deletions encompassing 
MKRN3, MAGEL2, and NDN are not hyperphagic nor obese and do not have Prader-Willi syndrome (91, 
92). One of the MKRN3, MAGEL2, NDN-deletion patients had developmental delay and impaired 
cognitive function while the other had delayed motor skills and was otherwise asymptomatic, indicating 
that deletion of NDN, MAGEL2, and MKRN3 are not sufficient to cause PWS (91, 92). Paternal deletion 
of NDN, MAGEL2, and MKRN3 is also not necessary to cause PWS (Figure 1.2).  
POMC is an anorexigenic neuropeptide produced in the arcuate nucleus in response to leptin 
signaling. POMC and the melanocortin receptor MC5R are significantly upregulated in a paternal 
imprinting center deletion mouse model of PWS (73). Because these mice die 2-3 days after birth, whole 
brain RNA was collected for microarray analysis at postnatal day 1 (73). POMC-derived MSH products 
are known anorexigenic agents acting in arcuate, paraventricular, ventromedial, and lateral nuclei of the 
hypothalamus. MC5R is involved in stress response and thermoregulation (73). The upregulation of these 
products may be secondary effects to other molecular derangements in these animals.  
 
Allele-specific, Dynamic Regulation of PWS Region Chromatin 
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Consistent with allele-specific transcription, in neurons, the PWS locus paternal allele chromatin 
is highly extended and decondensed, while the maternal allele chromatin remains compact. The chromatin 
decondensation at the PWS locus on the paternal allele is developmentally regulated in neurons with 
increasing decondensation from E15 to P70 in the mouse brain (77). This is associated with increased 
signal intensity from an RNA FISH probe against Snord116 snoRNAs. From P1 to P14 as the paternal 
Snord116 snoRNA signal increases nuclear radius and nuclear diameter also increase (77). Transcription 
is required for paternal PWS locus decondensation as treatment with α-amanitin condenses chromatin in a 
dose-responsive manner (77). Similar decondensation phenomena are seen at the Gtl2 locus, another 
imprinted region of the genome containing snoRNA clusters (77). Decondensation to this degree was not 
observed in other imprinted loci or other highly expressed neuronal genes in the mouse (77). 
 
The Molecular Genetics of Magel2, a PWS Region Gene 
While patients with deletions encompassing MKRN3, MAGEL2, NDN have not been diagnosed 
with autism spectrum disorder, whole exome sequencing has recently identified truncating mutations in 
MAGEL2 associated with developmental delay, cognitive impairment, autism spectrum disorder, 
hypotonia, and feeding difficulties (93, 94). This has recently been called “Schaaf-Yang syndrome” (93). 
Eighty two percent of individuals with truncating mutations in MAGEL2 have arthrogryposis, a 
phenotype rarely reported in Prader-Willi syndrome (93). Hyperphagic obesity is not a consistent 
phenotype among patients, 35% are reported to have hyperphagia and 47% are classified as having 
“excessive weight gain” (93). Against the background of increased rates of pediatric obesity in the general 
population, 47% of MAGEL2 mutant individuals having “excessive weight gain” without further 
classification of BMI z-scores obscures inferences as to the role of MAGEL2 in human obesity. 
Magel2-null (different model from Magel2-KO described earlier) mice have been extensively 
studied by Rachael Wevrick and colleagues. Male Magel2-null mice weigh slightly less than WT 
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littermates at 4 weeks of age, but from 4 weeks to 16 weeks of age there is no statistically significant 
difference in body weight compared to WT littermates (95). Sixteen week old male Magel2-null mice do 
have increased adiposity compared to WT littermates (95). Female Magel2-null mice weigh slightly more 
than WT littermates (~1-2 grams) from 7 to 16 weeks of age (95). Magel2-null mice also display 
abnormalities in circadian rhythm and a progressive decline in fertility in adulthood (90). Recently, 
Magel2 has been shown to be play a role in leptin-mediated depolarization of arcuate POMC neurons 
(96). In four week old Magel2-null mice, the POMC neurons respond normally to leptin, however by six 
weeks of age through adulthood there is a reduction in the percentage of POMC neurons responsive to 
leptin (96, 97).  
Magel2 has been shown to promote neurite outgrowth and a reduction the density of α-MSH 
fibers in the PVH of Magel2-null mice have been identified by two independent groups (97, 98). Adult 
Magel2-null mice are also insensitive to the anorexigenic effects of leptin and fail to decrease 24-hour 
food intake following peripheral administration of exogenous leptin (96). However, Magel2-null mice 
have increased sensitivity to the anorexigenic effects of MC4R agonists, MT-II and setmelanotide, 
suggesting that derangements in anorexigenic pathways may be confined to the first-order POMC neurons 
(96, 99). While deletions of or truncating mutations in MAGEL2 do not cause the complete PWS 
phenotype and do not cause severe hyperphagic obesity, hypomorphism for this gene might increase the 
risk of overweight/obesity in humans, consistent with the slight increases in adiposity and disturbances in 
leptin signaling in POMC neurons identified in mice. 
 
Deletion of Nhlh2 Causes Obesity in Mice 
Nhlh2 is a basic helix loop helix (bHLH) transcription factor expressed in the developing and adult 
mouse and human hypothalamus and pituitary (75). Nhlh2 regulates food intake, energy expenditure, 
reproductive processes, and body temperature (75, 100). Nhlh2 KO (N2KO) mice are obese, centrally 
23 
 
hypogonadal, and have a defective torpor response (75, 101). A SNP in the DNA binding domain of 
NHLH2 (NHLH2
83P
) is associated with obesity in humans (102).  
Nhlh2 colocalizes with 33% of Pomc-expressing neurons in the rostral arcuate nucleus and 41% of 
Trh-expressing neurons in the PVN (74). Nhlh2  is also expressed in GnRH-expressing neurons and 
Mc4r-expressing neurons (103, 104). Nhlh2 and Nhlh1/Nhlh2 compound knockout mice have fewer 
GnRH-expressing neurons than wild type mice (103). Nhlh1 is another bHLH transcription factor with 
some overlapping functionality to Nhlh2; however, Nhlh1 knockout mice are not obese. Transcriptional 
targets of Nhlh2 include: Pcsk1, Pcsk2, Mc4r Trh, and Ndn (103-106). Nhlh2 regulates Pcsk1 and Ndn 
gene expression through binding to E-box motifs in the Pcsk1 and Ndn promoter regions (105). Nhlh2 
and PStat3 act as a heterodimer to promote Pcsk1 transcription (105). Both Nhlh2 and PStat3 are 
necessary for a full Pcsk1 transcriptional response (105). N2KO mice have >50% reductions in Pcsk1 
transcript levels and PC1 protein levels (74). Likewise, the prohormone processing of POMC to αMSH 
and ACTH is impaired as well as prohormone processing of proTRH to TRH in N2KO mice (74).  
Nhlh2 is a nutrient, leptin, and cold responsive gene; Nhlh2 responds positively to increased energy 
availability and negatively to reduced energy availability (106). Nhlh2 decreases with food deprivation or 
cold exposure (101, 106). Whole brain Nhlh2 also increases with feeding or exogenous leptin 
administration following 24 hour fasting (106, 107). Nhlh2 transcript levels are decreased in the setting of 
deficient leptin signaling; ad lib ob/ob and db/db mice have reduced hypothalamic Nhlh2 levels compared 
to +/? littermates (108).   
Nhlh2 knockout mice develop obesity at 10 to 12 weeks of age (100). Interestingly, male N2KO mice 
initially have decreased body weight compared to WT littermates from 4-7 weeks of age and have 
increased body weight (are obese) by 12 weeks of age (100). Male mice that are heterozygous for Nhlh2 
as well as N2KO mice consume more calories than WT by 12 weeks of age (100). Between four to seven 
weeks of age there is not a statistically significant increase in food intake in N2KO mice, however, at this 
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age the mice weigh less than WT littermates, suggesting that the N2KO mice may be hyperphagic relative 
to body weight or lean mass (100). Energy expenditure is also dysregulated, N2KO mice have reduced 
voluntary activity compared to WT littermates (100). Furthermore, N2KO mice have smaller pituitary 
glands, the size reduction is apparently largely due to a reduction in the size of the anterior pituitary and is 
apparent by postnatal day 2 of life (109). The N2KO mouse growth patterns of initial runting with later 
development of obesity as well as the smaller pituitary size is remnisicent of the phenotype of individuals 
with Prader-Willi syndrome (38, 69). 
Chow fed mice in which Nhlh2 was deleted specifically in POMC neurons did not show any 
difference in body weight from control animals out to 24 weeks of age (110). There is also no 
hypogonadism or infertility in the Pomc-Cre/Nhlh2
Δloxp/Δloxp
 mice (110). There is a reduction in POMC 
processing to ACTH and αMSH in the Nhlh2
Pomc-/Pomc-
 mice; however there are cells that remain in which 
ACTH and αMSH are still produced (110). These results are similar to the knockout of LepR in POMC 
neurons only, which produces a much milder adiposity phenotype than the global knockout (111). It is 
also possible that the excision by the POMC Cre was inefficient in this setting or that Nhlh2 is not 
required for Pcsk1 expression in all POMC neurons (see next section for discussion of Pcsk1) (110). Npy-
Agrp-Cre/Nhlh2
Δloxp/Δloxp
 mice did not show any abnormalities in body weight regulation, visceral fat mass 
accumulation, and hypogonadism, compared with floxed controls (110). When Nhlh2 was deleted 
specifically from GnRH neurons, there was an increase in visceral fat mass; however, total body weight 
or food intake data were not reported (110). The number of GnRH neurons was also less in Deleter-
Cre/Nhlh2
Δloxp/Δloxp
 knockouts and these mice also have increased visceral fat (110). Interestingly, the 
number of POMC medial preoptic area (MPO) neurons in the MPO and posterior hypothalamus (PH) are 
reduced  in female GnRH-Cre/Nhlh2
Δloxp/Δloxp
 mice and there is a trend towards a reduction in number of 
POMC neurons in the ARC (110). In male mice GnRH-Cre/Nhlh2
Δloxp/Δloxp
 mice the number of POMC 
neurons in the ARC are reduced as well as number of MPO and PH neurons (110). Surprisingly, no 
hypogonadotropic gonadism was observed in the GnRH-Cre/Nhlh2
Δloxp/Δloxp





 mice (110). Reduction in the amount of POMC neurons was observed before visceral 
adiposity onset, suggesting that the loss of POMC neurons is not a secondary consequence of the visceral 
adiposity (110). Because the accumulation of visceral fat mass is quite mild in the Deleter-
Cre/Nhlh2
Δloxp/Δloxp
 mice and GnRH-Cre/Nhlh2
Δloxp/Δloxp
 mice and it is unclear what the effect was on total 
body weights, the exact molecular mechanism by which the loss of Nhlh2 causes obesity remains unclear. 
 
Prohormone Convertase 1 and Implications of Impaired Prohormone 
Processing on Body Weight 
Prohormone processing allows cells to increase the diversity of their gene products and can be carried 
out in a tissue-specific manner, further increasing gene diversity and product specificity. Prohormone 
processing also adds an additional, elegant level of regulation beyond transcriptional and translational 
control as the prohormones themselves are often (but not always) biologically inert or have reduced 
bioactivity (112).  
The proprotein convertases are a family of serine endoproteases that have homology to the bacterial 
substilisin and yeast kexin, hence many of the gene names are “proprotein convertase substilisin and 
kexin-like (PCSK)” (113). There are 9 members of this enzymatic family: PC1/3, (PCSK1), PC2 
(PCSK2), Furin (FURIN), PC4 (IFRD1), PC5 (PCSK5), PACE4 (PCSK6), PC7 (PCSK7), PCSK8 
(MBTPS1),and PC9 (PCSK9) (113). PC1/3 was initially cloned independently and around the same time 
by the Seidah and Steiner laboratories which is the reason for the “1/3” name, as the cloning of PC2 
occurred around the same time as well (113). For brevity, Prohormone convertase 1/3 will be referred to 
as PC1 in this document hereafter.  
PC1 and PC2 are specific to endocrine and neuroendocrine cells that contain secretory granules (114). 
They convert many peptide hormones from inactive, prohormones to active hormones. PC1 and/or PC2 
are known to process: proTRH, proinsulin, proenkephalin, prosomatostatin, proglucagon, proGHRH, 
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proGnRH, POMC, proNPY, proAgRP, proCART, proneurotensin, prorenin, pro-oxytocin, proghrelin, 
and others (76, 114, 115). PC1 and PC2 often work together to process propeptides, including POMC and 
proinsulin (114). PC1 itself is synthesized as a proprotein and autocatalyzes the removal of its pro-domain 
prior to exiting the endoplasmic reticulum (76). Synthesis of PC1 lacking a prodomain causes misfolding 
of PC1 in the ER and production of active enzyme is greatly diminished (76). Trans expression of just the 
pro-domain can partially rescue folding (76). PC1 can begin to cleave substrate at the start of the trans 
golgi network; however, PC1 cleavage efficiency increases in the acidic environment of the secretory 
vesicles, and this is where the most efficient processing takes place (76). PC1 preferentially cleaves at 
dibasic residues: Lys-Arg, Arg-Arg, Arg-Lys, or Arg-X-X-Arg (where X is any amino acid) (76). PC2 is 
more specific than PC1 and preferentially cleaves after Lys-Arg and Arg-Arg (76). PC1 can be inhibited 
by the chaperone protein proSAAS, while PC2 can be inhibited by the chaperone protein 7B2 (114). 
Processing within the secretory granule is generally carried out to near completion; pulse-chase 
experiments in AtT20 cells demonstrate that POMC is entirely converted to ACTH in secretory granules 
(112). The biolocially active peptides in the regulated secretory pathway are then secreted from the 
endocrine cell by exocytosis (114).  
The tissue-specific processing of proglucagon and POMC can result in preferential production of 
different products in different tissues. Pancreatic α-cells express PC2 but not PC1 and cleave proglucagon 
to glucagon, while the L-cells in the small intestine (primarily ileum) express PC1 and preferentially 
cleave proglucagon to the incretin, GLP1 (116). Both PC1 and PC2 are expressed in the hypothalamus 
and skin, resulting in preferential production of α-MSH in these tissues (115, 117). In the anterior 
pituitary, PC1 is expressed at much higher levels than PC2 and consequently ACTH is preferentially 
produced (117).  
Although processing within secretory granules themselves is thought to be carried out to completion, 
not all prohormones are processed with the same efficiency at the “whole cell” level (112). Proinsulin 
processing is highly efficient and there is typically about five times more insulin than proinsulin in the 
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circulation (112). On the other end, the processing of prorenin is much less efficient as only ~25-30% of 
prorenin is converted to renin (112). POMC processing is also inefficient. Pritchard and White propose 
that the unprocessed pro-peptides are instead secreted through the constitutive secretory pathway (in 
settings of PC1/PC2 sufficiency) (112). The “inefficiency” of prohormone processing may reflect an 
additional level of control such that additional prohormone is available for times of increased hormone 
demand.  
The neuroendocrine prohormone convertases are physiologically regulated by nutritional status, 
leptin, hyperglycemia, inflammation, and suckling (114). Leptin can increase PCSK1 and PCSK2 
promoter activity through a STAT3-dependent mechanism in 293T cells (114). For TRH, leptin can 
couple the upregulation of TRH transcription to increased proTRH processing (114). Likewise, 




 mouse models of 
obesity (112). POMC may be regulated by leptin in a similar manner; exogenous leptin administration 
can prevent the fasting-induced reduction in Pomc transcript levels and POMC processing, indicating that 
both POMC and PC1 are regulated by leptin (114).  
To date, 21 patients hypomorphic for PCSK1 have been identified. Hyperphagic obesity and impaired 
neuroendocrine prohormone processing are major features of the disease. Individuals with PCSK1 
mutations also present with hypogonadotropic hypogonandism, growth deficiency associated with low 
levels of circulating growth hormone, hypoadrenalism, diabetes insipidus, hyperproinsulinemia associated 
with hypoglycemia which can progress to type 2 diabetes later in life, and neonatal malabsorptive 
diarrhea (76). Seventeen out of seventeen patients with PCSK1 mutations for which BMI status was 
reported had early-onset, hyperphagic obesity; for the remaining four patients, BMI status was not 
reported (76).  
The first PCSK1 hypomorphic patient was described by O’Rahily et al., in 1995 (118). The patient 
presented with extreme childhood obesity, abnormal glucose homeostasis, hypogonadotropic 
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hypogonadism, hypocortisolism, elevated plasma proinsulin concentration with very low plasma insulin 
concentration, elevated plasma POMC concentration, and frequent diarrhea (76, 118). The patient was 
determined to be a compound heterozygote for inactivating mutations in PCSK1 (118). Jackson et al., 
described a second patient also compound heterozygous for inactivating mutations in the PCSK1 gene 
who was obese, hypoadrenal, had reactive hypoglycemia, elevated circulating levels of prohormones, and 
severe refractory malabsorptive diarrhea (119). A third patient from a highly consanguineous family was 
identified with a homozygous missense mutation Ser307Leu (120). This patient had severe childhood 
obesity despite persistent diarrhea and had no history of reactive hypoglycemia (120). This patient also 
had high levels of circulating POMC with normal levels of circulating ACTH, hypoinsulinemia, and low 
levels of circulating GLP-1 (120). A fourth PCSK1 hypomorphic patient was identified by the same group 
in 2013 and in the same year a cohort of thirteen PCSK1 mutation patients were published by Martin et 
al., identified by whole exome sequencing in a group of pediatric patients with malabsorptive diarrhea 
(121, 122). SNPs in PCSK1 (N221D (rs6232) and S690T (rs6235)) are associated with obesity risk in 
humans; PCSK1 N221D rs6232 is associated with childhood and adult obesity (123). Table 1.5 




Table 1.5: Phenotypes of PCSK1 mutation patients (adapted from Stijnen, et al. 2016. Endocrine 
Reviews). 




# Patients Not 
Reported in 
Hyperphagic Obesity (increased BMI, hyperphagia) 17 0 4 
Hypogonadotropic Hypogonadism (low FSH, low LH, 
low testosterone) 
7 9 5 
Decreased Linear Growth (low GH) 5 9 7 
Hypothyroidism (low TRH, high TSH, low free T4) 13 6 2 
Hypocortisolism (Normal ACTH, elevated ACTH 
precursors) 
12 4 5 
Malabsorptive diarrhea (mild villous atrophy, elevated 
progastrin and GLP-1 precursors, normal 
procalcitonin) 
21 0 0 
Abnormal glucose homeostasis (Increased proinsulin, 
low insulin, increased 65,64 des split proinsulin) 
15 5 1 
Polyuria/polydipsia (low serum osmolality) 7 12 2 
 





 mouse (124, 125). The PC1 null mice are normal weight at birth, but have postnatal 
growth retardation and by ten weeks of age weigh less than half that of WT littermates (124). The 
dwarfism of these animals is associated with impaired processing of proGHRH to GHRH (124). Northern 
blot analysis of hypothalamic RNA revealed a significant increase (160% of control) in Ghrh mRNA, 
which was also been seen in the little (hypomorphic for Ghrh) mouse (124). Pituitary growth hormone 
content is low and pituitary somatotrophs have shrunken, misshapen nuclei; liver Igf1 transcript is 
decreased compared to wild type littermates (124). Pomc mRNA levels were upregulated in whole 
pituitaries and POMC processing to ACTH was impaired, although blood corticosterone levels were 
normal (124). Hypothalamic levels of proAgRP are also elevated in Pcsk1
-/-
 mice (126). Impaired 
proinsulin processing as well as hyperproinsulinemia is also detected in the Pcsk1
-/-
 mice; however, 
glucose tolerance is normal (124). Furthermore, Pcsk1
-/-
 mice cannot process proghrelin to ghrelin and 
have increased levels of Ghrl mRNA in their stomachs (127). To date, circulating levels of ghrelin have 
not been measured in individuals or mice hypomorphic for PCSK1 or Pcsk1, respectively. Finally, 
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intestinal proglucagon processing is impaired and associated with poorly formed feces, although the 
prohormone candidate(s) responsible for the malabsorptive diarrhea phenotype remains unclear (124). 
Importantly, the runting of the Pcsk1
-/-
 mice may mask an obesity phenotype possibly due to 
developmental compensations occurring in the hypothalamus.  
Although, the dwarfed Pcsk1
-/-
 mice do not become obese, animals with a  spontaneous point 
mutation in Pcsk1 do exhibit hyperphagic obesity. Pcsk1
N222D
 are homozygous for an allele which reduces 
but does not totally ablate the catalytic activity of the mature PC1 protein (125). These mice are not 
runted and have normal levels of growth hormone as proGHRH is processed normally in these mice 
(125). Proinsulin to insulin processing is impaired while insulin sensitivity is normal but glucose handling 
is impaired (125). Plasma ACTH was slightly elevated in these animals (125). Plasma testosterone 
trended towards being low and the weights of the testes were reduced, suggesting partial hypogonadism 
(125). The obesity of these animals was caused by hyperphagia (increased food intake) there was a 45% 
reduction in the processing of POMC to αMSH (125). 
The impaired processing of POMC to αMSH is an obvious candidate for the hyperphagic obesity 
observed in human and animal models of PC1 deficiency; however, many hormones involved in food 
intake and energy expenditure are processed by PC1, including proAgRP, proNPY, POMC, and 
proCART. While levels of the anorexigenic αMSH are reduced in Pcsk1 hypomorphs, levels of the 
orexigenic ProAgRP are increased in Pcsk1 hypomorphs. Processing of AgRP is not necessary for its 
biological activity and ProAgRP has considerable activity at MC4R (115, 126). Without more specific 
models of PC1 deficiency as well as rescue experiments, it is difficult to tease out exactly which 





snoRNA Structure and Function 
Small nucleolar RNAs (snoRNAs) are trans-acting, non-coding RNA molecules; there are over 
200 snoRNA-containing loci in the human genome (128). Their name reflects the nucleolar localization 
pattern that was observed when they were first discovered, which was in contrast to the 
nucleocytoplasmic localization of their snRNA anologs (Figure 1.3) (128). They range from 60 to 300 
nucleotides in length. Most snoRNAs are located within introns of protein coding-genes (129). snoRNAs 
are then transcribed from pol-II transcribed pre-mRNA introns of protein-coding genes (129). They are 
processed out of intron lariats during splicing and likely are spared from degradation by association with 
proteins (129). A minority of snoRNAs, U3, U8, and U13 can be independently transcribed by pol-II with 
initiation from their own promoters (129). snoRNAs can be divided into two main classes, the box 
H/ACA snoRNAs and the box C/D snoRNAs (128). Traditionally, box H/ACA snoRNAs guide the 
pseudouridylation of ribosomal RNAs (rRNA), while box C/D snoRNAs guide the 2’-O-methylation of 
rRNA molecules (128). These chemical modifications are performed in conjunction with snoRNP protein 
molecules (128). The box C/D motif promotes the binding of fibrillarin, Nop56p, Nop58p, and 15.5 
KDa/Snu13p proteins to form the snoRNP complex (130). In this snoRNP complex, it is the snoRNA that 
guides selection of the correct target nucleotide species for methylation of the target’s 2’-hydroxyl group 
(130). The antisense element of the box C/D snoRNA binds to the target rRNA through Watson-Crick 
base pairing. The antisense element is 5 nucleotides upstream of the D or D’ box of the snoRNA (130). 
This brings the target rRNA close enough that fibrillarin can catalyze the 2’-O-methyl transfer (130). 
Recent studies have  identified localization patterns of snoRNAs that extend beyond the nucleolus 
(128). snoRNAs that modify the small nuclear RNAs are localized in Cajal bodies, not the nucleolus 
(130). Furthermore, exciting work from Jean E. Schaffer’s group has shown that during metabolic stress, 
such as lipotoxic cell culture conditions, the snoRNAs U32a, U33, and U35a, localize in the cytoplasm 
not the nucleolus (131). The non-nucleolar localization of snoRNAs suggests that these molecules may 
have novel functions outside the nucleolar modification of nascent rRNAs (Figure 1.3).  
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 As noted,  Jean E. Schaffer and colleagues have identified novel functions for snoRNAs in the 
regulation of metabolic stress and cholesterol trafficking (132). The group used retroviral promoter trap 
mutagenesis to identify a cell line resistant to lipotoxic stress (132). They found that the protein-coding 
rpL13a allele was disrupted in this line (132). From the introns of rpL13a, four snoRNAs are encoded: 
U32a, U33, U34, and U35 (132). Knockdown of just U32a, U33, and U35 was sufficient to protect cells 
from lipotoxic culture conditions as well as general metabolic stressors, such as H2O2 (132). As 
mentioned, they found that these snoRNAs accumulate in the cytoplasm of C2C12 cells following 
exposure to palmitic acid (132). Furthermore, U32a, U33, and U35 were significantly upregulated in liver 
of WT mice injected with lipopolysaccharide (LPS) (132). Knockdown of these snoRNAs prior to LPS 
injection reduced levels of oxidative stress in the liver (132). In the mutant “6F2” cells haploinsufficient 
for rpL13a and thus U32a, U33, U34, and U35 there was no change in methylation of rRNAs predicted to 
be targets of the rpL13a locus snoRNAs, suggesting that the snoRNAs contribute to the regulation of 
oxidative stress through novel mechanisms (132). 
 Using the same retroviral promoter trap mutagenesis technique a different cell line was identified 
that had defects in cholesterol trafficking from the plasma membrane to the endoplasmic reticulum, based 
on its resistance to amphotericin B (133). The cell line had reduced plasma membrane cholesterol 
esterification and increased de novo cholesterol synthesis; it was found that this cell line was 
haploinsufficient for a gene hosting the U60 snoRNA (133). Overexpression of the U60 locus rescued the 
phenotype but overexpression of a modified U60 locus containing point mutations in the U60 snoRNA 
did not (133). Furthermore, knockdown of just the U60 snoRNA recapitulated the impaired cholesterol 
trafficking phenotype (133). U60 forms a snoRNP complex containing the canonical proteins and is 
known to have complementarity to 28S rRNA (133). However haploinsufficiency of U60 snoRNA did 
not cause reduced G4340 methylation of 28S rRNA, suggesting that the mechanism by which U60 
regulates cholesterol trafficking is independent of its rRNA methylation activities (133). Another 
snoRNA, U17, has also been identified through a mutational screen to regulate cholesterol trafficking 
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(134). The hypoxia-upregulated mitochondrial movement regulator (HUMMR) mRNA is negatively 
regulated by U17 snoRNA (134). Knockdown of U17 in mouse ovaries upregulates HUMMR and 
increases the steroid hormone synthesis (134). Again, haploinsufficiency for U17 snoRNA does not affect 
18S rRNA maturation, suggesting that the mechanism by which U17 regulates HUMMR is independent 
of rRNA modification (134). 
 Viral double stranded RNA can activate Protein kinase RNA-activated (PKR), activated PKR can 
in turn phosphorylate eukaryotic initiation factor 2 (135). Obesity and ER stress can also activate PKR 
and inhibition of PKR improves glucose metabolism in obese mice (135). Activation of PKR by 
metabolic stressors suggests that it is activated by endogenous rather than viral RNAs (135). Cell culture-
based screens designed to identify endogenous activators of PKR followed by RNA 
immunoprecipitations and high throughput sequencing found that 90% of the candidate genes were 
snoRNAs (135). UV-C crosslinking immunoprecipitation for PKR followed by qRT-PCR confirmed that 
SNORD113, SNORA70, SNORA46, SNORA3, SNORA26, and SNORA20 physically interacted with PKR 
and were enriched following metabolic stress (palmitic acid treatment) (135). Gel shift assays 
demonstrated that PKR can also interact with SNORD113 in vitro (135). SNORD113 and other snoRNAs 
were also shown to induce phosphorylation (activation) of PKR in vitro (135). Finally, exogenous 
expression of SNORD113 can also activate PKR in cells and in lysates (135). There was no enrichment of 
rRNA or snoRNP proteins in the PKR-pull down products, suggesting that these snoRNAs activate PKR 
independently from their function in or association with snoRNP complexes (135). The cellular 
localization of snoRNA-mediated PKR activation remains unclear; PKR is located in the cytoplasm and 
nucleus and palmitic acid treatment does not induce significant translocation detectable by 
immunofluorescence (135). Further studies are needed to further address the cellular location(s) of this 
novel interaction.  
 Expression levels of multiple snoRNAs have also been identified as biomarkers for several 
cancers including chronic lymphocytic leukemia and multiple myeloma (136, 137). Specficially, 
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SNORD115 and SNORD116 are upregulated in malignant plasma cells from multiple myeloma patients 
(136). The upregulation was not associated with a loss of maternal DNA imprinting; the molecular 
mechanism causing the upregulation of SNORD115 and SNORD116 is not known. Furthermore, 
SNORD50A and SNORD50B have been identified as being recurrently deleted in 10-40% of 12 common 
human cancers (138). SNORD50A/B can directly bind to K-Ras (138). Deletion of SNORD50A and 
SNORD50B increases levels of GTP-bound, active K-Ras, hyperactivates Ras-ERK1/ERK2 signaling, 
and increases levels of prenylated K-Ras (138). Deletion of SNORD50A and SNORD50B by 
CRISPR/Cas9 in KRAS mutant cells and other tumorigenic cell lines with intact K-Ras signaling 
increased tumor growth in vivo (138). Increased tumorigenesis was associated with increased levels of 
phosphorylated ERK in SNORD50A and SNORD50B deleted tumor cells (138). In the aggregate, these 








Figure 1.3: The biosynthesis, canonical, and non-canonical functions of snoRNAs. (Image 
adapted from: Manuel Esteller. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011.)  The 
canonical function of snoRNAs is in the modification of nascent rRNAs and snRNAs. However, many 
recent studies have identfied novel roles for snoRNAs in diverse cellular processes that appear to be 
independent of their role as modifiers of rRNAs. 
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SNORD116 – An Orphan snoRNA Gene Cluster and Candidate Gene for the 
Prader-Willi Syndrome 
SNORD116 is a noncoding RNA gene cluster that contains three classes of noncoding RNA 
molecules: (1) box C/D snoRNAs, (2) long non-coding RNAs with snoRNA ends (sno-lnc RNAs), and 
(3) a long noncoding RNA, referred to as 116HG (Figure 1.4). There are 30 copies of box C/D snoRNA 
encoded from the SNORD116 gene cluster that are 85% homologous to one another (Figure 1.5). There 
are no known rRNA targets for SNORD116 snoRNAs. The encoded snoRNAs from human SNORD116 
are highly homologous to the encoded snoRNAs in mouse, however, there are about 40 snoRNA copies 
encoded from Snord116. The SNORD116 snoRNAs localize to the nucleolus, although cytoplasmic 
localization has not been definitively ruled out (77). The five sno-lnc RNAs encoded from SNORD116 
localize to the nucleus not the nucleolus and do not display homology to one another (139). Due to 
species-specific splicing, these are transcribed in human and rhesus but not in mouse (139). The long 
noncoding RNA, 116HG, is ~200 nucleotides in length and is transcribed from several different “introns” 
(meaning regions of SNORD116 that do not encode for snoRNAs) of the SNORD116 transcript, which are 
alternatively spliced to produce 116HG lncRNA (140).  The mouse 116Hg is highly homologous to 
human (140). 116Hg localizes to the nucleus, not the nucleolus (140). 
The human hypothalamus mainly expresses box C/D type snoRNAs (141). Human and mouse 
box C/D snoRNA cluster, SNORD116 are most highly expressed in the brain but lower-level expression 
can be detected in most peripheral tissues, particularly endocrine tissues (141). In situ hybridization 
studies for Snord116 expression in mouse brain found that at P0 Snord116 is expressed widely throughout 
the brain at low levels (142). Expression becomes more restricted to the hypothalamic ARC, PVN, and 
VMH and expression levels within these nuclei increase at weaning (P19); this expression pattern persists 
into adulthood (142). RNA sequencing across various various human tissues showed that within the 
hypothalamus, “group I” (SNORD116-1 through SNORD116-9) snoRNAs are expressed 23-fold higher 
than “group II” (SNORD116-10 through SNORD116-24) and 60-fold higher than “group III” 
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(SNORD116-25 through SNORD116-30) snoRNAs (141). Although this is speculation, it is possible that 
there is tissue-specific expression of the different SNORD116 with group II and/or group III snoRNAs 
being expressed more highly in other, non-CNS tissues than group I.  
The snoTARGET algorhthm searched the human transcriptome for complementary targets of 
SNORD116 snoRNA antisense elements (143). SNORD116 snoRNAs were found to “prefer” exons 
relative to introns and the targets were more likely to be located close to splice junctions (143). NTRK2, a 
BDNF receptor has antisense complementarity to SNORD116-23 (143). A patient heterozygous for a de 
novo missense mutation in NTRK2 presented with hyperphagic obesity, high pain threshold, infantile 
hypotonia, and developmental delay (144). RNA sequencing performed by myself and colleagues of 
iPSC-derived neurons from PWS patients compared to unaffected control did not identify alterations in 
NTRK2 expression levels or splicing patterns (data not shown). Finally, although it has been suggested 
that SNORD116 and SNORD115 snoRNAs may be processed into smaller species called p-snoRNAs, this 
remains unclear and a point of contention in the literature (145, 146). 
SNORD116 sno-lnc RNAs are expressed in human ES cells, brain, ovary, prostrate, skeletal 
muscle, and thyroid (139). SNORD116-derived sno-lncRNAs 1-5 associate with fibrillarin, a classic 
snoRNA-associated protein and localize in the nucleus and not the nucleolus or Cajal bodies (139). 
Knock-down of all SNORD116-derived sno-lncRNAs 1-5 does not significantly affect gene expression in 
PA1 cells (139). Sno-lncRNAs can associate with FOX2, a splicing factor (139). Due to species-specific 





Figure 1.4: A map of the SNORD116 gene cluster. The entire SNORD116 gene cluster is ~57 kb in 
length. SnoRNAs are shown in pink, sno-lnc RNAs are shown in orange, and introns, which do not 





Figure 1.5: SNORD116 snoRNAs are ~85% homologous to one another. The degree of homology 
ranges from ~64% to ~95% between Snord116 snoRNA copies. SNORD116-1 to SNORD116-9 cluster 
together and are ≥23-fold more highly expressed in the human hypothalamus than SNORD116-10 through 
SNORD116-30. Sequence alignment performed using LaserGene. 
 
116Hg, the long non-coding RNA transcribed from the SNORD116 gene cluster, forms an RNA 
cloud localized near the extended chromatin of the paternal Snord116 gene (140). Only one 116Hg RNA 
signal is observed per nucleus, indicative of monoparental expression (140). The diameter of the 116Hg 
cloud is developmentally regulated and reaches a maximum diameter by postnatal day 70 in the mouse 
brain (148). In mature neurons, the 116Hg cloud can reach 1.2 μm in diameter, suggesting that it may 
interact with other genes in trans (148). 
In PWS microdeletion patients, the deletion of SNORD116, SNORD109A, and IPW are sufficient 
to cause the major phenotypes of PWS, including neonatal hypotonia and failure to thrive, developmental 
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delay, hyperphagic obesity, hypogonadism, GH deficiency, and hyperghrelinemia. Mice harboring a 
deletion of only the paternal allele of the Snord116 gene cluster recapitulate many of the neuroendocrine 
features of PWS including relative hyperphagia, decreased linear growth, low GH, hyperghrelinemia, 
decreased motor learning and increased anxiety (149). Two independent groups have generated mice 
harboring paternal deletions of the Snord116 gene cluster; weights of Snord116
p-/m+
 mice at birth and 
embryos at E18.5 are not different from WT (149, 150). Runting in Snord116
p-/m+
 mice is apparent around 
postnatal day 9 (149, 150). Snord116
p-/m-
 mice display the same phenotypes as Snord116
p-/m+
 mice (151). 
Snord116
p+/m-
 mice are phenotypically indistinguishable from WT mice (151). Induction of maternal 
Snord116 transcription in Snord116
p-/m+
 mice rescues postnatal runting (152).  
Ding et al., showed that - consistent with dwarfism -  circulating Igf1 and liver Igf1 transcripts are 
reduced in Snord116
p-/m+
 mice compared to WT littermates (149). Pituitary structure was normal and 
pituitary somatotrophs were still able to produce growth hormone protein, suggesting that GH deficiency 
has central origins possibly at the level of GHRH (149). Snord116
p-/m+
 mice have increased glucose 
tolerance and increased insulin sensitivity compared to WT littermates (149). Snord116
p-/m+
 mice were 
also identified as being hyperphagic (relative to body weight) compared to WT littermates (149). Total 
circulating ghrelin levels are also elevated in Snord116
p-/m+
 mice (149). Treatment with several different 
GHSR inhibitors did not reduce the relative hyperphagia of Snord116
p-/m+
 mice, suggesting that 
hyperghrelinemia per se does not drive the relative hyperphagia (153). 
 Analyses of neuropeptide levels in the ARC by in situ hybridization found that Pomc, Npy, and 
Ghrh mRNA levels were all significantly upregulated in Snord116
p-/m-
 mice compared to WT littermates. 
Pomc and Ghrh are also upregulated in Pcsk1
-/-
 mice – Npy transcript levels were not reported (124). Oxt 
and Mch mRNA levels were slightly upregulated in the LHA. The number of α-MSH+ neurons per tissue 
section was increased in ad lib fed Snord116
p-/m-
 mice. POMC/α-MSH ratios were not examined, nor were 
Pcsk1 expression levels. The number of c-FOS positive neurons in the ARC was also increased following 
overnight fasting in Snord116
p-/m-
 mice compared to WT littermates. 
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Modified chromatin isolation by RNA purification (ChIRP)-Seq analysis in WT and Snord116
p-
/m+
 cortex was performed to identify interaction partners for the long noncoding RNA, 116Hg (148). 
Probes specific for the 116Hg lncRNA were used to pull down 116Hg and associated DNA, RNA, and 
protein products (148). Western blotting revealed that 116Hg associates with the transcriptional activator 
RBBP5 protein (148). Next generation sequencing of the pull down DNA product identified 2,403 genes 
as being bound by 116Hg, including Mtor (148). RNA sequencing identified that at Zt+6 (light cycle) 
Mtor, Clock, Cry1, and Per2 were upregulated in Snord116
p-/m+
 cortex (148). Cry1, Cry2, and Per1 were 
downregulated in Snord116
p-/m+
 cortex at Zt +16 (dark cycle) (148). The change in expression levels of 
these circadian rhythm-associated genes correlates with the increase and decrease of the 116Hg lncRNA 
cloud size at Zt+6 and Zt+16, respectively (148).  
Individuals with PWS are known to have sleep-wake distrubances, although these phenotypes 
have not been consistently reported among PWS microdeletion patients. Furthermore, the suprachiasmatic 
nucleus (SCN) of the hypothalamus is the major brain region controlling circadian rhythm, not the cortex. 
It is unclear how reflective changes in gene expression in the cortex are of changes in gene expression in 
the SCN. Snord116
p-/m+
 mice are null for the entire Snord116 gene cluster, not just the portion encoding 
116Hg. Without more specific deletion and re-expression models, the specificity of these phenotypes to 
116Hg per se remains an association. Interestingly, while the Nhlh2 and Pcsk1 genes were not identified 
as being bound by 116Hg in the cortex, Pcsk2 was bound by 116Hg in the cortex.  
Although several groups have investigated the physiological and molecular genetic consequences 
of loss of paternal Snord116, the molecular mechanism by which Snord116 contributes to the complex 
PWS phenotype remains unclear. To date there is no unified molecular mechanism for the pathogenesis of 





Induced Pluripotent Stem Cells and their Differentiated Products as a Novel 
Disease-Modeling Tool 
Pluripotent stem cells can self-renew and differentiate to every cell type in the human body. In 
2007, Yamanaka and colleagues revolutionized the stem cell field when they transformed human dermal 
fibroblasts into induced pluripotent stem cells (iPSC) using just four transcription factors: OCT4, KLF4, 
SOX2, and c-MYC (154). Induced pluripotent stem cells and their differentiated products may be a useful 
tool for in vitro disease modeling, as an in vitro drug screening platform, and potentially may be useful 
for regeneration of a patient’s own tissue, such as transplantation of patient-specific iPSC-derived β-cells 
for diabetics with depleted β-cell mass (Figure 1.6) (155). 
Dermal fibroblasts are typically utilized as the starting cell type from which iPSC are generated 
because they are easily biopsied from patients, their rate of proliferation is high, and they grow easily as a 
monolayer tissue culture. When the primary fibroblasts are transfected with KLF4, OCT4, SOX2, and c-
MYC, not all cells that are transfected will reprogram. The reprogramming efficiency is typically 0.01 – 
0.05% using retroviral methods (156). This is suggested to occur due to different epigenetic roadblocks 
that the four transcription factors encounter. 
Upon expression of the four reprogramming factors, a subset of cells will begin to divide faster 
and progress to a “pre-iPSC” stage (156). As the cells begin to divide more quickly they decrease in size 
and acquire a higher nucleus to cytoplasm ratio. Concurrently, the cells undergo mesenchymal to 
epithelial transition and begin to downregulate mesenchymal genes, such as Thy1, as well as upregulating 
epithelial genes, such as E-Cadherin (156). As the reprogramming cells progress to stage 2, their 
morphology continues to change as they begin to form small, round, compact ES cell-like colonies. 
Embryonic, as well as metabolic genes are upregulated at this point (156). Late-intermediate iPSC also 
begin to express characteristic pluripotency factors such as, Nanog, endogenous Oct4, and Essrb (156). 
Reprogramming iPSC begin to mirror embryonic stem cells not only through transcriptional changes but 
also changes to the chromatin structure and erasure of epigenetic marks reflective of the differentiated 
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state (156). Although much work has been done to characterize the key molecular events occurring during 
reprogramming the fine molecular details underpinning the process remain unclear. 
Specifically in the field of obesity research, iPSC may be useful in interrogation of the neuronal 
signaling pathways regulating appetite and energy homeostasis in monogenic and syndromic obesities 
(157). Current investigation of human brain tissues are limited to post mortem analyses or brain imaging 
studies on humans. The generation of hypothalamic neurons from human iPSC offers potentially very 
different approach to the study human body weight regulation. These cells (general iPSC-derived 
neurons) were used in the conduct of the research reported in this thesis. 
 
 
Figure 1.6: Induced pluripotent stem cells are a novel tool to for disease modeling and drug 
screening. (Graphics from: http://nyscf.org/stem-cells/stem-cells-101.) Reprogramming and neuronal 
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differentiation technologies may offer a new window into disease mechanisms of monogenic and 
syndromic obesities. 
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CHAPTER 2  
“Induced pluripotent stem cells (iPSC) created from skin fibroblasts of 
individuals with Prader-Willi Syndrome (PWS) retain the molecular 
signature of PWS” 
 
Introduction 
 In order to conduct some of the studies described in this thesis on the molecular 
neurophysiology of the Prader-Willi syndrome (PWS), it was necessary to reprogram fibroblasts 
from individuals with PWS to induced pluripotent stem cells (iPSC) that retain the molecular 
(imprint) signature of PWS. Because reprogramming fibroblasts to iPSC is associated with the 
erasure of epigenetic marks for some genes, it was necessary to ensure that the maternal DNA 
methylation at the PWS locus persisted following the reprogramming process. It was also 
necessary to confirm that the maternal DNA methylation of the PWS locus was preserved 
following neuronal differentiation. DNA methylation levels in iPSC and iPSC-derived neurons 
were measured using methylation specific multiplex ligation probe amplification assays. Gene 
expression of PWS region genes in iPSCs was also assessed. Patient-specific iPSC lines were 
fully characterized for the expression of pluripotency markers, spontaneous differentiation to 
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Prader-Willi syndrome (PWS) is caused by a loss of paternally-expressed genes in an 
imprinted region of 15q11.2-q13; the syndrome affects 1 in 25,000 live births (1, 2). Most 
instances of PWS (70%) are due to a “large” 4-5 Mb deletion in 15q11.2-q13 (Figure 2.1A). All 
large PWS deletions include six imprinted, protein-encoding genes (MKRN3, MAGEL2, 
NECDIN, C15ORF2, SNURF, SNRPN), seven snoRNA non-coding genes (SNORD107, 
SNORD64, SNORD108, SNORD109A, SNORD116, SNORD115, and SNORD109B), and the 
long non-coding RNA, IPW (3). About twenty five percent of instances of PWS are due to 
uniparental maternal disomy, while <5% of cases result from unbalanced paternal translocations, 
imprinting defects, or microdeletions (2, 3). The clinical phenotypes of PWS include 
hyperphagic obesity, hypogonadism, low growth hormone (GH) associated with short stature, 
hyperghrelinemia, and relative hypoinsulinemia (1, 2, 4). Although over a dozen mouse models 
of PWS have been generated, none develop the hallmark obesity associated with PWS. Patient-
specific iPSCs could provide a novel model system with which to study the molecular etiology 
of the disease.  
 
Results and Discussion 
 
Generation of iPS cell lines from PWS patients and confirmation of genotype  
We generated iPSCs from three large deletion (LD) PWS patients and one microdeletion 
(MD) PWS patient with the smallest deletion (118 kb deletion, Chr 15q: 15:25,257,217 – 
15:25,375,376) identified to date (Table 2.1) (5). All iPSC expressed pluripotency markers at the 
protein and transcript level, and differentiated to teratomas consisting of all three germ layers 
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(Supplemental Figures 2.1 - 2.3). MS-MLPA and CGH SNP arrays confirmed the genotypes of 
the cell lines utilized in the study (Supplemental Figures 2.4 and 2.5). Microdeletion 
breakpoints were confirmed with the Agilent HD SNP array to encompass only three genes, all 
of which are non-coding RNA genes: SNORD109A, SNORD116, and IPW (Supplemental 
Figure 2.5).  
 
Patient-derived iPSC retain the molecular signature of PWS 
Maternal DNA methylation patterns persisted after reprogramming and neural 
differentiation (Figure 2.1B-C). PWS microdeletion iPSCs and iPSC-derived neurons had mean 
methylation levels (expressed as digested sample peak height/non-digested sample peak height) 
at NDN and SNRPN that were not different from unaffected controls, including unaffected 
control gDNAs from peripheral blood lymphoblasts that were not subjected to manipulations 
such as reprogramming or neural differentiation (6). NDN and SNRPN are not included in the 
microdeletion interval (Figure 2.1A). PWS large deletion iPSC and iPSC-derived neurons 
display methylation levels at NDN and SNRPN approximately twice those of unaffected control 
and PWS microdeletion iPSC and iPSC-derived neurons (Figure 2.1B-C). Parthenogenetic ESC 
(PSC) and ESC-derived neurons were used as  positive controls as they only contain maternal 
genetic material (7). DNA methylation levels at the NDN and SNRPN loci were similar in PSC 
and PSC-derived neurons from PWS large deletion patients and parthenogenetic ESCs. 
Furthermore, the level of DNA methylation at the NDN and SNRPN loci did not differ between 
PWS large deletion peripheral blood and iPSC and iPSC-derived neurons, indicating that the 
manipulations of somatic cell reprogramming and neural differentiation did not cause de-
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methylation at the PWS loci (Figure 2.1B-C). Method of pluripotency induction had no impact 
on the DNA methylation level at NDN or SNRPN. 
Quantitative RT-PCR for PWS region genes was performed in iPSC (Figure 2.1D-H) 
from unaffected controls, PWS large deletion patients, and a PWS microdeletion patient. Induced 
pluripotent stem cells from unaffected controls expressed all genes within the PWS interval 
(Figure 2.1D-M). Expression levels of MAGEL2 and SNRPN are similar in PWS microdeletion 
and control iPSC (Figure 2.1D, 2.1E, 2.1I, 2.1J), as MAGEL2 and SNRPN are not included in 
the PWS microdeletion interval. However, SNORD109, SNORD116, and IPW are deleted on the 
paternal chromosome in the PWS microdeletion patient and the expression of these genes 
remained silenced in PWS iPSC. All of the PWS interval genes - specifically MAGEL2, SNRPN, 
SNORD109, SNORD116, and IPW - remained silenced in PWS large deletion iPSCs (Figure 
2.1D-M).  
In the aggregate, PWS iPSC and iPSC-derived neurons retain the molecular signature of 
PWS; in support of our findings, Chamberlain, et al. and Yang, et al., and Stelzer, et al. have 
also reprogrammed PWS fibroblasts to pluripotent iPSCs that maintain maternal DNA 
methylation at the PWS locus following reprogramming (8-10). PWS iPSC and iPSC-derived 
neurons have appropriate deletion breakpoints and gene copy numbers in PWS and non-PWS 
regions as indicated by MLPA and CGH-SNP arrays (Supplemental Figures 2.4, 2.5). PWS 
region maternal DNA methylation signatures persist following somatic cell reprogramming to 
iPSC and differentiation of iPSC to neurons (Figure 2.1B, 2.1C). Additionally, PWS iPSC 
display appropriate absence of PWS region gene expression in both large deletion and 




Materials and Methods 
Human Subjects 
All studies and consenting procedures were approved by the Institutional Review Boards of the 
participating institutions.  
Fibroblast Reprogramming to iPSC and PSC culture methods 
Primary human fibroblasts from unaffected controls and PWS patients were reprogrammed to 
iPSC using retrovirus reprogramming, sendai virus reprogramming or mRNA reprogramming 
(11, 12). The Stemgent mRNA reprogramming kit (00-0071) plus miRNA mixture were used. 
15K to 30K fibroblasts were plated on gelatin-coated tissue culture 12-well dishes. Ideal density 
was determined by eye. One to two days after seeding fibroblasts, the miRNA cocktail was 
added to the fibroblasts (day 0 of reprogramming). The mRNA cocktail consisting of Oct4, 
Sox2, Klf4, C-Myc, Lin28, and nGFP was added days 1 to 3. On day 4, both the miRNA and 
mRNA cocktails were added. On day 5 to day 11 of mRNA reprogramming the fibroblasts were 
treated with only the mRNA cocktail. Transfections were performed at the same time each day. 
Induced pluripotent stem cell colonies emerging from the fibroblast culture were hand-picked 
and transferred to a 24 well dish with MEFs. Colonies were then serially expanded. Sendai virus 
reprogramming was performed as previously described (11). Human iPSC cultures were 
routinely retained on MEFs (Globalstem) and cultured in human ES media: KO-DMEM, 10% 
KO-SR, 1% NEAA, 1% glutamax, 0.1% β-ME, 1% P/S, and 10 ng/mL bFGF. Media was 
supplemented with Y-27632 upon passaging. 
MS-MLPA Assay for gene copy number, and DNA methylation of PWS region genes 
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Genomic DNA was isolated from PSC and PSC-derived neurons using the Roche High Pure 
PCR Template Preparation Kit. gDNA was then analyzed using the SALSA MLPA ME028 
Prader Willi/Angelman probemix (MRC-Holland) for copy number and DNA methylation of 
PWS interval genes. 
Neuronal Differentiation 
Induced pluripotent stem cells were differentiated to neurons using a modified dual smad 
protocol (13). Undifferentiated iPSCs cultured on MEFs were dissociated and re-plated onto 
fresh MEFs at a density of 200,000 cells/well of a 6-well plate in human ES media with Y-27632 
day 0. On day 1, media was changed to EB media (HES media without bFGF) supplemented 
with 10µM SB431542 and 250 nM LDN193189 (LSB). Cells were treated with EB+LSB on 
days 2 and 3, 70% media changes were performed each day. On day 4, 75% EB + 25% N2 
(DMEM/F12 with 1X N2 supplement, 1% GlutaMAX, 1% penicillin/streptomycin, 0.2 mM 
ascorbic acid, and 1.6% glucose) with LSB was used. On day 5, 50% EB + 50% N2 with LSB 
was used. On day 6, 25% EB + 75% N2 with LSB was used. N2 supplemented with LSB was 
used on days 7 to 10. On day 10, cells were dissociated and plated onto poly-L-ornithine and 
laminin coated plates in N2 + LSB media with Y-27632. 200,000 cells per well for a 6 well plate 
or 80,000 cells per well for a 12 well plate were seeded. On day 11 the media was changed to N2 
plus B27 without retinoic acid and 20 ng/uL recombinant BDNF (R&D systems). Neuron were 
harvested at D34 for RNA isolation. 
qRT-PCR for PWS Region Genes in iPSC 
RNA was isolated from PSC using the Qiagen RNeasy kit with DNAse treatment. Total RNA 
was converted to cDNA using the Roche Transcriptor First Strand cDNA Synthesis kit. qRT-
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PCR was performed using Roche LightCycler 480 SYBR Green I Master mix. Primers are listed 
in Table 2.2. 
Pluripotency Analysis by Immunohistochemistry 
iPSC lines of at least passage 10 were fixed in 4% PFA for 10 minutes, washed with PBS twice 
for 5 minutes, blocked for 1 hour at room temperature using 10% donkey serum, in PBS with 
with 0.1% Triton X-100, washed with PBS three times for 5 minutes each, incubated in primary 
antibody overnight at 4°C, washed with PBS three times for 5 minutes, and incubated with 
secondary antibody at room temperature for two hours. Primary antibodies and dilutions used are 
as follows: Oct4 (1:500) (09-0023 Stemgent), Tra1-60 (1:500) (MAB4360 Millipore), Tra1-81 
(1:500) (MAB4381 Millipore), and Nanog (1:300) (Cell Signaling Technologies D73G4). All 
Alexafluor secondary antibodies were diluted 1:1000. Hoechst 33342 (Sigma) was used to mark 
nuclei. Imaging was done on Olympus IX71 epifluorescence microscope with an Olympus DP30 
monochrome camera. Monochrome images were then assigned the fluorophore color. 
Nanostring N-Counter Pluripotency Gene Expression Assay in iPSC 
iPSC were screened for endogenous expression of pluripotency markers LIN28, NANOG, OCT4, 
SOX2, ZFP42, endogenous expression of fibroblast marker KLF4, and exogenous expression of 
retroviral transgenes using the Nanostring N-Counter Gene Expression Assay. RNA was isolated 
from iPSC using the Qiagen RNeasy Plus kit. 100 ng total input RNA was used; the Pluri25 
custom code set was used for the Nanostring n-counter system. 
Pluripotency analysis by Teratoma formation 
Undifferentiatied iPSCs (~250K) were dissociated with TRP-LE and pelleted by centrifuging at 
0.8 RCF for 4 minutes at room temperature, the pellet was re-suspended in 50 µL human ES 
media supplemented with Y-27632. Cells were mixed 1:1 (vol:vol) in matrigel (Corning) and 
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were injected subcutaneously into the dorsal flank of NSG immunocompromised mice. Cells 
were allowed to grow for ~12 weeks; mice were monitored twice weekly for the appearance of 
growths and signs of distress. Mice were sacrificed and teratomas were removed and fixed 
overnight in 70% ethanol then paraffin embedded, sectioned, and stained with hematoxylin and 
eosin. 
CGH SNP Array 
Deletion breakpoints in PWS microdeletion and PWS large deletion iPSC were confirmed by 
Comparative Genome Hybridization Single Nucleotide Polymorphism Array using the 
Affymetrix Cytoscan SOMA kit. Genomic DNA was isolated from iPSC using the Roche High 
Pure PCR Template Preparation Kit. 
 
Figures and Figure Legends 
 
Table 2.1 – Anthropometric Data from PWS Patients and Reprogramming Methods 
Cell 
Line Genotype Gender 






PWS Type 1 
Large Deletion F 15.52* Stemgent mRNA 
129 
PWS Type 2 
Large Deletion M 49.4 Retrovirus 
139 
PWS Type 1 
Large Deletion M 57.3 Retrovirus 
066MD 
PWS 
Microdeletion F 55.4 Stemgent mRNA 







Figure 2.1: PWS iPSCs retain the molecular signature of PWS. A) The PWS locus contains non-
imprinted genes (green), maternally imprinted, paternally expressed genes (blue), and paternally 
imprinted, maternally expressed genes (pink). There are protein- coding (ovals) and non-protein 
coding RNA genes (squares and triangles) in the interval. Large deletions (LD) are bound by 
breakpoints 1 or 2 and breakpoint 3. Patients harboring microdeletions (MD) define a minimum 
critical deletion region highlighted in orange containing three non-coding, paternally expressed 
RNA genes. B,C)  DNA methylation at the PWS locus persists after reprogramming to iPSC and 
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differentiation to neurons. Genomic DNA from unaffected control (CON) peripheral white blood 
cells, iPSC’s, and iPSC-derived neurons have methylation levels ranging from 0.38 to 0.58 
indicating that one allele is methylated (methylation status is expressed as digested sample 
relative to non-digested sample fraction). In PWS large deletion iPSCs, iPSC-derived neurons, 
and peripheral white blood cells, methylation levels of genomic DNA range from 0.80 to 1.05 
indicating that all gDNA screened was methylated at both the NDN and SNRPN loci. There were 
no differences in methylation levels of PWS large deletion, parthenogenic ESCs, and ESC-
derived neurons. Parthenogenic ESC and ESC-derived neurons were used as a positive control as 
all genetic content is maternally derived. There were also no differences in methylation levels at 
NDN and SNRPN loci among unaffected control, PWS microdeletion iPSC and iPSC-derived 
neurons because these two genes are not included in the microdeletion interval. Furthermore, 
methylation differences between genotypes of reprogrammed or differentiated material were not 
different than those for gDNA from primary peripheral white blood cells on which no 
reprogramming or differentiation procedures have been performed.  D-H) Genes in the PWS 
locus remain silenced after iPSC generation. Expression of MAGEL2 and SNRPN can be 
detected in iPSC from unaffected control and PWS microdeletion individuals. However, 
SNORD109, SNORD116, and IPW expression are undetectable in iPSC from both PWS large 
deletion and PWS microdeletion patients. These transcripts are present in iPSC from unaffected 









Supplemental Figure 2.1: PWS and control iPSC express canonical pluripotency markers. A-N) 
Oct4 (green), Tra1-81 (red), Dapi (blue). O-BB) Tra1-60 (red), Nanog (green), Dapi (blue). CC-
PP SSEA4 (red), Dapi (blue). QQ-d: AP (red), Dapi (blue). A) 031MC iPS P7, B) 031MT iPS 
P7, C) 056LBT iPS P7, D) 066MDA iPS P7, E) 066MDE iPS P7, F) 1043B1 iPS P12, G) 
1043D3 iPS P11, H) 1058-6 iPS P11, I) 1058-B7 iPS P11, J) S1034A3 iPS P11, K) S1111B iPS 
P10, L) 129M iPS P11, M) 129C iPS P11, N) 139P iPS P17. O-BB) Tra1-60 (red), Nanog 
(green), dapi (blue). O) 031MC iPS P7, P) 031MT iPS P7, Q) 056LBT iPS P7, R) 066MDA iPS 
P7, S) 066MDE iPS P7, T) 1043B1 iPS P12, U) 1043D3 iPS P11, V) 1058-6 iPS P11, W) 1058-
B7 iPS P11, X) S1034A3 iPS P11, Y) S1111B iPS P10, Z) 129M iPS P11, AA) 129C iPS P11, 
A B C D E F G H I
J K L M N O P Q R
S T U V W X Y Z AA
BB CC DD EE FF GG HH II JJ
KK LL MM NN OO PP QQ RR SS




BB) 139P iPS P17. CC-PP SSEA4 (red), dapi (blue): CC) 031MC iPS P7, DD) 031MT iPS P7, 
EE) 056LBT iPS P7, FF) 066MDA iPS P7, GG) 066MDE iPS P7, HH) 1043B1 iPS P12, II) 
1043D3 iPS P11, JJ) 1058-6 iPS P11, KK) 1058-B7 iPS P11, LL) S1034A3 iPS P11, MM) 
S1111B iPS P10, NN) 129M iPS P11, OO) 129C iPS P11, PP) 139P iPS P17. QQ-d: AP(red) 
dapi (blue). QQ) 031MC iPS P7, RR) 031MT iPS P7, SS) 056LBT iPS P7, TT) 066MDA iPS 
P7, UU) 066MDE iPS P7, VV) 1043B1 iPS P12, WW) 1043D3 iPS P11, XX) 1058-6 iPS P11, 
YY) 1058-B7 iPS P11, ZZ) S1034A3 iPS P11, a) S1111B iPS P10, b) 129M iPS P11, c) 129C 




Supplemental Figure 2.2: PWS and unaffected control iPSC express pluripotency markers at the 
transcript level. Nanostring pluripotency analysis shows that the markers of pluripotency (assay 
uses Nanostring nCounter technology, gene expression level is counts of direct multiplexed 
detection of each gene listed), LIN28, NANOG, OCT4, and SOX2, were expressed in all PWS 
and unaffected control iPSC. Control hESC also expressed pluripotency markers (HES42 and 
HES16). Pluripotency markers LIN28, NANOG, OCT4, and SOX2 were not expressed in primary 
human fibroblasts (1043Fib). KLF4 is a fibroblast marker which was also expressed at lower 
levels in iPSC and hESC. KLF4 was most highly expressed in primary human fibroblasts. 
Fibroblast and pluripotency markers were not expressed in retrovirus (293V). The retroviral 
transgene probemix was no longer expressed in iPSC lines which were reprogrammed using 
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retrovirus, including 139, 129, 1043, 1058. Expression of retroviral transgene probemix was 







Supplemental Figure 2.3: PWS and unaffected control iPSCs form teratomas composed of all 3 
germ layers. 1 = Endoderm, 2 = Ectoderm, 3 = Mesoderm A-O: PWS and Control Teratomas. 
A) 031MT iPS P7, B) 056LBT iPS P7, C) 066MDA iPS P7, D) 066MDE iPS P7, E) 1043D3 iPS 
P11, F) 1058-6 iPS P11, G) 1058-B7 iPS P11, H) S1111B iPS P10, I) 129M iPS P11, J) 129C 

















Supplemental Figure 2.4: PWS large deletion and microdeletion have appropriately reduced 
gene copy numbers in the PWS loci. Black bars are unaffected control (CON). Light blue bars are 
PWS microdeletion (MD). Green bars are PWS type 2 large deletion (T2Del). Pink bars are PWS 
type 1 large deletion (T1Del). There was no change in copy number between the four genotypes 
in a non-PWS chromosomal region such as 10q26. NIPA1 is a non-imprinted gene which lies 
between PWS large deletion breakpoints 1 and 2 and is only deleted in PWS type 1 large 
deletion patients. There was no difference in copy number at NIPA1 between unaffected control, 
PWS type 2 deletion, and PWS microdeletion. SNRPN is a paternally imprinted gene that is 
deleted in both type 1 and type 2 PWS large deletion. SNRPN was not deleted in the PWS 
microdeletion patient and there was no difference in copy number between PWS microdeletion 
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and unaffected control. SNORD116 is a paternally imprinted snoRNA cluster that is deleted in 
both PWS large deletion and the PWS microdeletion patient. UBE3A is a maternally expressed 
gene that in the PWS large deletion interval. PWS type 1 and type 2 large deletion patients had a 
reduction in UBE3A copy number. There was no difference in UBE3A copy number between 







Supplemental Figure 2.5: CGH SNP array confirms deletion breakpoints in PWS large deletion 
(LD) and PWS microdeletion (MD) iPSC. Minimal loss of heterozygosity occurs within the PWS 
interval in unaffected control (blue). PWS microdeletion (green) breakpoints were confirmed as 
25,255,764 and 25,365,360 (human genome build 19). PWS Type 2 large deletion (orange) 





Supplemental Table 2.1: Control stem cell lines used in the study 
Cell Line Genotype Sex 
BMI at biopsy or 
maximum lifetime 
BMI 
056LB Unaffected Control M 19.6 
1013 Unaffected Control M 22.3 
1111 Unaffected Control F 20.6 
1034 Unaffected Control F 20.8 
1043 Unaffected Control F 19.8 
1058 Unaffected Control F 28.5 
HUES42 Unaffected Control M n/a 
SWAPS1 Parthenote Parthenote n/a 
PES2 Parthenote Parthenote n/a 
PES5 Parthenote Parthenote n/a 
 
 
Supplemental Table 2.2: Primers used for qRT-PCR 
  







NHLH2 GTCCGGACTCAGCATCATTT  ATATTTTCCGGAATCTCCCCT
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CHAPTER 3  
“Prader-Willi Syndrome is due to Impaired Prohormone Processing” 
 
Introduction 
  Chapter 2 provided evidence establishing that PWS patient-specific iPSC-derived 
neurons retain the molecular phenotype of the disease. I apply this novel in vitro model system 
here to study the role of SNORD116 in the molecular pathogenesis of Prader-Willi syndrome. 
Mice segregating for paternal deletion of Snord116 are used to investigate the role of Snord116 
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Prader-Willi syndrome (PWS) is the most common syndromic obesity, affecting 1 in 
25,000 live births (1, 2). PWS results from a loss of paternally-expressed genes at 15q11.2–q13 
(Figure 3.1A)  (3). Seventy percent of instances of PWS are due to a 5-6 Mb deletion in 
15q11.2-q13 (Figure 3.1A). The major phenotypes of PWS include: hyperphagic obesity, 
hypogonadism, low growth hormone (GH), hyperghrelinemia, and relative hypoinsulinemia (2, 
4). Five paternal microdeletion (118-237 kbp) PWS patients have been identified (5-9). The 
overlap among these patients’ paternal deletion regions identifies a 91 kb critical deletion region 
sufficient to cause the major physical and neuroendocrine phenotypes of PWS (Figure 3.1A). 
This region contains three non-coding RNA genes, including, SNORD109A, SNORD116, and 
IPW. None of the extant PWS mouse models (more than a dozen have been generated) develop 
obesity (10). However mice in which the paternal copy of Snord116 is deleted (Snord116
p-/m+
)  
display many of the neuroendocrine phenotypes of PWS, including hyperphagia, low GH, 
decreased body length, impaired motor learning, hypoinsulinemia, and hyperghrelinemia (11, 
12).  
C/D box snoRNAs are non-coding small nucleolar RNAs that methylate ribosomal 
RNAs. However, there are no known ribosomal RNA targets for SNORD116-encoded snoRNAs 
(13). Thus, SNORD116 is thought to be a non-canonical snoRNA; and the mechanisms by which 
SNORD116 influences biological processes are unknown. Although the endocrine features and 
natural history of PWS have been well described, a molecular mechanism linking these features 
to the genes deleted in the PWS minimum critical deletion region has not been identified. Using 
mice in which the paternal copy of only Snord116 has been deleted (Snord116
p-/m+
), iPSC-
derived neurons from PWS patients, and plasma from PWS patients, we find that the major PWS 
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clinical phenotypes can be accounted for by reduced expression of the prohormone processing 
enzyme, PC1 (PCSK1).   
 
Results 
The major PWS phenotypes are of CNS origin (hyperphagia, central hypogonadism, GH 
deficiency, intellectual disability, developmental delay). We generated iPSC-derived neurons 
from three large deletion (LD) PWS patients and one microdeletion (MD) PWS patient with the 
smallest deletion (118 kb deletion, Chr 15q: 15:25,257,217–15:25,375,376) identified to date; 
iPSC-derived neurons were also differentiated from six unaffected individuals (CON) (Figure 
3.1A, Supplemental Table 3.1). PWS iPSC were differentiated to neurons using a modified dual 
SMAD inhibition protocol (14). PWS region genes were expressed in proportion to gene dosage 
in iPSC-derived neurons from unaffected controls, PWS large deletion patients, and a PWS 
microdeletion patient (Figure 3.1B-F). PWS iPSC-derived neurons express canonical neural 
markers including -III-tubulin (TUJ1), NeuN, MAP2, and neural cell adhesion molecule 
(NCAM) (Supplemental Figure 3.1).  PWS genotype did not affect neuronal proliferation rates 
(percentage of Ki67+ neurons) (Supplemental Figure 3.2) or the percentage of NCAM+ neuron 
progenitors (measured by FACS) at D12 or D34 of differentiation (Supplemental Figure 3.3). 
These data suggest that general neuron differentiation efficiency using the modified dual SMAD 
inhibition protocol is similar between unaffected control and PWS large and microdeletion iPSC 
lines. 
Unidirectional RNA sequencing of iPSC/hESC-derived neurons FACS-sorted for NCAM 
(Supplemental Figure 4) identified PCSK1 among the top downregulated genes (Figure 3.1G). 
Quantitative RT-PCR from an independent differentiation experiment confirmed this (Figure 
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3.1H). By Western blotting PC1 protein was reduced >80% in both microdeletion and large 
deletion PWS iPSC-derived neurons (Figure 3.1I, Supplemental Figure 3.5). QRT-PCR and 
western blotting showed downregulation in NHLH2 at both the transcript and protein level in 
PWS microdeletion and large deletion iPSC-derived neurons compared to unaffected controls 
(Figure 3.1J-K, Supplemental Figure 3.6).  
Nhlh2 null mice are obese, hypogonadal, and display reduced linear growth (15). 
Hypothalamic levels of Pcsk1 transcript and PC1 protein are reduced by more than 50% in these 
animals (16). NHLH2  transcript levels were reduced 1.5-fold in lymphoblast RNA from 
individuals with PWS compared to controls (17). NHLH2 is a transcriptional regulator of 
PCSK1; PC1, its protein product, is a prohormone convertase that cleaves propeptides at dibasic 
residues. Known substrates include proinsulin, proGHRH, POMC, proGnRH, and proghrelin. 
Nhlh2 null and Pcsk1
N222D
 mice develop obesity that is associated with impaired hypothalamic 
processing of POMC to αMSH (16, 18).  In humans and mice, hypomorphic mutations of POMC 
or the αMSH receptor cause obesity (19, 20).  
SNORD116 may act upstream of NHLH2 and/or PCSK1. We sought to determine 
whether we could detect downregulation of Nhlh2 and Pcsk1 in vivo in mice in which only the 
paternal allele of Snord116 (Snord116
p-/m+
) is deleted (11). Snord116 is not expressed in 
hypothalami of Snord116
p-/m+ 
mice (Figure 3.1N). In wild type animals, Snord116 transcript 
levels increase 171% following 5-hour refeeding, suggesting an anorexigenic function for 
Snord116 (Figure 3.1N). In agreement with a putative anorexigenic function for Snord116, the 
food intake during 5-hour refeeding of Snord116
p-/m+
 mice is 67% greater than WT littermates 
(Figure 3.1L, M). Levels of Pcsk1 transcripts are reduced 41% after fasting but are unchanged 
after refeeding (Figure 3.1O). Compared to WT, in Snord116
p-/m+
 mice hypothalamic Nhlh2 
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transcript levels are decreased at fasting (-23%) and refeeding (-19%) (Figure 3.1P). After five 
hours of refeeding, hypothalamic transcript levels of the orexigenic neuropeptides, Npy and 
Agrp, remained elevated in Snord116
p-/m+
 animals, consistent with their relative hyperphagia 
(Figure 3.1L, Q-R). AgRP is also processed by PC1 and Pc1 null mice have 3.3-fold more full 
length AgRP in the hypothalamus; however unlike POMC, processing is not necessary for 
antagonist activity of AgRP at MC4R (21, 22). These mice are runted, confounding effects of 
genotype on obesity-related phenotypes. Nonetheless, Snord116
p-/m+
 mice also display long- and 
short-term increased energy intake relative to their diminished lean mass, associated with 
decreased hypothalamic Nhlh2 and Pcsk1 at fasting and persistence of increased Npy, Agrp 
following feeding (Figure 3.1L-R, Supplemental Figure 3.7). 
Based on the data in Figure 3.1, we hypothesized that specific endocrine phenotypes of 
PWS might be a consequence of defective prohormone processing owing to a functional 
deficiency of PC1 activity. We tested this hypothesis by measuring the processing of proinsulin 
to insulin, proGHRH to GHRH, and proghrelin to ghrelin in vivo in Snord116
p-/m+
 mice and WT 
littermates as well as in human PWS patients and controls matched for age and BMI (Figures 
3.2 – 3.4).  
Proinsulin is processed to insulin and c-peptide in β-cells by the combined actions of 
prohormone convertase 1 (PC1) and prohormone convertase 2 (PC2) (23). Patients with PCSK1 
inactivating mutations display hyperproinsulinemia and low circulating concentrations of insulin 
(24, 25). Snord116
p-/m+
 and WT mice were fasted overnight and injected intraperitoneally with 3 
mg/kg body weight of glucose. Fasting and post-injection blood glucose levels did not differ by 
genotype (Figure 3.2A). At 30 minutes, Snord116
p-/m+
 mice displayed elevated plasma 





 mice secreted higher ratios of proinsulin:c-peptide in response to 20 mM glucose (Figure 
3.2C). Pcsk1 and Pcsk2 transcripts and PC1 and PC2 protein levels were decreased in islets from 
Snord116
p-/m+
 mice (Figure 3.2E-H; Supplemental Figures 3.9 – 3.10). These results suggest 
that loss of Snord116 alone is sufficient to cause a downregulation in PC1 and PC2 with 
resulting functional impairment in proinsulin processing in vivo.  
We identified a 60% increase in the ratio of proinsulin to insulin in fasting plasma of 
individuals with PWS as compared to age- and BMI-matched controls (p=0.08) (Figure 3.2L, 
Supplemental Table 3.2). There was no difference in blood glucose or proinsulin concentrations 
between the subjects.  The increase in the proinsulin:insulin ratio was driven by reductions in 
mature insulin (Figure 3.2I-L). Plasma from a fasted patient compound heterozygous for 
inactivating mutations (heterozygous deletion c.71del/p.Ser24Met*73/stop codon position 72) in 
PCSK1 was included as a control.  The ratio of proinsulin:insulin was increased 267% compared 
to unaffected controls (Figure 3.2K). As we hypothesize that individuals with PWS have a 
downregulation of PC1, not a complete loss of function, an intermediate impairment in 
proinsulin processing as compared to PCSK1 mutation patients is expected.  
 Hyperghrelinemia (an orexigenic peptide) preceding the onset of obesity is a clinical 
feature of PWS that is not seen in common obesity or other syndromic or monogenetic obesities 
(26-32). Fasted Snord116
p-/m+
 mice displayed increased total levels of circulating ghrelin (Figure 
3.3A-B). Pcsk1 transcript levels were 20% lower in the stomachs of Snord116
p-/m+
 animals 
(Figure 3.3C). A trend towards decreased PC1 protein was identified in stomach lysates from 
Snord116
p-/m+
 mice compared to WT littermates (p=0.052) (Figure 3.3D; Supplemental Figure 
3.11). Transcript levels of Ghrl, which encodes the full-length preproghrelin protein, are reported  
to be elevated by 40% in the stomachs of PC1 null mice (33). This is the only other rodent 
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obesity model in which hyperghrelinemia has been identified. Ghrl transcripts were also 
increased in the stomachs of the Snord116
p-/m+
 mice (Figure 3.3E). Snord116 transcripts are 
increased >10-fold in stomachs of Pcsk1
+/-
 mice, suggesting a possible negative feedback loop 
(Supplemental Figure 3.12). Ratios of proghrelin to mature ghrelin protein are elevated in 
Snord116
p-/m+
 stomach lysates (Figure 3.3F; Supplemental Figure 3.13). Stomach lysates from 
Pc1-null mice were included as a positive control for impaired proghrelin processing. The 
processing defect in Snord116
p-/m+
 mice appears to be less severe than that of Pc1-null mice, 
consistent with the ~50% decrease of PC1 protein in their stomachs. The antibody used in 
conventional ghrelin assays also detects proghrelin (Supplemental Figure 3.14). Thus, the 
reported hyperghrelinemia in PWS patients as well as the Snord116
p-/m+
 mice likely reflects 
elevated circulating proghrelin, consistent with our results in Snord116
p-/m+
 stomach lysates 
(Figure 3.3A-F, Supplemental Figure 3.13 – 3.14). 
Pro-growth hormone releasing hormone (ProGHRH) is processed to its active form by 
PC1 in the arcuate nucleus of the hypothalamus (34, 35). Similar to PWS patients, Pc1-null 
mice, and PC1 deficient patients, Snord116
p-/m+
 mice exhibit growth retardation and decreased 
circulating GH/Igf1 (3, 35-37). At weaning and throughout adulthood, Snord116
p-/m+
 animals 
display decreased body length and weight (Figure 3.3G-H). GH stimulates Igf1 production in 
the liver, generating the major endocrine mediator of GH effects on somatic growth. Both 
circulating Igf1, and liver transcript levels of Igf1, were decreased in Snord116
p-/m+
 mice (Figure 
3.3I-J).  
Although circulating levels of Igf1 and liver transcript levels of Igf1 were decreased, GH 
levels in the pituitaries of four-week old, overnight fasted male Snord116
p-/m+
 mice were the 
same as WT littermates, suggesting impaired release of GH rather than impaired pituitary 
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production of GH (Figure 3.3K, Supplemental Figure 3.15). Mice null for Nhlh2 have reduced 
growth from 4-7 weeks of age and a >50% reduction in hypothalamic PC1 (15, 16). In PC1 null 
animals, impaired release of GH is associated with a defect in the processing of proGHRH to 
GHRH (35). We detected a trend towards an elevated ratio of proGHRH to GHRH in 
hypothalamic lysates of six week old overnight-fasted Snord116
p-/m+
 mice as compared to their 
WT littermates (Figure 3.3L). Nhlh2 and Pcsk1 transcripts are reduced in the hypothalami of 
fasted Snord116
p-/m+
 mice (Figure 3.1O-P). Individuals with PWS do respond to GHRH 
administration by release of GH into the plasma (38). This finding is consistent with the 
inference that the short stature and decreased GH levels of individuals with PWS results from a 
hypothalamic deficiency of PC1. 
 
Discussion 
Our finding of reductions in NHLH2 and PC1 at both the transcript and protein levels in 
PWS iPSC-derived neurons is consistent with the possibility that the major neuroendocrine 
phenotypes of PWS are due to defects in prohormone processing. The deleted region of the PWS 
microdeletion patient studied here includes only three noncoding RNA genes: SNORD109A, 
SNORD116, and IPW. Mice lacking the paternal copy of Snord116 have reduced levels of 
hypothalamic Nhlh2 and Pcsk1 at fasting, reductions in stomach and pancreatic islet PC1 
transcript and protein levels and display endocrine phenotypes similar to PC1-null mice, 
including: hyperghrelinemia associated with impaired processing of proghrelin to ghrelin in the 
stomach, dwarfism associated with low growth hormone due to impaired processing of 
proGHRH to GHRH in the hypothalamus, and impaired processing of proinsulin to insulin in 
pancreatic islets. Furthermore, an elevated ratio of proinsulin to insulin at fasting was detected in 
88 
 
the plasma of PWS patients compared to age- and BMI-matched controls, suggesting that 
proinsulin processing is impaired in human PWS patients as well.   
These data suggest a unified mechanism for the  seemingly disparate neuroendocrine 
features of PWS including: hyperphagic obesity (impaired hypothalamic POMC processing to 
MSH; upregulation via misprocessing of proAgRP, leading to elevated bio-active AgRP), 
hypogonadism (impaired processing proGnRH to GnRH), short stature and low GH (impaired 
proGHRH processing to GHRH), hyperghrelinemia (impaired proghrelin processing to ghrelin), 
relative hypoinsulinemia (impaired proinsulin processing to insulin), and central adrenal 
insufficiency (impaired pituitary processing of POMC to ACTH, and impaired hypothalamic 
processing of proCRH to CRH) (Figure 3.4). In support of this formulation, the phenotypes of 
PWS patients mirror those of individuals with hypomorphic PCSK1 mutations (Supplemental 
Table 3.3). These data also identify potential therapeutic interventions for individuals with PWS; 
agents that increase cellular PC1 levels may ameliorate the salient endocrine and neuroendocrine 
abnormalities of PWS.  
SNORD116 is an imprinted, paternally expressed, non-coding RNA cluster that contains 
thirty snoRNAs which are 85% homologous to one another, five sno-lnc RNAs, and one long 
non-coding RNA, 116HG. We have implicated NHLH2 and PCSK1 as major molecular targets 
of SNORD116, although it is unclear if there are direct interactions between SNORD116 and 
PCSK1 and/or SNORD116 and NHLH2. It is also unclear if such an interaction(s) were to occur, 
exactly which non-coding RNA sequences encoded from the SNORD116 snoRNA cluster would 
interact with PCSK1 and/or NHLH2. Furthermore, it is not known if such interactions would 
occur at the RNA-DNA, RNA-RNA, or RNA-protein levels. It is also likely that there are targets 
of SNORD116 other than PCSK1 and NHLH2 that may be clinically relevant in PWS. It is 
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possible that other targets of SNORD116 may account for aspects of the PWS phenotype that are 
not present in PCSK1 deficient patients, such as delayed gastric emptying, characteristic PWS 




All studies and consenting procedures were approved by the Institutional Review Boards of the 
participating institutions.  
iPSC and PSC culture methods 
Human iPSC were routinely cultured on MEFs (Globalstem) and in human ES media: KO-
DMEM, 10% KO-SR, 1% NEAA, 1% glutamax, 0.1% β-ME, 1% P/S, and 10 ng/mL bFGF. 
Media was supplemented with Y-27632 upon passaging. 
Neuronal differentiation 
Neuronal differentiation was performed using a modified dual smad protocol (14). 
Undifferentiated iPSCs grown on MEFs were dissociated and re-plated onto fresh MEFs at a 
density of 200,000 cells/well of a 6-well plate on in human ES media with Y-27632 day 0. On 
day 1, media was changed to EB media (HES media without bFGF) supplemented with 10µM 
SB431542 and 250 nM LDN193189 (LSB). Cells were treated with EB+LSB on days 2 and 3, 
70% media changes were performed each day. On day 4, 75% EB + 25% N2 (DMEM/F12 with 
1x N2 supplement, 1% ml GlutaMAX, 1% ml penicillin/streptomycin, 0.2 mM ascorbic acid, 
and 1.6% glucose) with LSB was used. On day 5, 50% EB with 50% N2 with LSB was used. On 
day 6, 25% EB + 75% N2 with LSB was used. N2 supplemented with LSB was used on days 7 
to 10. On day 10, cells were dissociated and plated onto poly-L-ornithine and laminin coated 
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plates in N2 + LSB media with Y-27632. 200,000 cells per well for a 6 well plate or 80,000 cells 
per well for a 12 well plate were seeded. On day 11 the media was changed to N2 plus B27 
without retinoic acid and 20 ng/uL recombinant BDNF (R&D systems). Neuron progenitors 
were allowed to mature until D33 or D34 at which point they were FACS sorted for the neural 
marker NCAM (CD56), see FACS methodology below. Neurons were also collected at D12 for 
FACS analysis of %NCAM+ cells. 
Fluorescence Activated Cell Sorting (FACS) for CD56  
Cells were enzymatically dissociated with Accutase and filtered through a 35 mm cell strainer 
(BD Biosciences) to obtain a single cell suspension prior to resuspension in 100 µl of a 
sterile iPSC staining buffer [DPBS containing 0.5% bovine serum albumin fraction V (BSA; 
Invitrogen), 100 U/ml penicillin/streptomycin (Invitrogen), 2 mM EDTA (Invitrogen), and 
20 mM glucose (Sigma)].  1 uL of CD56-V450 (BD Biosciences, #560360 or Stem Cell 
Technologies Anti-Human CD56 (NCAM) Antibody 60021AZ) was added to the cells and 
incubated at room temperature (RT) for 15 minutes shielded from light. The stained cells were 
washed once with iPSC staining buffer and sorted immediately on a 5 laser BD Biosciences 
ARIA-IIu™ SOU Cell Sorter configured with a 100 µm ceramic nozzle and operating at 20 psi 
sheath fluid pressure. Cells were sorted into a 15ml tube containing growth media as described 
above. 
RNA Sequencing 
CD56+ iPSC-derived neurons were immediately pelleted following FACS. Total RNA was 
isolated from CD56+ iPSC-derived neurons using the Norgen Biotek Total RNA Purification 
Micro Kit with DNAse treatment. RNA sequencing was performed at the Columbia Genome 
Center, 1x100 bp read length, 30 M read count. 
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qPCR in iPSC-derived neurons 
RNA was isolated from PSC using the Qiagen RNeasy kit with DNAse treatment. RNA was 
isolated from iPSC-derived neurons using the Norgen Biotek Total RNA Purification Micro Kit 
with DNAse treatment. Total RNA was converted to cDNA using the Roche Transcriptor First 
Strand cDNA Synthesis kit. qPCR was performed using Roche LightCycler 480 SYBR Green I 
Master mix. Primers are listed in Table 4. Main text Figure 1B-F, H, K: n=7 unaffected control 
PSC, n=1 PWS microdeletion (2 clones used), n=3 PWS large deletion lines used. 
Western blot in iPSC-derived neurons for Nhlh2 and PC1 
Protein levels of NHLH2 (WH0004808M1 SIGMA), PC1 (11914 Cell Signaling Technology), 
and α-tubulin (2144 or 3873, Cell Signaling Technology) were examined by western blot. Whole 
cell lysates from D34 PSC-derived neurons were obtained by reconstituting and lysing frozen 
cell pellets (-80°C) in RIPA buffer (Thermo Fisher 89900) with protease inhibitors (Halt 
protease & phosphatase inhibitor cocktail, Thermo Scientific 78442). Samples were sonicated for 
15 seconds. Total protein content was quantified using the Pierce BCA Protein assay kit (Thermo 
Fisher 23227). 15 µg of total protein was mixed with sample reducing agent (Nupage NP0009) 
and LDS sample buffer (Nupage NP0008); samples were incubated at 90°C for 5 minutes. 15 µg 
of total protein was run on 4-12% Bis-tris mini gels (Nupage NP0321) with MOPS SDS running 
buffer (Novex Life Technologies B0001); 1X antioxidant (Nupage NP0005) was added to the 
inner chamber. Electrophoresis was run at 70 volts for 15 minutes and then 200 volts until 
desired molecular weight separation was achieved. Protein was transferred to nitrocellulose blots 
using the Invitrogen iBlot system run at P1. Primary antibody was incubated overnight at 4°C 
with gentle rocking. Blots were washed 3 times for 5 minutes in TBST. Licor secondary 
antibodies (IR-Dye 800 CW goat anti rabbit 926-32211, IR-Dye 680 LT donkey anti mouse 926-
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68022, IR-Dye 800 CW goat anti mouse 926-32210, IR-Dye 680LT donkey anti rabbit 926-
68023) were used at 1:5,000 dilution and incubated at room temperature with gentle rocking for 
1 hour. Blots were washed twice in TBST for 5 minutes then twice in TBS for 5 minutes. Blots 
were then imaged using the Odyssey Classic imaging system (LI-COR Biotechnology). Data was 
analyzed using Image Studio Lite Version 5.0 and Graphpad Prism 6.  
Mouse Breeding, Genotyping, and Anthropometric Measurements  
All animal work was carried out in accordance with IACUC and CUMC standards and was 
IACUC approved under protocol AC-AAAH1203. Snord116
p-/m+
 mice on C57/BL6 were ordered 
from Jackson Laboratory (stock number 008149). A male Snord116
p-/m+
 mouse was mated to 
wild type C57/BL6 females. Ovulation cycles of wild type C57/BL6 females were synced by 
exposure to male mouse urine. Offspring were genotyped using methods published by Ding, et 
al., 2008 (11). Only male mice were kept for study. Mice were weighed weekly (main text 
Figure 3G n=4-20 mice/time point) and body composition was measured by NMR monthly using 
a Bruker Minispec TD NMR. Mice were fed 21.56% fat breeder chow for the entirety of the 
study (Purina Irradiated 5058 Picomouse Diet 20). Mouse nasal to anal length was measured at 
one and six months of age immediately following sacrifice (main text Figure 3H n=6 WT, n=7 
Snord116
p-/m+
 mice/time point).  
IPGTT Snord116 deletion mice, ELISA for Proinsulin, Insulin, C-Peptide Islet isolation 
procedures; expression levels of PC1 and PC2 
Mice were fasted overnight. In the morning, mice were intraperitoneally injected with 50% 
dextrose at a dose of three mg glucose per kg body weight (Hospira, Inc. NDC 0409-6648702). 
Blood glucose was assayed at time zero (fasting, prior to injection) and thirty minutes following 
injection using a FreeStyle Lite blood glucose meter and strips (accurate range 30-372 mg/dL) 
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(n=9 WT, n=7 Snord116
p-/m+
 mice). Whole blood was also collected into heparin tubes on ice at 
time zero and 30 minutes after injection. Heparin treated blood was centrifuged at 2,000 RCF for 
15 minutes 4°C; plasma was collected and frozen at -80°C for analysis of insulin and proinsulin 
content. Proinsulin, insulin and c-peptide content were measured by ELISA (Crystal Chem Ultra 
Sensitive Mouse Insulin ELISA Kit 90080, Mercodia Rat/Mouse Proinsulin ELISA 10-1232-01, 
Alpco Mouse C-peptide ELISA 80-CPTMS-E01). Prior to islet isolation mice were fasted 
overnight. Mice were sacrificed by cervical dislocation. A 30 gauge needed connected to a 5 mL 
syringe filled with 50% w/v collagenase P (dissolved in M199 media with 1% Pen Strep (Roche, 
11249002001; Gibco 31150022) was inserted into the common bile duct and the pancreas was 
perfused with collagenase P. Islet isolation was carried out as described (39). After picking, islets 
recovered overnight in RMPI media (#11875 Thermo Fisher) with 15% FBS, 1% Pen Strep, 1% 
Glutamax at 37 °C, 5% CO2. The following day, islets were placed into 1.7 mL microcentrifuge 
tubes (40 islets/tube for RNA analysis; n=6 WT, n=5 Snord116
p-/m+
 mice, islets were pooled 
according to genotype, 20 islets/tube for protein analysis; n=15 WT mice, n=15 Snord116
p-/m+
 
mice ranged in age from 6-8 mo) containing 200 µL of basal media, RMPI media (#11879, 
Thermo Fisher) with 1% Pen Strep, 1% Glutamax, 2mM glucose. Islets were allowed to recover 
for 1 hour. Islets were then incubated in basal media for 1 hour, high glucose (20 mM glucose) 
for 30 minutes (for RNA collection) or 90 minutes (for protein analysis). Total RNA was isolated 
as described for PSC-derived neurons. Primer sequences are listed in Table 2. Protein levels of 
PC1 (11914 Cell Signaling Technology), PC2 (14013 Cell Signaling Technology), and β-actin 
(3700 Cell Signaling Technology) were probed as described for PSC-derived neurons. 
qPCR of Liver Igf1 
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Livers from p30 ad lib fed animals were homogenized in Qiazol followed by phenol chloroform 
separation and precipitation with 70% ethanol of the aqueous fraction which was subsequently 
applied to Qiagen RNeasy columns. DNase treatment was performed. RT and QPCR were 
performed as described for PSC-derived neurons (n=6 WT, n=7 Snord116
p-/m+
 P30 male mice). 
5-hour refeeding; Hypothalamus QPCR Fast Refeed 
Mice were fasted overnight and refed for 5 hours. Mice were individually housed in order to 
obtain food intake measurements on a per mouse basis. One cohort of animals was sacrificed 
following an overnight fast. Another cohort was sacrificed following an overnight fast with 5-
hour refeeding. Mice were sacrificed by cervical dislocation. The hypothalamus was dissected 
out of the brain using a brain block and clean razor blades. Hypothalami were immediately 
homogenized in Qiazol and subsequent isolation of RNA was carried out as described for liver. 
RT and QPCR were performed as described for PSC-derived neurons; primers are listed in Table 
4 (n=11 WT, n=13 DEL adult males, overnight fasted; n=15 WT, n=14 DEL adult males, 5 hour 
refeed).  
Igf1 ELISA 
Circulating Igf1 levels were measured from ad lib fed one month old mice; the Mouse/Rat IGF-I 
Quantikine ELISA Kit MG100 from R&D systems was used (n=6 WT, n=7 Snord116
p-/m+
 P30 
male mice).  
ProGHRH/GHRH Measurements 
Hypothalami were dissected out of 6 week old overnight fasted male mice using a brain block 
and clean razor blades (changed between each mouse). Preparation of hypothalamic extract was 
done according to Miki, et al., 1994; hypothalamus was immediately placed into 500 µL of 1 N 
acetic acid, 0.02 N HCl, 10 mM EDTA, 1 µg/mL pepstatin (40). These extracts were then 
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lyophilized and re-suspended in 100 µL 3 N acetic acid. Further sample preparation and protein 
gel electrophoresis conditions were the same as for the stomach lysate western blot probing for 
ghrelin. Electrophoresis was stopped once desired molecular weight separation between mature 
GHRH, 5.2 kDa, and proGHRH, 12.3 kDa, was achieved as visualized by the SeeBlue Plus2 Pre-
Stained molecular weight standard (Life Technologies, LC5925). Clean razor blades were then 
used to excise gel slices from the proGHRH and mature GHRH fractions for each sample lane at 
12.3 kDa and 5.2 kDa, respectively. Gel slices were placed into 1.0 mL of elution buffer (50 mM 
Tris-Hcl, 150 mM NaCl, 0.1 mM EDTA; pH 7.5) in clean 1.7 mL microcentrifuge tubes. Gel 
pieces were then chopped into much smaller pieces approximately of uniform size, to increase 
the surface area from which protein could passively diffuse into elution buffer with clean 
surgical scissors. The chopped gel slice and elution buffer mixture was then incubated on a 
shaking heat block overnight at 50 °C. The following day, samples were centrifuged at 10,000 x 
g for 15 minutes and supernatant was collected. Immunoreactive GHRH content was then 
measured using a GHRH ELISA kit (Clone-Cloud Corp. ELISA Kit for Growth Hormone 
Releasing Hormone, CEA438Mu). Six-week old male mice were used, n=14 WT, n=11 Del, 
error bars are SEM in main text Figure 3L. 
Pituitary GH Western Blotting 
Pituitaries were removed from overnight fasted 4 week old male mice. De-brained skulls were 
placed in petri dishes with PBS. While viewing pituitary in de-brained skull via dissecting 
microscope, fine tip tweezers were used to excise pituitary out of skull. Use of the PBS-filled 
petri dish prevented pituitaries from folding in on itself. Excised pituitaries were then flash 
frozen in LN2. Pituitaries were homogenized in RIPA buffer (Thermo Fisher 89900) 
supplemented with protease inhibitors (Halt protease & phosphatase inhibitor cocktail, Thermo 
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Scientific 78442). Five micrograms of total protein was loaded onto 4-12% bis-tris gels, 
transferred to nitrocellulose membranes using iBlot program 0. Primary GH antibody (National 
Hormone and Peptide Program) in Licor blocking buffer and 1% Tween 20 was incubated for 2 
hours at room temperature; blots were then washed three times for 5 minutes each in PBST. 
Blots were incubated with secondary antibodies at room temperature for 1 hour with gentle 
shaking. Blots were again washed three times for 5 minutes each in PBST. Two final washes 
were performed in PBS. Blots were imaged using the Odyssey Classic imaging system (LI-COR 
Biotechnology). Data was analyzed using Image Studio Lite Version 5.0 and Graphpad Prism 6 
(n=5 WT, n=4 Snord116
p-/m+
 P30 male mice). 
Total Ghrelin ELISA 
Total circulating ghrelin was measured from adult male mice that were fasted overnight. Whole 
blood was collected in the morning into heparinized tubes on ice, which was spun at 2,000 RCF 
at 4 °C for 15 minutes. Total ghrelin content of plasma was measured using the Millipore 
Rat/Mouse Total Ghrelin ELISA kit EZRGRT-91K (n=21 WT, n=17 DEL adult males, fasted). 
QPCR Snord116 and Ghrl Stomach & PC1 Western blot P30 Stomachs 
Whole stomachs were excised from overnight fasted 1 month (P30) old male mice. Stomachs 
were cut open sagitally and residual food content was removed from stomachs.  Stomach tissue 
was rinsed 2X in room temperature PBS before flash freezing in liquid nitrogen. Frozen 
stomachs were then cryohomogenized (Cryo-Cup Grinders, Research Products International, 
Cat. No. 206) and 25% of the homogenate was used for RNA analysis while 75% was used for 
protein analysis. RNA was isolated as described for liver. For protein analysis the homogenate 
was further homogenized briefly in RIPA buffer (Thermo Fisher 89900) supplemented with 
protease inhibitors (Halt protease & phosphatase inhibitor cocktail, Thermo Scientific 78442) 
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using a handheld homogenizer. Lysates were centrifuged at for 20 minutes at 20,000 RCF at 
4°C; clear supernatant was collected for analysis. Western blot for PC1 was performed as 
described for iPSC-derived neurons (n=6 WT, n=6 DEL P30 male mice).  
Proghrelin/Ghrelin Western blot Stomachs 
Stomach lysates from adult mice fasted overnight were probed for ghrelin content by western 
blot following the methods based on that of Zhu, et al. 2006, and Yang, et al., 2008 (33, 41). 
Stomachs were dissected out from the mouse and rinsed twice in deionized (DI) H2O. Stomachs 
were placed into 200 µL DI H2O and boiled for 10 minutes using a water bath. Boiled stomachs 
were then cooled on ice. Next, stomachs were minced and 200 µL 2M acetic acid, 0.04 N HCl 
were added such that the final concentration was 1 M acetic acid and 0.02 N HCl. This mixture 
was then homogenized. Stomach homogenate was centrifuged at 20,000 x g for 1.5 hours at 4°C 
in order to obtain a clear supernatant. Supernatant was collected and reduced to 300 µL in a 
vacuum centrifuge. Acetone precipitation was then performed. Acetone was cooled to -20 °C. 
600 µL (2x volume of sample) acetone was added to the protein sample. Samples were incubated 
overnight at -20 °C. Samples were then centrifuged for 10 minutes at 15,000 RCF at 4 °C. 
Supernatant was collected as ghrelin is dissolved in the hydrophobic fraction. The supernatant 
was then dried in vacuo overnight. Dried protein was then re-suspended in 30 µL DI H2O. Total 
protein content for each sample was determined by BCA assay. Ten µg total protein was mixed 
with loading buffer such that final concentrations were 0.1 M tris chloride at pH 6.8, 5% w/v 
SDS, 0.1 M DTT, 5% glycerol. Sample-loading buffer mixture was then incubated at 100 °C for 
5 minutes. Ten µg total protein was loaded onto a 16% tricine gel which was ran in Tricine-SDS 
running buffer. 500 µL antioxidant was added to the center chamber. The gel was run at 70 volts 
for 15 minutes then 126 volts until optimal migration was achieved. Proteins were transferred 
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from the electrophoresis gel to a PVDF membrane using the iBlot system. Transfer conditions 
were 20 volts for 5 minutes (program 3 run for 5 minutes). PVDF blots were immediately placed 
in PBST. To prevent diffusion of the 3.4 kDa mature ghrelin, blots were fixed at room 
temperature for 15 minutes (on a shaker) in 50 mM HEPES-NaOH, pH 7.4, and containing 2.5% 
w/v glutaraldehyde. The membrane was then washed three times, 5 minutes each, in PBST. The 
membrane was blocked for 30 minutes at room temperature in Licor blocking buffer with 1% 
Tween 20. The blot was exposed to anti-ghrelin (Santa Cruz Biotechnology sc-10368) and anti-
preproghrelin (H-031-34 Pheonix Pharmaceuticals) primary antibodies during an overnight 
incubation at 4 °C and gentle shaking. Blots were then washed three times for 5 minutes each in 
PBST. Blots were incubated with secondary antibodies at room temperature for 1 hour with 
gentle shaking. Blots were again washed three times for 5 minutes each in PBST. Two final 
washes were performed in PBS. Blots were imaged using the Odyssey Classic imaging system 
(LI-COR Biotechnology). Data was analyzed using Image Studio Lite Version 5.0 and Graphpad 
Prism 6 (W = wild type, PKO = PC1 null, D = Snord116 deletion; n=9 W; n=7 D; n=2 PKO; 
adult mice fasted overnight). 
Measurement of proinsulin, insulin, and glucose in human plasma 
Plasma glucose levels were measured using the Wako Diagnostics AUTOKIT GLUCOSE C2. 
Proinsulin was measured using a Human Total Proinsulin ELISA kit (Millipore EZHPI-15K). 
Insulin was measured using an Ultrasensitive Human Insulin ELISA kit (Mercodia 10-1132-01).  
Neuron IHC 
iPSC-derived neurons were stained with the neural makers: TUJ1 (Sigma T2200), NCAM (Santa 
Cruz sc-106) and Ki67 (Abcam, ab15580). Staining procedure was the same as for iPSCs. 
Calorimetry of Snord116 deletion mice and WT littermates 
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Food intake and energy expenditure were monitored using LabMaster-CaloSys-Calorimetry 
System (TSE Systems). The first 24 hours was an acclimation period; data from this period was 
not used in analyses. Mice were weighed and body composition was measured using the Bruker 
Minispec TD NMR prior to and following housing in the calorimetry system. Mice were 
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Figures and Figure Legends 
 
Figure 3.1: NHLH2 and PCSK1 are reduced in PWS iPSC-derived neurons and Snord116p-/m+ 
(DEL) hypothalami. A) The PWS locus contains non-imprinted genes (green), paternally 
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expressed genes (blue), and maternally expressed genes (pink). There are protein- coding (ovals), 
snoRNA genes (rectangles), and long non-coding RNA (triangles) genes in the interval. Large 
deletions (LD) are bound by breakpoints 1 or 2 and breakpoint 3. Patients harboring 
microdeletions (MD) define a minimum critical deletion region highlighted in orange containing 
three non-coding, paternally expressed RNA genes, including SNORD116. B-F) Gene expression 
in the PWS locus following neuron differentiation. G) RNA sequencing identified a 
downregulation in PCSK1 in the PWS neurons. H) An independent differentiation confirmed the 
RNA sequencing results, In comparison to control there is a 71% and 59% reduction in PCSK1 
transcript level in PWS MD and LD neurons, respectively, as measured by qRT-PCR. I) The 
protein product of PCSK1, PC1, is also reduced in PWS MD and LD neurons by 84% and 82%, 
respectively. J) NHLH2 transcript is reduced 80% and 58% in PWS LD and MD neurons, 
respectively. K) NHLH2 protein is reduced by 93% and 99% in MD and LD PWS neurons, 
respectively. L-M) Following refeeding, Snord116
p-/m+
 mice ingest more calories than WT 
littermates when food intake is normalized to lean mass. N) Snord116 is expressed in WT 
hypothalami; expression is absent in Snord116
p-/m+
 hypothalami. In WT hypothalami, upon 
refeeding, Snord116 levels increase >10-fold. O) Pcsk1 transcript is decreased 41% in 
Snord116
p-/m+
 hypothalami compared to WT littermates at fasting; there is no difference in Pcsk1 
levels at refeeding. P) Transcript levels of Nhlh2 are decreased at both fasting and after refeeding 
in Snord116
p-/m+
 hypothalami compared to WT littermates. Q-R) Agrp and Npy transcript levels 
are increased in Snord116
p-/m+






Figure 3.2: Proinsulin processing is impaired in Snord116p-/m+ (DEL) mice and human PWS 
patients have impaired proinsulin processing compared to age- and BMI-matched controls. A) 
There is no difference in blood glucose levels by genotype. B) An increase in the ratio of 
proinsulin to insulin is detected 30 minutes after glucose stimulation. C) The ratio of proinsulin 
to c-peptide in culture media is also increased in Snord116
p-/m+
 isolated islets. D) Snord116 is not 
expressed in Snord116
p-/m+
 islets. E, G) Pcsk1 and Pcsk2 are downregulated in Snord116
p-/m+
 
islets. F, H) Both PC1 and PC2 protein levels are decreased in Snord116
p-/m+
 islets I) Fasting 
plasma glucose levels of PWS patients, a patient with an inactivating mutation in PCSK1, and 
age- and BMI-matched controls were measured. J-K) Fasting proinsulin and insulin levels were 
measured. L) The plasma proinsulin to insulin ratio is increased by 60% in individuals with PWS 























































































































































































































































































































































patients segregating for hypomorphic alleles of PCSK1 and manifesting a 170% increase in 






Figure 3.3: Proghrelin and ProGHRH processing are impaired in Snord116p-/m+ mice. A) 
Levels of total circulating ghrelin are increased in Snord116
p-/m+
 mice. B) Snord116 is expressed 
in stomachs of WT mice but not of Snord116
p-/m+
 mice. C) Pcsk1 transcript and levels are 
decreased in stomachs of Snord116
p-/m+
 mice compared to WT littermates. (D) PC1 protein is 
decreased in the stomach of Snord116
p-/m+
 mice, p=0.052. E) Preproghrelin transcript (Ghrl), is 
increased in Snord116
p-/m+
 mice. F) The ratio of proghrelin:ghrelin is increased in the stomachs 
of Snord116
p-/m+
 and PC1 KO animals. G, H) From weaning throughout adulthood, Snord116
p-
/m+
 mice weigh less and are shorter than wild type littermates. I) Circulating Igf1 is reduced by 
45% in P30 Snord116
p-/m+ 
mice compared to WT littermates. J) Transcript levels of liver Igf1 are 
reduced by 64% in Snord116
p-/m+ 
P30 livers compared to WT littermates. K) There is no change 
in pituitary growth hormone content between Snord116
p-/m+

































































































































































































































































































of hypothalamic proGHRH to GHRH content suggests that proGHRH to GHRH processing is 
impaired in Snord116
p-/m+








Figure 3.4: Deficiencies in PC1 drive the major neuroendocrine phenotypes of PWS. This 
schematic illustrates our hypothesis that paternal loss of SNORD116 is sufficient to cause 
deficiencies in the expression of NHLH2 and PCSK1 (PC1), resulting in impaired prohormone 
processing. We propose that deficiencies in prohormone processing (owing to deficits in PC1 







Supplemental Table 3.1 – Anthropometric Data of patients and unaffected controls from 
which iPSC were made 
Cell 
Line Genotype Sex 
BMI at biopsy or 
maximum lifetime 
BMI 
056LB Unaffected Control M 19.6 
1013 Unaffected Control M 22.3 
1111 Unaffected Control F 20.6 
1034 Unaffected Control F 20.8 
1043 Unaffected Control F 19.8 
1058 Unaffected Control F 28.5 
HUES42 Unaffected Control M n/a 
031M 








PWS Type 1 Large 
Deletion M 
57.3 
066MD PWS Microdeletion F 55.4 
SWAPS1 Parthenote Parthenote n/a 
PES2 Parthenote Parthenote n/a 
PES5 Parthenote Parthenote n/a 








Supplemental Table 3.2 – Anthropometric Data of PWS patients, fasting controls, and PCSK1 
mutation patient from which plasma glucose, proinsulin, and insulin measurements were 
made 
Sample ID Genotype Sub Type 
BMI z-score Gender  Age (years) Weight (kg) 
1 PWS N/A 2.69 Male 6 28.7 
2 PWS N/A 2.27 Female 4 18.78 
3 PWS Deletion - Type 2 -2.62 Female 0.75 5.5 
4 PWS Deletion - Type 1 3.80 Female 4 16.5 
5 PWS Deletion - Type 2 0.37 Female 3 14.2 
6 PWS UPD 2.71 Male 8 43 
7 PWS  Deletion - Type 1 -2.12 Female 0.75 6.17 
8 PWS UPD 1.92 Male 11 58.17 
9 PWS UPD 8.32 Male 4 32.2 
10 PWS Deletion - Type 2 2.93 Female 5.11 N/A 
19 PWS Deletion - Type 1 0.5 Male 10.17 43.7 
20 PWS Deletion - Type 1 1.87 Male 7.35 31.8 
21 PWS Deletion - Type 2 1.11 Male 7.8 32.4 
22 PWS Deletion - Type 2 0.8 Female 6.85 23.1 
23 PWS Deletion - Type 2 1.12 Female 8.78 38.2 
24 PWS Deletion - Type 2 2.76 Female 7.3 48.2 
26 PWS Deletion - Type 2 2.27 Male 7.42 40.4 
27 PWS Deletion - Type 2 2.63 Female 8.04 41.1 
11 Control Obese Control 3.08 Male 6.01 42.4 
12 Control Obese Control 2.11 Female 7.7 37.4 
13 Control Obese Control 2.47 Female 8.76 49.5 
14 Control Obese Control 2.88 Male 7.49 59.4 
15 Control Sib of PWS -0.16 Female 6.89 26 
16 Control Sib of PWS -0.94 Male 8.42 24.5 
17 Control Sib of PWS 0.94 Male 9.23 39.6 
18 Control Sib of PWS -0.18 Female 8.93 29.2 
28 Control Obese Control 2.74 Female 12.7 112.4 
29 Control Obese Control 2.72 Female 11.8 88.9 
30 Control Obese Control 2.67 Female 13 92.4 
31 Control Obese Control 2.63 Male 13.4 121.2 
32 Control Obese Control 2.62 Male 12.8 88.4 
33 Control Obese Control 2.61 Female 12 87.2 
34 Control Obese Control 2.31 Female 11.7 75.45 
35 Control Obese Control 2.27 Male 11.7 64.1 
36 Control Obese Control 2.26 Male 12.1 78.93 
37 Control Obese Control 1.96 Male 12 65 
38 Control Obese Control 1.87 Male 11.4 67.1 
39 Control Lean Control 0.4 Female 11.3 40.2 
40 Control Lean Control 0.34 Female 11.1 44.6 
41 Control Lean Control -2.07 Female 11 27 
42 Control Lean Control -2.07 Female 12.7 31.7 
43 Control Lean Control -2.28 Male 11.1 30.1 
44 Control Lean Control -2.41 Female 11.1 28.1 






p codon position 72) 




Supplemental Table 3.3 – Phenotypic comparison between PWS, PWS Microdeletion, Human 







Molecular Candidate due to PC1 






patients PC1 null mouse PC1 N222D Mouse Nhlh2 KO mouse Snord116del mouse
Infantile poor weight gain/FTT no x x
Yes - severe 
malabsorptive 
diarrhea severe runting not runted slight runting severe runting
Developmental delay
may be partially explained by 
impaired processing proBDNF-BDNF? x x Never reported severe runting not runted slight runting
severe runting; reduced 
brain weight at P30, 
normalizes by 6m/o
GH Deficiency Impaired processing ProGhrh to Ghrh x x x x no not tested well see above x
Excessive/rapid wt gain b/w 6mo and 6yrs Impaired processing POMC-aMSH x x x no obesity yes yes , obese after 14 wksnot obese
Obesity Impaired processing POMC-aMSH x x x no x x no
Hyperphagia Impaired processing POMC-aMSH x x x not tested x x x
Hypogonadism Impaired processing ProGnrh-Gnrh x x x x slight see above comment x no but see above comment
Hyperghrelinemia
Impaired processing proghrelin to 
ghrelin (predict actual decrease 
mGhrelin in PWS) x x never reported not tested not tested not tested x
Hypoinsulinemia Impaired processing proinsulin-insulin Not tested x x x x not tested x
Impaired processing of proinuslin to insulin Impaired processing proinsulin-insulin Not tested
Hypoinsulinemi
a - processing 
not tested x x x not tested x
Low circulating BDNF Impaired processing proBDNF-BDNF? Not tested x never reported not tested not tested not tested not tested
Hypothyroidism impaired processing proTRH to TRH x
Yes - 72% Low 
TT4, FT4 in 
pediatric cohort 
<2 y/o x did not test did not test
Yes  decreased 
express ion Trh  w/ 
lep fol lowing o/n 
fast not tested
Adrenal insufficiency impaired processing pituitary pomc Not tested
Yes  - 60% low 
ACTH in res  
metyrapone x x x x not tested
cognitive impairment
may be partially explained by 





n B. Dubern. not tested not tested not tested
impaired learning via  
rotarod test
Hypopigmentation
impaired processing POMC and/or 
PMCH? x x never reported no no no no
Neonatal hypotonia no x x No no no no no
PWS facial features no x x
Never reported however 
picture of init ial pc1 pt 
shows f lat  nasal bridge, 
thin upper lip, mouth 
downturned at corners 
cannot see eyes in pic n/a n/a n/a n/a
Behavior problems
may be partially explained by 
impaired processing proBDNF-BDNF? x x never reported not tested not tested not tested not tested
Sleep disturbance no x x never reported not tested not tested not tested
circadian genes 
dysregulated: mtor, clock, 
cry1, per2
Skin picking unclear, likely related to OCD-like symptomsx x no n/a n/a n/a n/a
OCD-like symptoms
may be partially explained by 





n B. Dubern. not tested not tested not tested not tested
High pain threshold
may be partially explained by 
impaired processing proBDNF-BDNF? Not reported x never reported not tested not tested not tested not tested
Temperature instability
May be partially related to β-
endorphin dysregulation (POMC 
product) Not reported x never reported not tested not tested
yes core body temp dec 
following 24 h fast and 
unable to reduce circ 
leptin following 24 h 4 
deg exposure however 
can regulate body temp 
during cold expos but 
lose more wt
better able to maintain core 
body temperature upon 
exposure to 4 deg than WT - 
did not meas BW during cold 
exposure
Diabetes impaired processing proinsulin-insulin Not tested
some 
develop 
T2DM not a l l x mild ins res in hets glucose intol not tested well no
Neonatal Malabsorptive diarrhea
related to PC1 deficiency but not sure 
what downstream target is - in PWS, 
may be complicated by PWS delayed 
gastric emptying issues No No x yes diarrhea no not tested not tested
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Supplemental Figure 3.1 
 
Supplemental Figure 3.1: PWS and unaffected control iPSC-derived neurons express pan-
neuronal markers. PWS and unaffected control iPSC were differentiated to iPSC-derived 
neurons using a modified dual SMAD inhibition protocol; staining was performed at day 34 of 
differentiation. -III-tubulin (TUJ1) and neural cell adhesion molecule (NCAM) mark neuronal 










Supplemental Figure 3.2: There is no difference in the percentage of Ki67 positive cells during 
neuronal differentiation between PWS and unaffected control genotypes. Unaffected control 
hESC (HES42), unaffected control iPSC (1013ASV) and PWS iPSC (129M and 139P) were 
subjected to neuronal differentiation. Ki67 staining was performed at days 7 (D7) and 10 (D10) 



































Ki67 is a marker of proliferating cells and is shown in red while DAPI marks DNA and is shown 





Supplemental Figure 3.3 
 
Supplemental Figure 3.3: There is no difference in the percentage of NCAM+ cells at day 12 and 
day 34 of neuronal differentiation between unaffected control and PWS genotypes. Unaffected 
control, PWS microdeletion, and PWS large deletion iPSC were differentiated to neurons and 
analyzed for the percentage of NCAM (also known as CD56) positive cells at days 12 and 34 of 
differentiation by fluorescence activated cell sorting (FACS). A) There is no difference in the 
percentage of NCAM+ cells at day 12 of differentiation (n=5 unaffected control PSC lines, n=1 
PWS microdeletion line (3 clones used), n=2 PWS large deletion lines). B) A representative 
FACS plot of NCAM fluorescence intensity at day 12 of differentiation. C) There is no 
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PSC, n=1 PWS microdeletion (2 clones used), n=3 PWS large deletion). D) A representative 









Supplemental Figure 3.4: RNA sequencing identifies downregulation of PCSK1 in PWS iPSC-
derived neurons. A) Differentially expressed genes common between Microdeletion PWS and 
Large Deletion PWS genotypes as compared to unaffected control genotypes (Student t test, 2 
tailed, type 3, without Bonferroni correction; no genes were significant with Bonferroni 
correction). Forty-five genes were differentially expressed in both PWS genotypes. Of the 45 
differentially expressed genes, 42 were differentially expressed in the same direction, including 
IPW and LOC1005069 from the PWS locus; snoRNA genes are not picked up by the RNA 
sequencing package used, 30 million, 100 bp reads.  PCSK1 (also known as PCSK1/3) is 
downregulated by 51% and 61% in microdeletion and large deletion, respectively (P<0.05). B) 
Gene expression in the PWS region in unaffected control (CON), PWS microdeletion (MD), and 
PWS large deletion (LD) NCAM+ iPSC-derived neurons as measured by RNA sequencing. PWS 
region genes remain appropriately silenced in PWS iPSC-derived neurons. PWS region genes are 
expressed in unaffected control iPSC-derived neurons. The green line denotes non-imprinted 
genes, the pink line denotes maternally-expressed genes, and the blue line denotes paternally-
expressed genes (n=7 unaffected control PSC, n=1 PWS microdeletion (2 clones used), n=3 





Supplemental Figure 3.5 
 
Supplemental Figure 3.5: PC1 protein is downregulated in PWS iPSC-derived neurons 
compared to unaffected control iPSC-derived neurons. Quantification is shown in Main Text 
Figure 1. Day 34 neurons were probed for PC1 protein levels by western blotting. (n=5 controls 
(3 lines), n=2 PWS large deletion, n=1 PWS microdeletion; error bars SEM). Ldel = PWS large 




Supplemental Figure 3.6 
 
Supplemental Figure 3.6: Nhlh2 protein is down-regulated in PWS iPSC-derived neurons 
compared to unaffected control iPSC-derived neurons. Quantification is shown in Main Text 
Figure 1. Day 34 neurons were probed for Nhlh2 protein levels by western blotting. (n=2 
unaffected control lines, 2 PWS microdeletion clones, 2 PWS large deletion lines; 1-way 
ANOVA, Tukey/Fishers Post hoc test, *=P<0.05, Error bars are SEM). Lgdel = PWS large 





Supplemental Figure 3.7 
 
Supplemental Figure 3.7: Long-term cumulative food intake of Snord116p-/m+ mice does not 
differ from WT despite decreased body size and weight. A) Cumulative food intake is not 
different between 20 week old male Snord116
p-/m+
 mice and WT littermates, despite 24% lower 
body weight and 16% lower lean mass of Snord116
p-/m+
 mice. Error bars are SEM Unpaired t-
test, n=10 wt, n=9 deletion, 6 mo males. B) When 24 hour food intake is expressed in proportion 
to body weight, Snord116
p-/m+
 mice consume ~ 25% more than WT. C) When energy 
expenditure is plotted against BW
2/3
, a single linear regression equation can be used to describe 
both Snord116
p-/m+
 and WT data sets, suggesting that the increased energy expenditure of  
Snord116
p-/m+
 mice may be accounted for  by increased heat loss due to  higher surface area to 
body mass ratio of  Snord116
p-/m+
 animals. The same result is also found when plotting VO2 
Cumulative Food Intake
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against FFM. (Data were plotted as a non-linear regression using least squares (ordinary fit), 
extra sum of squares F-test was used to determine best-fit values of unshared parameters differed 
between the 2  data sets (WT and DEL), the null hypothesis was not rejected (p=0.09) n=8 wt, 
n=8 deletion, 6 mo males.) D) Mean daily movement is not different between Snord116
p-/m+ 
and 
WT mice. E) There is no change in the 24 hour respiratory exchange (RER) ratio between 
Snord116
p-/m+
 and WT mice; there is also no difference between light cycle and dark cycle RER 
amongst genotypes (data not shown). F) Snord116
p-/m+
 mice have decreased body weight as 
compared to WT littermates; there is no change in body weight before and after time in the 
metabolic cage within genotype. G) Fat mass is decreased in Snord116
p-/m+
 mice; there is no 
change in fat mass before and after time in the metabolic cage within genotype. H) Snord116
p-/m+
 
mice have decreased lean mass as compared to WT littermates; there is no change in lean mass 













Supplemental Figure 3.8 
 
 
Supplemental Figure 3.8: A disproportionate reduction in insulin levels 30 minutes following 
glucose injection accounts for the increase in the proinsulin to insulin ratio in Snord116p-/m+ 
(Del) mice. Blood glucose levels and proinsulin to insulin ratio is shown in main text Figure 3A-


































































































Supplemental Figure 3.9 
 
Supplemental Figure 3.9: PC1 protein levels are reduced in Snord116p-/m+ islets. 





Supplemental Figure 3.10 
 
Supplemental Figure 3.10: PC2 protein levels are reduced in Snord116p-/m+ islets. 





Supplemental Figure 3.11 
 
Supplemental Figure 3.11: PC1 protein levels trend towards a decrease in Snord116p-/m+ 






Supplemental Figure 3.12 
 
 
Supplemental Figure 3.12: Snord116 expression is upregulated in stomachs of PC1+/- mice. A) 
Pcsk1 expression in the stomach is downregulated 50% in mice that are heterozygous for Pcsk1. 
B) Ghrl, which encodes the full length, unprocessed Preproghrelin, is upregulated in stomachs 
of Pcsk1
+/-
 mice compared to WT, suggesting that just a 50% reduction in Pcsk1 levels are 
sufficient for increased Ghrl expression. C) Snord116 expression is increased greater than 10-
fold in the stomachs of Pcsk1
+/-
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Supplemental Figure 3.13 
 
Supplemental Figure 3.13: Processing of proghrelin to mature ghrelin is impaired in 
Snord116p-/m+ mouse stomach lysates. Quantification is shown in Main Text Figure 3. Red 
bands at 12 to 17 kDa are preproghrelin. Green bands at 3.4 kDa are mature ghrelin. Imaging 
was done using the Licor Odyssey two color imaging system; blots were probed for mature 
ghrelin and preproghrelin separately using two different antibodies, anti-ghrelin and anti-
preproghrelin, respectively. Bands at 12-17 kDa and 3.4 kDa below are from the same blots and 
same gel lanes (W = wild type, PKO = PC1 null, D = Snord116 deletion; n=9 W; n=7 D; n=2 
PKO; adult mice fasted overnight). Note, blots are cropped here to show regions from which 
quantification was done. Full blots are shown in the following figure, Supplemental Figure 21; 
top is H-0310-34 Phoenix Peptide anti preproghrelin antibody, bottom is Santa Cruz C-18 anti 
ghrelin antibody. Note also that due to the stomach lysate preparation methodology to probe for 
ghrelin (see methods) in which the hydrophobic supernatant fraction is taken following acetone 
precipitiation, typical loading controls such as -tubulin or -actin are not present in this 
fraction. Hydrophobic proteins that might be used as a loading control such as pan-cadherin or 
Sodium Potassium ATPase were tried but could not be identified by western blotting in this 
lysate fraction. Thus, the most relevant comparison here is the ratio of proghrelin to mature 
ghrelin; absolute quantities of proghrelin or mature ghrelin in Snord116
p-/m+
 compared to WT are 
difficult to interpret without a proper loading control.  
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Supplemental Figure 3.14: Ghrelin western blot blotting identifies proghrelin reactivity of anti-
ghrelin antibodies. A) Preproghrelin antibody is specific to preproghrelin and proghrelin 
peptides, 14 kDa and 17 kDa, respectively; no band is detected at 3.4 kDa, the size of mature 
ghrelin. B) The Santa Cruz C-18 anti-ghrelin antibody detects both mature ghrelin at 3.4 kDa and 
weakly reacts with proghrelin and preproghrelin at 14 and 17 kDa, respectively. C) The Phoenix 
Peptide H-031-31 anti-ghrelin (mouse) antibody detects proghrelin peptides and can detect an 
increase in proghrelin in Snord116
p-/m+
 and PC1 null mice.  H-031-31 is also used in the Phoenix 
Peptide RK-031-31 ghrelin rat, mouse RIA kit that has been previously used by other groups to 
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detect increased circulating ghrelin in Snord116
p-/m+
 mice compared to WT (11). D) The Phoenix 
Peptide H-031-30 anti-ghrelin (human) antibody also detects proghrelin peptides and can detect 
an increase in proghrelin in Snord116
p-/m+
 and PC1 null mice compared to WT. This antibody is 
also used in the Pheonix Peptide RK-031-30 RIA kit that has been used in multiple studies of 
human plasma that detected ‘hyperghrelinemia’ in PWS as well as decreased circulating 
‘ghrelin’ in common human obesity (26, 42-45). It is possible that the hyperghrelinemia reported 
in PWS may be reflective of hyperproghrelinemia (W = wild type, PKO = PC1 null, D = 







Supplemental Figure 3.15 
 
 
Supplemental Figure 3.15: There is no change in pituitary growth hormone levels in 
Snord116p-/m+ mice compared to WT littermates at 1 month of age. Quantification is shown in 
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CHAPTER 4  
“Neuronal and endocrine pancreatic developmental defects in Prader-




 Chapter 3 presented a putative molecular mechanism of impaired prohormone processing 
due to downregulation of PC1 in humans and patients deficient in Snord116. In addition to 
endocrinopathies, individuals with PWS also have global developmental delay (delayed motor 
milestones, delayed language development) and characteristic structural abnormalities in the 
brain. Additionally, developmental defects in the endocrine pancreas have been identified in a 
“large deletion” PWS mouse model, including decreased circulating insulin and glucagon 
accompanied by decreased pancreatic insulin and glucagon content. This chapter investigates the 
possible contribution of loss of Snord116 on the developmental defects in the PWS brain and 





Figure 4.0: Proposed dual role of Snord116 in neuroendocrine regulation and development. In 
addition to the regulation of prohormone processing, Snord116 may also affect developmental 
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Prader-Willi syndrome is caused by a loss of paternally-expressed genes on 15q11.2-13. 
Individuals with PWS are hyperphagic, hypogonadal, have low circulating growth hormone and 
short stature, relative hypoinsulinemia, and hyperghrelinemia (1, 2). Additionally, developmental 
delay (delayed motor milestones, delayed language development) and cognitive disorders are 
characteristic (1). Specific neurodevelopmental phenotypes of individuals with PWS include, 
psychiatric and behavior problems, anxiety and depression, temper control problems, repetitive 
speech, delayed speech onset, speech impediments, obsessive compulsive behavior (ordering, 
arranging, sorting), and self-harming behaviors including skin picking (3). MRI brain analyses 
have revealed ventriculomegaly in 100% of PWS patients scanned, decreased volume of brain 
tissue in parietal-occipital lobe (50%), sylvian fissure polymicrogyria (60%), incomplete insular 
closure (65%), and decreased cerebellar volume (3, 4). 
In post-mortem PWS brain tissue neuronal cerebellar nucleoli are smaller (decreased 
nucleolar diameter) than unaffected individuals (5). The +/PWS-IC
del35kb
 mouse model has a 35 
kb deletion encompassing the PWS imprinting center; the deletion region begins 16 kb proximal 
to Snrpn exon 1 and ends in Snrpn exon 6 (6, 7). The +/PWS-IC
del35kb
 mouse lacks expression of 
paternally-expressed PWS region genes, including Snord116, and expresses Ube3a from both 
alleles (6, 7). Neurons of the +/PWS-IC
del35kb
 mice have reduced nucleolar diameter (5). 
Conversely, the PWS-IC
hs
/+ mouse model which (over) expresses PWS region genes including 
Snord116, from both the maternal and paternal alleles, display increased nucleolar diameter and 
increased numbers of nucleoli per nucleus (5, 8). The nucleolus is the site of ribosome 
biogenesis, and neuronal nucleolar size is directly proportional to rates of ribosomal biogenesis 
(9). Nucleoli regulate translation and cell growth. In developing neurons or neuron progenitors, 
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the nucleolus is critical for cellular growth and neurite morphogenesis. Prominent nucleoli are 
often seen in mature, post-mitotic neurons and are critical to neurite maintenance (9). Nucleolar 
size and number correlates with neuronal cell body size (10, 11). 
In addition to neurodevelopmental defects there may also be developmental defects in the 
endocrine pancreas in PWS. Individuals with PWS have relative hypoinsulinemia and reduced 
concentrations of post-meal circulating pancreatic polypeptide (12-15). Developmental defects 
are present in the endocrine pancreas of a PWS ‘large deletion’ mouse model (16). The PWS 
mouse model that recapitulates the most common 5-6 Mb deletion genotype in PWS, the 
“TgPWS” mouse, exhibits failure to thrive and dies by postnatal day 5 (17). The TgPWS 
neonates manifest decreased circulating insulin and glucagon accompanied by decreased 
pancreatic insulin and glucagon content (16). Islet α and β cell populations display deranged 
morphology in the TgPWS mice (16). 
While most instances of PWS are caused by a large 5-6 Mb deletion of the paternal 
chromosome, five microdeletion patients have been identified whom present all major 
phenotypes of PWS (1, 18-22). The 91 kb minimum critical deletion region includes three non-
coding RNA genes: the single copy snoRNA SNORD109A, the snoRNA cluster SNORD116, and 
the long non-coding RNA, IPW (21). While none of the existing PWS mouse models recapitulate 
all PWS phenotypes, the Snord116
p-/m+
 mouse most closely resembles the major endocrine 
phenotypes of PWS, including, relative hypoinsulinemia, hyperghrelinemia, hyperphagia, low 
circulating growth hormone, dwarfism, and impaired motor learning (23). SNORD116 is a gene 
cluster containing thirty C/D box small nucleolar RNAs that are ~85% homologous to one 
another. Small nucleolar RNAs localize to the nucleolus and this has been demonstrated for 
Snord116 in WT mouse neurons, there is no expression of Snord116 snoRNAs in the nucleolus 
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in mice lacking the paternal allele of Snord116 (5). C/D box snoRNAs methylate rRNAs in the 
nucleolus, aiding in their maturation prior to nucleolar export (24). However, SNORD116 is an 
“orphan” snoRNA in that no rRNA targets have been identified for any of the SNORD116 
snoRNAs (25). The role(s) of SNORD116 in the nucleolus or elsewhere in the cell remain 
unknown. 
 Multiple long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been 
identified that regulate the endocrine pancreas (26, 27). LncRNAs play an enhancer-like role for 
transcription factors important for β-cell development and function, while miRNAs can regulate 
insulin biosynthesis (27). To date, no snoRNAs have been identified that regulate pancreatic islet 
development or function (27).  
While a molecular mechanism for many of the neuroendocrine features of PWS has been 
proposed by us, a cellular-molecular basis for the developmental aspects of PWS has yet to be 
identified. Here, we identify developmental defects in the central nervous system and endocrine 
pancreas due to loss of the paternal allele of SNORD116 (28). 
Research Design and Methods 
Human procedures 
All studies and consenting procedures were approved by the Institutional Review Boards of the 





All animal work was carried out in accordance with IACUC and CUMC standards and was 
IACUC approved under protocol AC-AAAH1203. Mating and genotyping were carried out as 
previously described. 
Neural Processes and Cell Body Size Assay in iPSC-derived neurons 
Induced pluripotent stem cell (iPSC) reprogramming, maintenance cell culture, and 
neuron differentiation techniques were carried out as previously described. All PSC lines used 
have been previously published and fully characterized; from Figure 4.1, Con1 is HES42, Con2 
is 1013ASV, PWS1 is 129, PWS2 is 139 (29). At Day 12 or Day 34 of differentiation, cells were 
dissociated using accutase, counted and then plated at a density of 9,375 cells/cm
2
 (i.e. 3,000 
cells/well of a 96-well plate). Cells were cultured in N2/B27/BDNF/ROCKI for 48 hours, then 
were fixed in 4% PFA and stained with beta-III-tubulin (Tuj1) antibody (T2200 SIGMA), a 488 
anti-rabbit AlexaFluor secondary antibody was used. Nuclei were marked with HOECSHT stain. 
Imaging was done using PlateRunner Imager and Trophos software. Images were analyzed using 
Metamorph software, Neurite outgrowth application. Statistical analyses were performed with 
Prism 6 Graph Pad software.  
Isolation of Primary Neurons 
Primary forebrain neurons were isolated from E15-5 embryos using a protocol modified 
from Thermo Fisher Protocols (#LT176, revised 06-21-2013). Following isolation cells were 
treated as above. 96-well plates were imaged at 20X magnification using the Life Technologies 
EVOS automatic microscope. A 5x5 frame area was collected at the center of each well for a 
total of 25 images per well stitched together with the Life Technologies EVOS software. Images 
were analyzed as described above. 
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Quantification of Purkinje Neuron Cell Body Diameter and Nucleolar Diameter 
Postnatal day 30 (P30) mice (n=5 WT, n=5 Del) were injected intraperitoneally with 10 
mg Xylazine/ kg body weight and 100 mg Ketamine/kg body weight. Mice were perfused 
intracardially with 4% PFA. Whole brains were post fixed, cryoprotected, and frozen in OCT 
Compound. Brains were sectioned for cerebellum; sagittal sections were taken from -0.05 to 
+2.40, 3 sections were taken and then 100 μm was skipped. Sections were then permeabilized 
with  1% Triton X-100 in PBS (1% PBST) for 10 minutes followed by antigen retrieval with 
heated 10 mM sodium citrate, pH 6.0, for 10 minutes at room temperature (RT). Sections were 
blocked in 5% donkey serum for 30 minutes at RT. Slides were incubated with anti-fibrillan 
antibody at 37 °C overnight in 500 μL resevoirs (Thomas Scientific #6690J20). Secondary 
antibody was incubated at RT for 2 hours. Nuclei were marked with Hoechst stain. Staining 
procedures for Calbindin D28K were the same with the exception that the primary antibody 
incubation was carried out overnight at 4 °C. Imaging was performed using 63X magnification 
and 1.1X zoom on a Zeiss LSM 710 Confocal microscope; quantification of cell body diameter 
and nucleolar diameter was done with the Zeiss LSM  software. Statistical analysis was 
performed with Prism 6 Graph Pad software. 
Quantification of Islet Size and Endocrine Cell Type Islet Populations.  
N=3 WT and n=4 Snord116
p-/m+
 adult male mice were selected so that body weights 
would not be different between genotypes. N=2 WT and n=2 Snord116
p-/m+
 1 month old mice 
(P30) were picked at random such and the body weights reflect runting of Snord116
p-/m+
 mice 
compared to WT littermates. N=5 WT and n=5 Snord116
p-/m+
 P0.5 mice were used, body 
weights are not different at this age. Pancreata were fixed in 4% PFA and paraffin-embedded. 
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Pancreta were sectioned at 5-6 levels such that sections were obtained throughout the pancreas. 
In each level, the first and last slides were reserved for hematoxylin and eosin (H&E) staining for 
quantification of total cells per islet. Quantification of the number of nuclei per islet in H&E 
stained sections was performed by manual counting. Immunohistochemistry was carried out as 
described for Calbindin stain above, with the exception that 0.3% PBST was used. A Nikon 
Eclipse CF160 epifluoresence microscope was used with a Qimaging RETIGA Exi-Fast cooled 
mono 12-bit camera and Q-Capture Pro software. Quantification was performed using HALO 
software epifluorescence module (Indica Labs, Corales, NM). Statistical analyses were 
performed with Graphpad prism version 6. Islet isolation procedures, RNA isolation, and QRT-
PCR were carried out as described previously. Primers are listed in Table 2.  
 
Table 4.1: Antibody Names and Supplier 
Antibody Name Catalog Number/Vendor 
TUJ1 Sigma, T2200 
Fibrillarin Cell Signaling Technologies, #2639 
Calbindin-D-28K Sigma, C9848 
Insulin Dako, A056401-2 
Glucagon Sigma, G2654 
Pancreatic Polypeptide Sigma, SAB2500747 
Somatostatin Phoenix Peptide, H-060-03 
Ghrelin Santa Cruz Biotechnology, sc-10368 
 
Table 4.2: Primers for QRT-PCR 
Gene Name Forward Primer Sequence Reverse Primer Sequence 
Ins1 CACTTCCTACCCCTGCTGG ACCACAAAGATGCTGTTTGACA 
Ins2 GCTTCTTCTACACACCCATGTC AGCACTGATCTACAATGCCAC 
Gcg CATTCACCAGCGACTACAGCAA TCATCAACCACTGCACAAAATCT 
Ppy TTCGAGCCTCTCTTGTCTTGA TAGTTTGCAAGGGAGCAGGTT 
Sst ACAGAGAATGATGCCCTGGAG AAGTTCTTGCAGCCAGCTTTG 
Ghrl CCATCTGCAGTTTGCTGCTA GCTTCTCCTCTGTCCTCTGG 
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Hhex CTCCAAGCCATTTTCAGAGCA GGACTGCGTCATCCCTTAACA 
Pdx1 GAAATCCACCAAGCTCAGG CGGGTTCCGCTGTGTAAG 
Nkx6-1 AACACACCAGACCCACGTTCT ATCCCCAGAGAATAGGCCAAG 
Pax6 AAACAAACGCCCTAGCTGTGC CCGCCCTTGGTTAAACTCCTC 
 
Results 
PWS Neurons Display Phenotypic Changes  Caused by Loss of Paternal Snord116  
 PWS and unaffected control PSC were differentiated to neurons using a modified dual 
smad inhibition protocol; inhibition of smad signaling pushes PSCs to a neuronal lineage (30).  
After 2 weeks of neuronal differentiation, PWS Tuj1+ neuron progenitors show a 38% reduction 
in mean cell body area; after 1 month of neuronal differentiation these neurons show a 58% 
reduction in mean cell body area in comparison to unaffected control PSC-derived neurons 
(Figure 4.1, A-B). The PWS iPSC lines utilized in the assay are from large deletion PWS 
patients. To determine if the phenotype of smaller neuronal soma is dependent on the loss of 
paternal Snord116, we isolated primary forebrain neurons from E15.5 WT and Snord116
p-/m+
 
embryos (Figure 4.1C). Tuj1+ primary neurons from Snord116
p-/m+
 embryos display 31% 
reduction in mean cell body area as compared to wild type, indicating that the loss of paternal 
Snord116 alone is sufficient to cause a phenotype of reduced cell body size in neurons isolated 
from E15.5 embryos (Figure 4.1C). As these neurons were isolated from an in vivo developing 
mouse brain, these results suggest that the reduction in cell body size caused by loss of paternal 
Snord116 is not an artifact of in vitro neural differentiation. We also found a 52% reduction in 
the mean number of neural processes per cell in PWS iPSC-derived neuron progenitors (D14 of 
differentiation) in comparison to unaffected controls (Figure 4.1D). Following one month of 
neural differentiation, PWS Tuj1+ iPSC-derived neurons show a 49% decrease in mean 
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processes per cell compared to unaffected control cells (Figure 4.1E). Likewise, the mean 
processes per neuron in Tuj1+ primary neurons from E15.5 Snord116
p-/m+
 embryos are reduced 
by 11% compared WT littermates (Figure 4.1F). For both iPSC-derived neurons and E15.5 
primary neurons there are no differences in mean branching or mean outgrowth per neuron 
detected between PWS and unaffected control genotypes, or Snord116
p-/m+
 and WT genotypes, 
respectively (Supplemental Figure 4.1). Representative images of primary neurons are shown 
in Supplemental Figure 4.2.  
We next asked whether neurons from fixed brains of adolescent mice lacking the paternal 
copy of Snord116 would also display reduced cell body size. The highest level of Snord116 
expression is in the cerebellum; we measured Purkinje neuron cell body size in fixed brains of 
one month old (P30) Snord116
p-/m+
 and WT littermates (Supplemental Figure 4.3). We found a 
21% reduction in the mean cell body diameter of cerebellar Purkinje neurons in Snord116
p-/m+
 
mice compared to WT littermates. This result suggests that the reduction in cell body size is not 
an artifact of the neuron isolation manipulations or cell culture conditions (Figure 4.1G); nor is 
the effect brain region-specific. The size of the neuronal nucleolus is proportional to the neuron 
soma size (10). Leung et al. have previously reported that the neuronal nucleolus diameter is 
reduced in Purkinje neurons of PWS patients and of +/PWS-IC
del35kb
 mice which lack expression 
of paternally expressed PWS region genes (5, 31). Conversely, PWS-IC
hs
/+ mice that effectively 
over-express PWS region genes, including Snord116, from both alleles had larger and more 
numerous neuronal nucleoli (5). We asked whether deletion of just the paternal copy of the 
Snord116 gene cluster is sufficient to cause a reduction in the neuronal nucleolar diameter. We 
examined the diameters of neuronal nucleoli in cerebellar Purkinje neurons because of their 





 mice was reduced 16% compared to WT littermates (Figure 4.1H). 
Representative images of the cerebellar Purkinje neurons (Calbindin D28K green, Hoechst blue) 
and nucleouli (Fibrillarin red, Hoechst blue) are shown in Figure 4.1I. 
 The phenotype of reduced cell body size in Snord116
p-/m+
 mice persists at least until 4 
weeks (these are the oldest mice we examined). The reduced cell body size and reduced neuronal 
nucleolar size begin in development and persist into adulthood, i.e. any developmental ‘catch up’ 
mechanisms are apparently unable to compensate for the congenital loss of paternal Snord116. 
Consistent with this inference, Leung et al., found decreased neuronal nucleolus diameter in post 
mortem adult brain tissue of PWS patients compared to unaffected control (5).  
 
Endocrine Pancreas Developmental Differences in Snord116
p-/m+ 
Mice Persist into Adulthood 
 We have previously shown that proinsulin to insulin processing is impaired in the 
pancreata of Snord116
p-/m+
 mice due to decreases in both PC1 and PC2. Here we also asked 
whether aspects of the endocrine pancreas development are also affected by loss of paternal 
Snord116. At birth there is no difference in the body weights of Snord116
p-/m+
 mice compared to 
WT littermates (Figure 4.2A). The mean islet size of Snord116
p-/m+
 P0.5 mice is decreased 23% 
compared to WT (Figure 4.2B). We quantified the relative proportion of each endocrine cell 
type in P0.5 primordial pancreata and found no change in the proportion of insulin or pancreatic 
polypeptide positive cells; however, the percentage of somatostatin positive cells was increased 
3-fold in Snord116
p-/m+
 mice compared to WT (Figure 4.2, C,D,F). The proportion of  glucagon 
positive cells was decreased (Figure 4.2E). There was no difference in the proportion of ghrelin 
positive cells at P0.5 (Supplemental Figure 4.4). Representative images of each stain are shown 
in Figure 4.2, G-I. These proportions persists at 4 weeks of age (Supplemental Figure 4.5) and 
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into adulthood (Figure 4.2J-S). Snord116
p-/m+
 mice are runted beginning after birth (runting is 
apparent by postnatal day 9) and continuing into adulthood; body weight-matched adult mice 
were selected to assess pancreatic islet size and cell proportions (Figure 4.2J) (23). Mean islet 
size was decreased by 32% in body weight matched adult Snord116
p-/m+
 mice compared to WT 
(Figure 4.2K). Mean islet density per field was unchanged at all ages (Supplemental Figure 
4.6). We found that the proportion of insulin positive and pancreatic polypeptide positive cells 
are unchanged (Figure 4.2, L,O). The proportion of somatostatin positive cells is increased 1.5-
fold in adult Snord116
p-/m+
 animals compared to WT while the percentage of glucagon positive 
cells are 30% reduced (Figure 4.2, M-N). Representative images of all stains are shown in 
Figure 4.2, P-S.  
 
We also measured gene expression levels of each pancreatic islet cell type in isolated 
islets from 6 month old mice. Consistent with the ~30% reduction in mean islet size in 
Snord116
p-/m+
 mice (Figure 4.2, B,K), gene expression levels of both Ins1 and Ins2 were 
decreased in isolated islets from Snord116
p-/m+
 adult mice compared to WT (Figure 4.2, T-U). 
There was no change in expression levels of Gcg, Ppy, or Ghrl (Figure 4.2, W-Y). Gene 
expression levels of Sst in Snord116
p-/m+
 isolated islets were increased 2-fold compared to WT 
(Figure 4.1V). Somatostatin is also expressed in the stomach, ileum, and hypothalamus; Sst 
expression levels in Snord116
p-/m+
 were not different from WT in these tissues indicating that the 
upregulation of Sst is pancreas-specific (Supplemental Figure 4.7). Islet cell body size and 
nuclear size were not different between genotypes, indicating that the effects of  Snord116 on 








 Immunofluorescent analysis of the P0.5 pancreata revealed a greater percentage of 
polyhormonal cells in islets of Snord116
p-/m+
 mice. We also identified that key transcription 
factors for pancreatic development were dysregulated in Snord116
p-/m+
 mice. The percentage of 
islet cells co-positive for insulin, somatostatin, and pancreatic polypeptide was increased 3.4-fold 
increase in in P0.5 Snord116
p-/m+
 mice (Figure 4.3A). Likewise, there is a 2.7-fold and 3.4-fold 
increase in insulin and somatostatin double positive and pancreatic peptide and somatostatin 
double positive cells, respectively, in Snord116
p-/m+
 P0.5 pancreata (Figure 4.3, B-C). There was 
no change in the proportion of somatostatin and glucagon double positive islet cells (Figure 
4.3D). There was also no change in the proportion of INS+, PP+ or INS+, GCG+ islet cells in 
P0.5 primordial pancreata (Supplemental Figure 4.9). Representative images are shown in 
Figure 4.3, E-H. Hhex, a transcription factor controlling somatostatin expression was 
upregulated 1.5-fold in isolated islets from Snord116
p-/m+
 mice compared to WT (32). Expression 
of Pdx1, a transcription factor critical to pancreatic development and the maintenance of mature 
beta cell identity and function was downregulated 72% in Snord116
p-/m+
 isolated islets compared 
to WT (33, 34). Likewise, the transcription factors, Pax6 and Nkx6-1 are downregulated by 46% 
and 60%, respectively in isolated islets from adult Snord116
p-/m+
 mice compared to WT. 
 
Discussion  
 Here we report developmental phenotypes in the central nervous system and endocrine 
pancreas of mice lacking paternal Snord116 that persist into adulthood. Individuals with Prader-
Willi syndrome have characteristic brain structural abnormalities that probably contribute to their 
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complex behavioral and neurodendocrine phenotypes (3, 4). We hypothesized that the loss of 
paternal Snord116 would be sufficient to cause these changes. We found that the absence of 
paternal Snord116 was associated with reduced size of the neuronal soma in general forebrain 
neurons of the mouse and in iPSC-derived neurons. The earliest timepoint at which we detected 
this phenotype was in Tuj1+ PWS large deletion iPSC-derived PWS neuron progenitors at day 
12 of differentiation (Figure 4.1A). We also found reduced cell body size in PWS large deletion 
iPSC-derived neurons at day 34 of differentiation (Figure 4.1B). Because PWS large deletion 
patient neurons have many genes deleted, we repeated this experiment in E15.5 primary neurons 
from Snord116
p-/m+
 and WT embryos. Tuj1+ primary forebrain neurons from Snord116
p-/m+
 had 
reduced cell body size indicating that the loss of just paternal Snord116 is sufficient to cause a 
reduction in cell body size (Figure 4.1C). We also found that the soma of Purkinje neurons in 1 
month old Snord116
p-/m+
 mice were reduced in size as well (Figure 4.1G). These findings 
suggest that there are no developmental compensation mechanisms to fully compensate for the 
congenital loss of paternal Snord116 expression. The demonstration of reduced neuronal cell 
body size in fixed whole brain tissue suggests that the results from the iPSC-derived neurons and 
primary neurons are not an artifact of reduced viability or recovery from tissue culture or 
isolation manipulations.  
 Neuronal nucleolar diameter is proportional to neuronal soma size (11). Nucleoli are 
centers of ribosome biogenesis and are critical to maintaining normal neuronal functions in both 
growing and post-mitotic neurons (9). We found that Snord116
p-/m+
 mice had smaller neuronal 
nucleoli compared to WT littermates (Figure 4.1H). Ribosome biogenesis occurring in the 
neuronal nucleolus is thought to support the formation of neurites (9). We found that Tuj1+ PWS 
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large deletion iPSC-derived neurons and Tuj1+ Snord116
p-/m+
 E15.5 primary neurons had  
decreased numbers of processes per neuron (Figure 4.1, E-F).  
SNORD116 is a gene cluster from which 30 highly homologous snoRNA products are 
transcribed. Although SNORD116 is considered an “orphan” snoRNA without any known rRNA 
targets, SNORD116 snoRNAs are localized to the nucleolus (35). mTORC1 signaling through 
p70s6 kinase and ribosomal protein s6 are known mediators of cell size and growth (36). 
mTORC2 signaling also regulates the size of cerebellar neurons; Rictor knockout mice display 
smaller soma in the hippocampal and in cerebellar Purkinje neurons, as well as impaired 
foliation in the cerebellum (37).  
 While Snord116 is expressed at much higher levels in the brain than in other organs, 
expression is present in other organs, including pancreatic islets (Supplemental Figure 4.3). We 
investigated the cellular composition of the developing islets of Snord116
p-/m+
 mice. The 
expression of SNORD116 was highest in iPSC-derived islets at day 15, during the period of β-
cell differentiation (Supplemental Figure 4.3). SNORD116 was also much more highly 
expressed in β-cells than other genes in the PWS interval (Supplemental Figure 4.3). We found 
that Snord116
p-/m+
 mice have smaller pancreatic islets (decreased #nuclei/islet) at birth, prior to 
over somatic runting, that persists into adulthood (Figure 4.2, B, K; Supplemental Figure 4.5). 
The endocrine cell makeup of these islets is affected: Snord116
p-/m+
 mice have a 3-fold increase 
in the proportion of somatostatin positive cells and a 25-30% reduction in the proportion of 
glucagon positive cells (Figure 4.2, D-E, M-N). There was no change in the proportion of 
insulin, pancreatic polypeptide, or ghrelin positive cells (Figure 4.2). The altered islet 
architecture was present at birth (P0.5), persisted into adolescence (P30) and adulthood (6 
months – 1 year). Gene expression levels in isolated islets from adult mice were consistent with 
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the altered proportion of endocrine cell types in the islet: Sst expression was increased 1.5-fold in 
Snord116
p-/m+
 islets (Figure 4.2V). Ins1 and Ins2 were downregulated x fold in Snord116
p-/m+
 
islets indicative of the overall reduction in islet size (Figure 4.2, T-U). The β-cell marker, Mafa, 
trended towards a >50% reduction, p=0.09 (Supplemental Figure 4.10). Gene expression levels 
of Gcg, Ppy, and Ghrl were unchanged (Figure 4.2, W-Y). 
Altered pancreatic islet architecture was associated with a >3-fold increase in 
polyhormonal cells in P0.5 pancreata (Figure 4.3A). The polyhormonal phenotype was 
associated with an increase Somatostatin co-expressing cells (Figure 4.3B-D). Consistent with 
this association, Hhex expression was increased in isolated islets (Figure 4.3I). Hhex is a 
transcription factor that regulates expression of somatostatin in the endocrine pancreas (32). 
Mice in which Hhex expression has been ablated specifically in Ngn3-expressing cells, manifest 
a 75% reduction in δ-cell area (32). It is possible that the expression of Snord116 acts in some 
way to repress Hhex. In the absence of Snord116 there is an upregulation of Hhex which may be 
causing inappropriate Hhex expression in non-δ-cells possibly driving the increase in 
polyhormonal cells co-positive for Somatostatin. That is, Snord116 may play a role in endocrine 
cell fate specification.  
 Polyhormonal cells in the islet are observed in developing mouse and human pancreatic 
islets (38-40). Polyhormonal cells have also been recently observed in adult human Type II 
diabetic islets (41-43). Insulin+, Somatostatin+ double positive cells are increased in the 
pancreata of individuals with impaired glucose tolerance and newly diagnosed diabetes mellitus 
compared to normoglycemic controls (41). Cinti et al., reported a 5-fold increase in islet cells 
coexpressing NKX6.1 and Somatostatin in islets from diabetic organ donors compared to non-
diabetic controls;  they postulate that these cells represent failing β-cells transdifferentiating to δ-
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cells (43). Islets from individuals with long standing Type 1 diabetes mellitus islets also have an 
excess of δ-cells compared to non-diabetic controls (44). Excess of δ-cells are also noted in the 
NOD mouse model of Type 1 Diabetes Mellitus (44).  
Interestingly, we did not observe overt disorganization of the islets of adolescent (4 
weeks) and adult (6 months – 1 year) Snord116
p-/m+
 mice. We also did not see polyhormonal 
cells in adolescent or adult Snord116
p-/m+ 
mice. The changes in islet phenotype were reduced islet 
size, an increased percentage of Somatostatin positive cells and a decreased percentage of 
Glucagon positive cells. Although the proportion of Somatostatin positive cells was increased, 
they remained at the periphery of the islet, suggesting that there may be sub-populations of cells 
that are more susceptible than others. The cells in which Somatostatin is a polyhormone  at P0.5 
may take on the δ-cell lineage in adult animals.  
 Isolated islets of Snord116
p-/m+
 mice also displayed downregulation of Pdx1, Pax6, and 
Nkx6-1 (Figure 4.3, J-K). Pdx1 is a transcription factor important for pancreatic development as 
well as maintenance of mature beta cell function and identity (34, 45). It is possible that the 
downregulation of Pdx1 may be responsible for the reduction in islet size as well as the altered 
distribution of islet cell types. Following Ngn3 specification, Pdx1 expression is restricted to β- 
and δ-cells which are both dysregulated in the Snord116
p-/m+
 pancreata (46). Pdx1 participates in 
the regulation insulin gene expression; its reduction in Snord116
p-/m+
 beta cells  could account in 
part for  the downregulation of Ins1 and Ins2 in Snord116
p-/m+
 islets (47). Pax6 is directly 
regulated by Pdx1 and its downregulation may be secondary to the downregulation of Pdx1 (48). 
The main phenotype of Pax6 knockout mice is a reduction in α-cells which is consist with what 
we observed in the Snord116
p-m+
 pancreata (49).  
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Nkx6-1 expression is specific to β-cells after the secondary transition and deletion of 
Nkx6-1 causes loss of β-cell precursor cells (45). The downregulation of Nkx6-1 in Snord116
p-/m+
 
islets likely also contributes to the reduction in expression of Ins1 and Ins2. Deletion of Nkx6-1 
specifically in β-cells induces loss of β-cell identity and conversion of the β-cells into δ-cells 
(50). The downregulation of Nkx6-1 may contribute not only to the reduction in β-cells but may 
also contribute to the increase in δ-cells in Snord116
p-/m+
 mice.  
We have previously shown that PC1 and PC2 transcripts and protein are downregulated 
in islets of Snord116
p-/m+
 mice and that these mice display impaired processing of proinsulin to 
insulin. Impaired prohormone processing may also have developmental consequences. In the 
islet, PC1 is predominantly expressed in β-cells, while PC2 expression occurs in α-, β- δ-, and 
PP-cells (51). PC1 is not expressed in α-, δ-, and PP-cells (51). PC1 and PC2 expression in the 
islet are dectected at E14 and E17, respectively (51). Interestingly, in murine models of insulin 
resistance, expression of PC1 is increased in α-cells and can result in processing of proglucagon 
to GLP1 (rather than to glucagon) (52). GLP1 may stimulate β-cell proliferation (52). This 
phenomenon could be blunted in the Snord116 mice in which PC1 expression is downregulated. 
Furthermore, mice that express a dominant-negative form of the FGF receptor, FGFR1c, in β-
cells have reducted postnatal β-cell mass, disorganized islets, and decreased expression of PC1 in 
β-cells (53, 54). These mice develop diabetes due partially to impaired proinsulin processing 
(54). While islet development has not been carefully assessed in PC1 null animals, PC2 null 
animals have dysregulated islet development (55). PC2 null mice mis-express of Pdx1 and Nkx6-
1 past normal developmental timepoints and display polyhormonal Insulin+, Somatostatin+ cells 
into adulthood (55). Based on these considerations, it is possible that the reduction in PC2 levels 
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in the islets of the Snord116
p-/m+
 mice may also contribute to the phenotype of reduced Pdx1 and 
Nkx6-1 levels as well as the increase in polyhormonal cells co-expressing Somatostatin. 
The experiments reported here demonstrate that Snord116 is likely to play an important 
role in pancreas development and endocrine cell type specification and maturation. It would be 
of interest to delete paternal Snord116 in the pancreas only (Pdx1-CRE) and in β-cells only (RIP-
CRE). Finally, identification of exactly which products generated from the Snord116 gene 
cluster are critical mediators of pancreatic islet development and function, and by what 
molecular mechansims these effects are conveyed could point to novel aspects of islet biology 
and PWS pathogenesis. 
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Figures and Figure Legends 
 
Figure 4.1: Loss of paternal Snord116 results in smaller neuronal cell body size and decreased 
neural processes. A) The mean cell body area of PWS iPSC-derived Tuj1+ neuron progenitors 
(day 14 of differentiation) is 38% smaller than unaffected control. B) Mature PWS Tuj1+ iPSC-
derived neurons show a 58% reduction in mean cell body area. C) Tuj1+ primary neurons 
isolated from E15.5 embryos of Snord116
p-/m+
 mice also display an ~ 31% reduction in mean cell 
body area as compared to wild type (WT). D) PWS Tuj1+ neuron progenitors have 52% less 
processes per cell than control neuron progenitors. E) Mature (day 34) PWS Tuj1+ iPSC-derived 
neurons display 49% decrease in mean processes per cell compared to control. F) There is an 
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11% decrease in the mean number of processes per neuron in primary neurons from E15.5 
Snord116
p-/m+ 
embryos compared to WT littermates. G) There is a 21% reduction in the mean 
Purkinje neuron diameter in Snord116
p-/m+
 fixed brain sections compared to WT littermates. H) 
Purkinje neuron nucoleoar diameter is 16% less in P30 Snord116
p-/m+
 mice compared to WT 
littermates. I) Representative images of calbindin D28K (green) positive neurons and fibrillarin 
(red) positive neucleoli from cerebellar sections of P30 WT and Snord116
p-/m+
 (DEL) fixed 
brains; nuclei are marked in blue by Hoechst stain. All images were taken obtained with a 63X 






Figure 4.2: Snord116p-/m+ mice display altered islet cell type proportions persisting into 
adulthood. A) There is no difference in the body weight of P0.5 Snord116
p-/m+
 neonates 
compared to WT littermates. B) There is a 23% decrease in the mean islet size of P0.5 
Snord116
p-/m+
 mice compared to WT littermates. C) The proportion of insulin positive cells in 
the islet is unchanged. D) There is a 3-fold increase in the proportion of somatostatin (SST) 
positive cells in the islet in Snord116
p-/m+
 mice compared to WT. E) The percentage of glucagon 
(GCG) positive cells is decreased in islets of Snord116
p-/m+ 
animals compared to WT. F) There is 
no difference in the percentage of pancreatic polypeptide (PP) positive cells. G) Representative 
images of the hematoxylin and eosin (H&E) stain sections from which the number of nuclei per 
islet was quantified in P0.5 mice. H-I) Representative images of insulin, glucagon, somatostin, 
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and pancreatic polypeptide immunofluorescent staining. J) Adult Snord116
p-/m+
 mice are runted 
and weigh less than WT littermates into adulthood, however, body weight-matched adult mice 
were picked for islet size and immunohistochemical analyses of endocrine cell type populations 
in the islets of wild type and Snord116
p-/m+
 mice. K) The mean islet size is decreased in adult 
Snord116
p-/m+
 mice compared to WT by 32%. L) The proportion of insulin positive cells in the 
islet is unchanged in adult mice. M) There is a 1.5-fold increase in the percentage of somatostatin 
positive cells in adults Snord116
p-/m+
 animals compared to WT. N) The percentage of glucagon 
positive cells is decreased by 30% in Snord116
p-/m+
 mice compared to WT. O) The proportion of 
pancreatic polypeptide positive cells is not different in adult mice. P) Representative H&E 
images used for quantification of mean islet size. Q-S) Representative images of the 
immunofluoresent staining for insulin, somatostatin, glucagon, and pancreatic polypeptide. T,U) 
Ins1 and Ins2 gene expression levels are decreased in isolated islets from Snord116
p-/m+
 adult 
mice compared to WT. V) Sst gene expression levels are increased 2-fold in Snord116
p-/m+
 
isolated islets. W-Y) There is no change in the gene expression levels of Gcg, Ppy, or Ghrl in 








Figure 4.3: The increase in δ-cells in Snord116p-/m+ mice is associated with an increased 
percentage of polyhormonal endocrine cells in the neonatal pancreas and altered 
transcription factor expression levels. A) There is a 3.4-fold increase in the percentage of 
polyhormonal cells positive for insulin, somatostatin, and pancreatic polypeptide in P0.5 
Snord116
p-/m+
 pancreata compared to WT littermates. B) There is a 2.7-fold increase in 
polyhormonal cells co-staining for insulin and somatostatin in Snord116
p-/m+
 neonatal pancreata 
compared to WT. C) Similarly, there is a 3.4-fold increase in somatostatin and pancreatic 
polypeptide double positive cells in P0.5 Snord116
p-/m+
 pancreata. D) There is no change in the 
percentage of glucagon and somatostatin double positive cells. E-H) Represenative images of 
polyhormonal cells in WT (E) and Snord116
p-/m+
 pancreata (F-H). I) Hhex expression is 
increased 1.5-fold in isolated islets from adult Snord116
p-/m+
 mice compared to WT littermates. 
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J) Pdx1 gene expression levels are decreased 72% in Snord116
p-/m+
 isolated islets. K) Pax6 is 
downregulated 46% in isolated islets from adult Snord116
p-/m+
 mice compared to WT littermates. 
L) Nkx6-1 gene expression levels are decreased 60% in Snord116
p-/m+



















Across Brain Region Expression Analysis for Snord116 
Ten week old, male, C57/BL6 were ordered from Jackson Laboratory (stock number 008149). Mice were 
fasted overnight and sacrificed; brain regions were dissected out using a brain block as well as freehand 
dissection. RNA was isolated with Trizol and Qiagen RNeasy columns with DNAse treatment for 
striatum (STR), cortex (CTX), amygdala (AMG), periaqueductal grey (PAG), brain stem (BS) and 
cerebellum (CB). RNA was isolated with Norgen Biotek Total RNA Purification Micro Kit with DNAse 
treatment for arcuate nucleus of hypothalamus (ARC), medial basal hypothalamus (MBH), anterior 
hypothalamus (AH), and pituitary (PIT). Total RNA was converted to cDNA using the Roche 
Transcriptor First Strand cDNA Synthesis kit. qRT-PCR was performed using Roche LightCycler 480 
SYBR Green I Master mix. Primers are listed in Supplemental Table 1. 
Across Tissue Expression Analysis for Snord116 
Ten week old, male, C57/BL6 were ordered from Jackson Laboratory (stock number 008149). Ad lib fed 
mice were sacrificed; brain regions were dissected with a brain block, non-brain tissues were dissected 
out freehand. RNA was isolated with Trizol and Qiagen RNeasy columns with DNAse treatment for 
cortex, whole hypothalamus, cerebellum, brain stem, eyes, tongue, liver, stomach, jejunum, duodenum, 
ileum, kidney, testes, perigonadal adipose tissue (PGAT), skin, and muscle. RNA was isolated with 
Norgen Biotek Total RNA Purification Micro Kit with DNAse treatment for isolated islets, adrenal gland, 
and pituitary. Procedures for islet isolation have been previously described. RT and QRT-PCR procedures 
were the same as described above. 
Time course expression analysis for SNORD116 in PSC-derived hypothalamic neurons and β-cells 
Pluripotent stem cells (PSC) were differentiated to hypothalamic neurons and β-cells using methods 
previously described (29, 56). RNA was isolated with Norgen Biotek Total RNA Purification Micro Kit 
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with DNAse treatment, RT and QRT-PCR procedures were the same as described above. Primers are 
listed in Supplemental Table 1. 
Analysis of Sst Gene Expression Levels in Stomach, Ileum, and Hypothalamus 
Ad lib fed, adult wild type (WT) (n=5) and Snord116
p-/m+
 (n=6) were sacrificed and stomach, ileum, and 
hypothalamus were dissected out using the same procedures as described above. RNA was isolated with 
Trizol and Qiagen RNeasy columns with DNAse treatment, RT and QRT-PCR procedures were the same 
as described above. Primers for Sst are listed in Main Text Table 2. 
 
 
Supplemental Table 4.1: Primers 
Gene Name Forward Primer Sequence Reverse Primer Sequence 
SNORD116 CGATGATGAGTCCCCCATAAAAAC CAGTTCCGATGAGAACGACG 
Snord116 TGGATCTATGATGATTCCCAG TGGACCTCAGTTCCGATGAG 
116Hg AAGCTGCTGGTAGAAGAAATGG AAGTGTCACCACAACACTGGAC 
Nkx2-2 TCGCTCTCCCCTTTGAACTTT GTTAACGTTGGGATGGTTTGG 
Mafa GAGGAGGTCATCCGACTGAAA GCACTTCTCGCTCTCCAAGAAT 
Mafb GGCAACTAACGCTGCAACTCT CAACGGAAGGGACTTGAAGAC 
Islet1 CGGAGAGACATGATGGTGGTT GGCTGATCTATGTCGCTTTGC 
Arx TTCCAGAAGACGCACTACGC TCTGTCAGGTCCAGCCTCAT 
Foxa2 GAGCACCATTACGCCTTCAAC AGGCCTTGAGGTCCATTTTGT 
Brn4 GGCTGATTCATCCACAGGAAG TTCCAGTACGCCCTTGACACT 









Supplemental Figure 4.1: There is no difference in mean branching or mean process length per 
cell in Tuj1+ iPSC-derived neurons or E15.5 primary neurons. Corresponding to Main Text Figure 
1, from the neurite extension assay, there were no differences in mean branching of neurites per cell or the 
mean length of neurites (mean outgrowth) per cell in PWS iPSC-derived neurons (A,B) compared to 
unaffected control of E15-5 primary neurons of Snord116
p-/m+


















Supplemental Figure 4.3: Expression Patterns of SNORD116. A) In adult, WT mice, the cerebellum 
is the brain region in with the highest level of Snord116 expression. B) SNORD116 expression peaks at 
the start (D3) of iPSC-derived hypothalamic neuronal differentiation, then declines until the progenitor 
stage (D12), and increases again in more mature (D24) hypothalamic neurons. C,D) Comparing Snord116 
snoRNA and 116Hg lncRNA expression levels across different tissues, the highest expression is in the 
brain, specifically the cerebellum. E,F) However, Snord116 snoRNAs and 116Hg lncRNA are expressed 
in other tissues, if expression is normalized to that of stomach such that expression can be appreciated in 
tissues with lower levels of expression, the testes, pituitary, and isolated islets, express Snord116 
snoRNAs at moderate levels. 116Hg expression is lower in isolated islets than adrenal gland, muscle, and 
kidney. G) Expression of SNORD116 steadily increases during differentiation of unaffected control iPSC 
to iPSC-derived β-cells. H) Comparing SNORD116 expression levels to that of other PWS-region genes 
in iPSC-derived β-cells (D15 of differentiation) reveals that it is expressed at significantly higher levels 






Supplemental Figure 4.4: No difference in the proportion of ε-cells in the P0.5 pancreas. A) 
There is no difference in the percentage of ghrelin positive cells in the pancreata of P0.5 mice. B,C) 
Representative images from WT and Snord116
p-/m+







Supplemental Figure 4.5: P30 Snord116p-/m+ mice have smaller islets and dysregulated islet 
cell populations. A) Snord116p-/m+ mice weigh less than WT littermates (n=2 WT, n=2 DEL). B) There 
are a decreased number of cells in the islets of P30 Snord116
p-/m+
 mice compared to WT littermates. C) 
Representative images of H&E stained pancreatic sections. D) There is no change in there proportion of 
insulin positive cells per islet in Snord116
p-/m+
 mice. E) The percentage of Somatostatin postitive cells is 
increased in Snord116
p-/m+
 mice compared to WT littermates. F) The percentage of Glucagon positive 
cells is decreased in Snord116
p-/m+ 







Supplemental Figure 4.6: Islet Density is unchanged at all ages. A-C) There is no difference in the 
frequency of islets observed in sections from WT or Snord116
p-/m+







Supplemental Figure 4.7: No change in Sst gene expression levels in stomach, ileum, or 
hypothalamus. A-C) Stomach, Ileum, and hypothalamus was assayed for expression levels of Sst in 
adult WT and Snord116
p-/m+








Supplemental Figure 4.8: No change in islet cell body size or nuclear size. A-D) Using 
quantification from HALO software Epifluorescence module, there was no difference in cell body size or 
nuclear size between Snord116
p-/m+






Supplemental Figure 4.9: No difference in the proportion of polyhormonal INS+/PP+ or 
INS+/GCG+ cells in P0.5 mice. A, B) There is no difference in the percentage of cells double positive 






Supplemental Figure 4.10: Gene expression levels of other islet transcription factors and 
markers. A) There is no difference is gene expression levels of Nkx2-2 in isolated islets from adult 
Snord116
p-/m+
 and WT mice. B) Mafa trends towards a decrease in Snord116
p-/m+
 isolated islets compared 
to WT. C-H) There is no difference in the gene expression levels of Mafb, Islet1, Arx, Foxa2, Brn4, or 
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CHAPTER 5  
“Future Directions and Concluding Remarks”   
Future Directions 
 
Define the molecular mechanisms by which genes in the PWS minimum interval (primarily 
SNORD116) confer effects implicated in Chapters 2 and 3. 
Based on the results presented in Chapters 2 and 3, my working hypothesis is that 
paternal deficiency of human or mouse SNORD116 causes hyperphagic obesity due, in part, to 
decreases in PC1 and a functional impairment in the processing of neuropeptides critical to body 
weight regulation. I further hypothesize that a major function of SNORD116 is to maintain 
cellular levels of PCSK1 by direct interaction with either PCSK1 itself and/or other transcription 
factors that also control PCSK1 expression (e.g. NHLH2).  
The impaired processing of POMC to αMSH is an obvious candidate for the hyperphagic obesity 
observed in human and animal models of PC1 deficiency. Thus, I have hypothesized that the impaired 
processing of POMC to αMSH may contribute to the hyperphagic obesity of individuals with PWS. 
However, many hormones involved in food intake and energy expenditure are processed by PC1, 
including proAgRP, proNPY, POMC, proCART, pro-oxytocin, and proBDNF. While levels of the 
anorexigenic αMSH are reduced in Pcsk1 hypomorphs, levels of the orexigenic ProAgRP are increased in 
Pcsk1 hypomorphs. I found that Snord116
p-/m+ 
mice have increased transcript levels of Npy and Agrp and 
decreased transcript levels of Pcsk1 in the hypothalamus. Processing of AgRP is not necessary for its 
biological activity and ProAgRP has considerable antagonistic activity at MC4R (1, 2). Thus, it may also 
be the case that increased hypothalamic levels of ProAgRP could drive hyperphagia. More specific 
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models of PC1 and Snord116 deficiency as well as rescue experiments are needed to tease out exactly 
which hormone(s) may drive the hyperphagic obesity phenotype. 
Furthermore, because the runting of Snord116
p-/m+
 mice is likely masking the 
development of obesity in these animals, the exact mechanism for the severe hyperphagia in 
PWS is still unclear. Therefore, I cannot definitively conclude whether SNORD116, SNORD109, 
or IPW are, individually or in combination, the main drivers of downregulation of NHLH2 and 
PCSK1.  
I propose to use CRISPR-Cas9 technology to delete SNORD116, SNORD109, and IPW 
independently in ESCs and to examine transcriptional and functional consequences in derived 
hypothalamic neurons. CRISPR-Cas9 deletion lines for NHLH2 and PCSK1 will also be 
generated to elucidate possible molecular mechanisms. Because the Snord116
p-/m+
 mice do not 
develop obesity, likely due to their extreme runting, investigations of a hyperphagic phenotype in 
these mice are limited. To address this issue, I propose to develop three new mouse models of 
PWS, including an adult-onset Snord116 deletion mouse, a mouse in which Snord116 is deleted 
only from POMC-expressing neurons, and a mouse in which Snord116 is deleted only from 
AgRP-expressing neurons.  
To investigate the individual contributions of SNORD116, IPW, and SNORD109A to 
PWS, I will use CRISPR-Cas9 to independently delete each gene in hESCs, which I will then 
differentiate to hypothalamic neurons. I will perform batch and single cell RNA sequencing in 
these lines. I will look specifically at both transcript and protein levels of NHLH2, PC1, PC2, 
CPE and POMC. I will also measure POMC processing to MSH, -endorphin, and ACTH in 
these cells. Processing of other neuropeptides including proNPY, proAgRP, proCART, pro-
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oxytocin, and proBDNF, will also be assessed. I will perform rescue experiments in each 
instance to determine if in SNORD116del neurons whether re-expressing SNORD116 and/or 
NHLH2 can rescue PC1 expression and increase processing of neuropeptides critical to body 
weight regulation. 
 I also want to identify the molecular mechanisms by which the deletion interval gene(s) 
identified above cause downregulation of NHLH2 and PCSK1. Assuming that SNORD116 is 
implicated, it is unclear if SNORD116 can interact directly with NHLH2 and/or PC1 (in theory 
transcript, protein, both),  and if a direct interaction does occur, if it is happening at the (1) 
RNA(SNORD116)-DNA(NHLH2/PCSK1), (2) RNA(SNORD116)-RNA(NHLH2/PCSK1), or 
(3) RNA(SNORD116)-protein(NHLH2/PCSK1) level. 
I will investigate (1) using DNA/RNA fish, probing against S NORD116 RNA and the 
NHLH2 and PCSK1 gene loci (in separate experiments) in hESC-derived hypothalamic neurons.  
S NORD116, NHLH2, and PCSK1 deletion hESC-derived neurons and PWS iPSC-derived 
neurons will be used as negative controls.  This question can also be investigated using a 
modified ChiRP; however the previous approach is more cost-effective. I will investigate (2) in 
the same experimental set-up as (1) instead using two color RNA FISH probes against 
SNORD116 and NHLH2 or PCSK1. An RNA-protein interaction (3) can be tested using RNA-
protein pulldown technologies. Probes specific to SNORD116 can be used, and/or antibodies 
specific to NHLH2 or PCSK1 can be used. Quantitative RT-PCR and western blotting can then 
be performed to see if SNORD116 and NHLH2 or PCSK1 exist in the same complex. The 
CRISPR-induced deletion cell lines for SNORD116, SNORD109, IPW, NHLH2 and PCSK1 will 
serve as controls for these studies. These studies may provide insight not only into the molecular 
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mechanism of neuroendocrine dysregulation in PWS but also basic molecular biology by which 
non-coding RNAs function. 
I propose to also perform additional studies in mice to determine if loss of Snord116 can 
produce a hyperphagic, obese mouse. I have hypothesized that the severe dwarfism of 
Snord116
p-/m+
 associated with impaired proGHRH processing and low circulating GH causes 
developmental compensations which impede the development of obesity in these mice. I will 
induce Snord116 deletion at 6-8 weeks of age by breeding floxed Snord116 mice to B6.129-
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J mice, in which of Cre recombinase under the ubiquitous 
ROSA26 promoter is inducible by tamoxifen administration. I will also breed floxed Snord116 
mice with mice expressing Cre recombinase under the control of the Pomc promoter as well as 
mice expressing Cre recombinase under the control of the AgRP promoter. This will yield mice 
in which Snord116 (paternal or both copies) is deleted only in Pomc-expressing neurons or 
AgRP-expressing neurons, respectively. I will investigate whether deletion of Snord116 
specifically in Pomc neurons or AgRP neurons causes hyperphagic obesity in the absence of 
runting. 
 
Define the molecular mechanism(s) by which Snord116 aids in the development of the 
endocrine pancreas (Chapter 4). 
Because the mice investigated in Chapter 4 are globally deleted for Snord116, I cannot 
rule out that the developmental defects we identified in the endocrine pancreas are not due to the 
lack of Snord116 expression in another tissue; perhaps lack of Snord116 expression in cells 
innervating the pancreatic islets are the primary cause of the phenotype. In order to investigate 
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this further, I propose to delete paternal Snord116 in the pancreas only (Pdx1-CRE) and in β-
cells only (RIP-CRE). iPSC-derived β-cells could also be employed to investigate this phenotype 
further as these cells are not subject to effects of the in vivo physiological milieu.  
 
Which non-coding RNA species is critical in PWS pathogenesis (Chapters 2-4)? 
As mentioned, multiple non-coding RNA products are transcribed from the Snord116 
gene cluster. Contingent on results of the whole cluster SNORD116 deletion, generation of 
deletion models that delete only specific components of the SNORD116/Snord116 gene cluster 
may be performed. Using CRISPR/Cas9, I can design guide RNAs and attempt to specifically 
delete individual snoRNAs, groups of snoRNAs, individual sno-lnc RNAs, or 116HG. These 
cells can then be differentiated to neurons or β-cells and I can investigate transcriptional, 
morphological, and functional aspects of these cells to identify which non-coding species 
transcribed from the gene cluster are important for specific phenotypes identified in whole-
cluster deletion models. Rescue experiments in which the specific non-coding RNAs species are 








 Reductions in PCSK1 levels were identified by RNA sequencing – a hypothesis-free, 
data-driven experiment – of iPSC-derived neurons from unaffected control individuals, PWS 
large deletion patients, and PWS microdeletion patients. I confirmed by qRT-PCR in 
independent differentiation experiments that PCSK1 transcripts and PC1 protein levels are 
reduced in PWS neurons.  Then, using the Snord116
p-/m+
 mouse model of PWS I asked if 
functional defects in prohormone processing could be measured in vivo in mice harboring 
deletion of only paternal Snord116. I found that the processing of proinsulin, proGHRH, and 
proghrelin was impaired in these animals, and that these effects were associated with tissue-
specific reductions in PC1.  
 These data led to the formulation of the hypothesis presented graphically in Figure 3.4: 
that PC1 deficiency is the major driver of the salient clinical phenotypes of Prader-Willi 
syndrome. The major phenotypes of PWS that could be accounted for by PC1 deficiency 
include: hyperphagic obesity (multiple candidate prohormones), low GH and short stature 
(impaired proGHRH processing), hypogonadism (impaired proGnRH processing), 
hyperghrelinemia (impaired proghrelin processing), relative hypoinsulinemia and type II diabetes 
mellitus (impaired proinsulin processing), adrenal insufficiency (impaired processing of 
proCRH), and hypothyroidism (impaired proTRH processing). Individuals with inactivating 
mutations of PCSK1 (21 patients have been identified to date) phenocopy Prader-Willi syndrome 
patients in many aspects. PCSK1 mutation patients also present with severe, early-onset 
hyperphagic obesity (multiple prohormone candidates) hypogonadotropic hypogonandism 
(impaired proGnRH processing), growth deficiency associated with low levels of circulating 
growth hormone (impaired proGHRH processing), hypoadrenalism (impaired processing of 
CRH), diabetes insipidus (impaired proinsulin and provasopressin processing), 
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hyperproinsulinemia associated with hypoglycemia which can progress to type 2 diabetes later in 
life (impaired proinsulin processing), and neonatal malabsorptive diarrhea (possibly impaired 
intestinal proglucagon processing to GLP1) (also see Table 1.5) (3). It is important to note that 
patient-specific iPSC-derived neurons were used as a discovery model system and that 
confirmation studies were then carried out using the Snord116
p-/m+
 mouse model. This strategy 
differs from many stem cell models that have been used as confirmatory models for molecular 
processes initially identified in mice.  
  
How do reductions in PC1 drive hyperphagic obesity: roles of melanocortin and non-
melanocortin candidate hormones 
 I hypothesize that a reduction in PC1 in the central nervous system due to paternal 
deletion of SNORD116 is a major driver of hyperphagic obesity in Prader-Willi syndrome. 
However, the precise molecular physiology by which deficiency of PC1 drives hyperphagic 
obesity has not been definitively determined. While impaired processing of POMC to αMSH is 
an obvious candidate for the hyperphagia, POMC transcript and protein levels can be 
upregulated in the setting of PC1 deficiency and could compensate for impaired POMC 
processing (likely due to impairment of  negative feedback regulatory mechanism) (4, 5). There 
are conflicting reports in the literature regarding αMSH levels in mouse models of PC1 
deficiency. Initial studies of PC1-deficient mice reported reductions in hypothalamic and 
pituitary αMSH by gel filtration and RIA; however, follow-up studies using LC-MS did not 
detect reductions in pituitary αMSH (4-6). The quantitative LC-MS data suggest that other 
prohormones in the central nervous system that are processed by PC1 may drive the hyperphagia 
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in PC1-deficient models. Oxytocin is an anorexigenic hormone important for the regulation of 
body weight whose pro-form is cleaved by PC1 (6).  
 In the central nervous system, oxytocin is produced primarily in parvocellular and 
magnocellular neurons in the PVN and SON (7). Oxytocin-producing neurons in the PVN and 
SON express MC4R, the receptor for αMSH (endogenous ligand) and AgRP (endogenous 
antagonist) (7). Signaling by αMSH through MC4R induces the central release of oxytocin by a 
calcium-dependent mechanism (7). Central and peripheral administration of oxytocin reduces 
food intake in humans, rhesus monkeys, rats, and mice (7-9). Oxytocin receptor knockout mice 
weigh ~16% more (p<0.05) than WT littermates; however the mechanism of increased body 
weight remains unclear (10). Oxytocin-deficient mice do not display alterations in body weight 
(11). Association of mutations in the human OXY or OXTR genes with obesity have not been 
identified to date. However, patients with inactivating mutations in SIM1 have severe, early-
onset hyperphagic obesity (12). Oxytocin is produced in Sim1-expressing neurons in the PVN 
(13). Mice haploinsufficient for Sim1 are hyperphagic and obese and have reductions in PVN 
oxytocin levels (13). Sim1
+/-
 mice are hyporesponsive to the MC4R agonist MTII, but oxytocin 
administration can reverse hyperphagia (14). Sim1 deletion in mice around postnatal day 1 
(CaMKII-Cre x Sim1 floxed allele) or in adults around 8 weeks of age (CaMK-Cre-ER
T2
 x Sim1 
floxed allele) causes hyperphagic obesity associated with reductions in hypothalamic Oxy 
transcript levels (15, 16). The effect of administration of exogenous oxytocin was not tested in 
the eight-week old adult Sim1 inducible or postnatal Sim1 knockout models. These data 
demonstrate that hypothalamic oxytocin likely contributes to the regulation of body weight 
directly downstream of melanocortin signaling.  
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 Pro-oxytocin is processed to oxytocin by PC1. In PC1-null mice processed oxytocin is 
severely reduced in the pituitary (hypothalami were not assessed) (6). Thus, improper pro-
oxytocin processing resulting in reduced levels of oxytocin in the setting of PC1 deficiency is a 
plausible candidate mechanism for the associated hyperphagia. 
Swaab, et al., identified a reduction in the number of oxytocin positive neurons in the 
PVH of post mortem brains of PWS patients compared to unaffected control (17). Adult PWS 
patients have been reported to have decreased plasma oxytocin levels, while pediatric PWS 
patients (aged 5 to 11 years of age) have been reported to have increased plasma oxytocin levels 
(18, 19). Phenotypes of PWS including impaired suckling and behavioral symptoms consistent 
with Autism Spectrum Disorder could be attributed to impaired oxytocin function in PWS(20, 
21). 
Further studies are needed to identify if hypothalamic oxytocin processing is impaired in 
models of SNORD116 and PCSK1 deficiency. If oxytocin processing is a primary contributor to 
the hyperphagia in individuals with PWS and PC1 deficiency, then these individuals would be 
predicted to then be hyporesponsive to treatment with MC4R agonists. However agents that 
agonize the oxytocin receptor may be advantageous in the treatment of hyperphagic obesity. 
Three clinical trials have been performed to test the effect of intranasal administration of 
oxytocin in individuals with PWS. The first trial found that a single dose intranasal oxytocin 
decreased disruptive behavior, decreased sadness tendencies, and increased trust in others for the 
48 hours following oxytocin administration in PWS adults (22). Following these promising 
results, a second double-blind, placebo-controlled trial was performed in thirty individuals with 
PWS aged 12-30 years (23). This study found no statistically significant differences between 
treatment and control, with the exception of increased temper outbursts during oxytocin 
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treatment (23). More recently, another double-blind, placebo-controlled trial found that in PWS 
patients under 11 years of age, oxytocin treatment decreased measures of anger, sadness, 
conflicts, and improved food-related and social behaviors (24). The developmental timing of 
treatment may be critical in PWS.  
BDNF is highly expressed in the hypothalamic paraventricular and ventromedial nuclei; 
while NTRK2 (nominal mature BDNF receptor) is highly expressed in the paraventricular and 
ventromedial hypothalamic nuclei as well as the lateral hypothalamic area. BDNF has been 
implicated in regulation of human body weight as a molecule able to increase energy expenditure 
and decrease food intake. In common obesity as well as in Prader-Will syndrome, serum BDNF 
levels are reduced (25). A patient heterozygous for a de novo missense mutation in NTRK2 was 
hyperphagic and obese, had an elevated pain threshold, was hypotonic in infancy, experienced 
rapid weight gain after 6 months, and had marked developmental delay (26). WAGR syndrome 
(Wilm’s tumor, aniridia, genitourinary anomalies, mental retardation) patients’ whose 11p 
deletion region includes BDNF have significantly higher BMI z scores at 8 to 10 years of age 
(27). WAGR patients heterozygous for BDNF are obese whereas only 20% of patients whose 
deletion region does not include BDNF are obese (27). WAGR patients heterozygous for BDNF 
display 50% lower serum levels of BDNF than WAGR patients possessing both BDNF alleles 
(27). SNPs in BDNF are associated with common obesity while the Val66Met (rs6265) 
polymorphism in BDNF increases risk of anorexia nervosa in both humans and rodents (28, 29).  
BDNF is synthesized as a prohormone. ProBDNF can be cleaved by PC7 and furin to 
mature BDNF, which is released by both the regulated and constitutive secretory pathways (30). 
Hypothalamic BDNF involved in the control of body weight is most likely secreted by the 
regulated secretory pathway. Pcsk7
-/-
 mice are not obese, whereas Bdnf
+/-
 mice are obese (31). 
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Pcsk1 expression is upregulated in injured nerve cells in association with an increased demand 
for proBDNF and proNGF cleavage; so it has been suggested that PC1 is capable of processing 
proBDNF (32). Although speculative, Stijnen and others have postulated that perhaps, PC1 may 
process proBDNF in the regulated secretory pathway in neurons such as in the PVH, involved in 
the regulation of food intake and energy expenditure (33). Hypothalamic or circulating levels of 
BDNF have not been assessed in models of PC1 deficiency. Further studies are needed to 
determine if hypothalamic processing of pro-BDNF is impaired in PC1 null mice or iPSC-
derived neurons hypomorphic for PC1. ProBDNF processing should also be assessed in mouse 
and iPSC-derived neuron models of PWS. Although existing data supporting a major role for 
PC1 in BDNF processing are scarce, impaired processing of proBDNF cannot be definitively 
ruled out as a major contributor to the hyperphagia of individuals with PWS without further 
study.  
Thus, the impaired processing of pro-oxytocin and proBDNF are two candidate hormones 
that may contribute to hyperphagia in the setting of PC1 deficiency.  These possibilities are, of 
course, not mutually exclusive.  Further studies are necessary to determine if these hormones are 
misprocessed in the hypothalamic neurons of mice and humans (iPSC-derived neurons) 
hypomorphic for PCSK1 or SNORD116. Impaired processing of proAgRP may also contribute to 
the hyperphagic obesity phenotype in PC1 hypomorphic mice and humans. Future studies are 
required to define the exact molecular mechanisms by which PC1 deficiency leads to 
hyperphagia and, whether the hyperphagic obesity in PWS is caused by the same mechanisms.  
 
Agents that increase PC1 could be effective therapeutics for Prader-Willi syndrome 
190 
 
The newly identified PCSK1 deficiency provides a novel therapeutic target for PWS. The 
PCSK1 gene itself is not affected in individuals with PWS, thus small molecules that could 
increase transcript and protein levels of PC1 may yield functional improvements in prohormone 
processing and consequently improvement of the multiple endocrinopathies present in PWS 
patients. However, as shown in Chapter 4, there are also developmental defects that are present 
in Prader-Willi syndrome patients. It is unclear whether or not these phenotypes are dependent 
on PC1 or on other molecular targets of Snord116. Gene therapy, to either deliver active 
SNORD116 copies to cells or to reactivate maternal SNORD116 could be explored. Importantly, 
to bypass developmental defects that persist into adulthood resulting from paternal Snord116 
deficiency, in utero delivery of such therapies would be necessary. There are obviously multiple 
technical challenges to the implementation of such a therapy. 
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